

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

A retrospective, longitudinal study of the healthcare resource utilisation and costs among patients with and without infection following intramedullary nailing for a tibial shaft fracture in England

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-035404
Article Type:	Original research
Date Submitted by the Author:	30-Oct-2019
Complete List of Authors:	Galvain, Thibaut; Johnson and Johnson Medical SAS, Chitnis, Abhishek ; Johnson and Johnson Paparouni, Konstantina; Synthes GmbH Tong, Cindy; Johnson and Johnson Medical Devices, HEMA Analytics Holy, Chantal; Johnson & Johnson, Real World Analytics and Research Giannoudis, Peter; Leeds Teaching Hospitals NHS Trust, Academic Department of Trauma and Orthopaedics; University of Leeds, School of Medicine
Keywords:	ACCIDENT & EMERGENCY MEDICINE, WOUND MANAGEMENT, TRAUMA MANAGEMENT, EPIDEMIOLOGY, HEALTH ECONOMICS, Infection control < INFECTIOUS DISEASES

SCHOLARONE	тн
Manuscripts	



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez on

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

3 4	1	Title: A retrospective, longitudinal study of the healthcare resource utilisation and costs
5 6 7 8	2	among patients with and without infection following intramedullary nailing for a tibial
	3	shaft fracture in England
9 10	4	Thibault Galvain, ^{1†} Abhishek Chitnis, ² Konstantina Paparouni, ³ Cindy Tong, ⁴ Chantal Holy, ²
11 12	5	Peter V Giannoudis⁵
13 14	6	1. Johnson & Johnson Medical SAS, 1 rue Camille Desmoulins, 92130, Issy-les-Moulineaux,
15 16 17	7	France. tgalvain@its.jnj.com
18 19	8	2. Johnson & Johnson, Real World Analytics and Research, New Brunswick, NJ, USA.
20 21	9	achitni@its.jnj.com, CHoly1@its.jnj.com
22 23	10	3. Synthes GmbH, Luzernstrasse 21, 4528 Zuchwil, Switzerland. kpaparou@its.jnj.com
24 25 26	11	4. Johnson & Johnson Medical Devices, HEMA Analytics, Somerville, NJ, USA.
27 28	12	stong2@its.jnj.com
29 30	13	5. Academic Department of Trauma and Orthopaedics, Leeds Teaching Hospitals, School of
31 32	14	Medicine, University of Leeds, Leeds, United Kingdom; NIHR Leeds Biomedical Research
33 34	15	Centre, Chapel Allerton Hospital, Leeds, UK. pgiannoudi@aol.com
35 36	16	+Corresponding author
37 38 39	17	Running head:
40 41 42	18	Resource use and costs in patients with and without infection after tibial fracture nailing
42 43 44	19	Key words:
45 46	20	Tibial shaft fracture
47 48	21	• CPRD
49 50	22	• HES
51 52	23	Infection
53 54	24	• Cost
55 56 57 58	25	England
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2		
3 4	26	• Trauma
5 6	27	Burden of disease
6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 10 11 2 3 4 5 6 7 8 9 0 12 2 3 4 5 6 7 8 9 0 12 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 11 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 2 3 4 5 6 7 8 9 0 1 2 3 3 4 5 6 7 8 9 0 1 2 3 3 4 5 3 6 7 8 9 0 1 2 3 3 4 5 5 6 7 8 9 0 1 2 3 3 4 5 5 6 7 8 9 0 1 2 3 3 4 5 5 6 7 8 9 0 1 2 3 3 4 5 5 6 7 8 9 0 1 2 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	27 28	
60		For peer review only - http://bmjopen.bmj.com/site/about/g

1		
2 3 4	29	Abstract
5 6 7	30	Objectives
8 9	31	To determine the impact of infections on direct costs and healthcare resource use in England for
10 11 12	32	patients undergoing intramedullary nailing (IMN) for tibial shaft fractures.
13 14	33	Design
15 16 17	34	A retrospective longitudinal (2 year) cohort study.
18 19	35	Setting
20 21 22	36	England.
23 24	37	Participants
25 26 27	38	The study population included adult patients (≥18 years) in England with a diagnosis of tibial
28 29	39	shaft fracture (ICD-10, S822) in the inpatient setting between May 2003 and June 2017 followed
30 31	40	by a procedure for IMN for tibial shaft fracture within 30 days. Patient data were derived from
32 33	41	the Clinical Practice Research Datalink (CPRD) linked to NHS Hospital Episode Statistics
34 35 36	42	datasets.
37 38	43	Primary independent variable
39 40 41	44	Infection.
42 43	45	Primary and secondary outcome measures
44 45 46	46	The primary outcome measure was total inpatient costs from index stay admission through one-
47 48	47	year of follow-up. Secondary outcome measures included cumulative total healthcare costs, and
49 50 51	48	resource utilisation at 30 days, 90 days, 1 year and 2 years.
52		
53 54		
55		
56 57		
58		

2		
3 4	49	
5 6	50	ł
7 8	51	i
9 10 11	52	i
12 13	53	;
14 15	54	:
16 17	55	4
18 19	56	t
20 21	57	
22 23	58	,
24 25 26	59	l
27 28 20	60	
29 30 31	61	i
32 33	62	:
34 35 36	63	;
37 38	64	
39 40	65	
41 42	66	
43 44	67	
45 46	68	
47 48 49	69	
50 51	70	
52 53	71	
54 55		
56 57		
58 59		
60		

49	Results
50	805 patients met the inclusion criteria. At the index inpatient stay, 3.7% had a post IMN
51	infection, rising to 11.7% at 1-year. One-year inpatient costs were 80% higher for patients with
52	infection (p<0.001). Total costs were estimated to be £14,756 (95% confidence interval [CI];
53	£13,123, £16,593) for patients with infection versus £8,279 (95% CI; £7,946, £8,626). Length of
54	stay (LOS), readmission, and reoperation were the key drivers of healthcare costs (all p<0.001).
55	After adjustment, LOS was higher by 109% (95% CI: 62%, 169%), from 10.5 days to 21.9 days,
56	for patients with infection. The odds of being readmitted or requiring reoperation were higher by
57	5.18 times (95% CI: 3.01, 9.13) and 2.47 times (95% CI: 1.48, 4.09), respectively, for patients
58	with infection versus those without infection.
59	Conclusions
60	Post IMN infection significantly increases inpatient costs, LOS, readmissions, and reoperations
61	associated with tibial fracture fixation. Healthcare burden could be reduced through novel
62	surgical site infection prevention strategies.
63	Strengths and limitations of this study
64	This is the first study to quantify the healthcare resource burden of infections following
65	tibial shaft fractures treated with intramedullary nailing in England.
66	The study had a long term and cross-sector perspective that included inpatient, hospital
67	outpatient and primary care parameters.
68	This study only considered patients with complete follow-up, thus excluding very severe
69	patients with short life expectancy.
70	Some costs were not directly available from the CPRD dataset and were sourced from
71	published national sources.

The study relied on clinical codes to identify superficial and deep infections which may be subject to coding errors and misclassifications. Introduction Tibial shaft fractures are the most common type of long-bone fracture. They can be either closed fractures, where the skin remains intact, or open fractures (accounting for 25% of all tibial shaft fractures) where the skin is broken (1). Intramedullary nailing is a common surgical treatment for the fixation of the fractured bone: an intramedullary nail is inserted through the top of the tibia, into the inner cavity, and held in place with screws (1). Nailing allows preservation of the soft tissues surrounding the fracture site (1), and provides the greatest mechanical stability (2). In addition, as the nail is load-sharing rather than load-bearing, intramedullary nailing permits earlier weight-bearing on the fractured limb than other surgical treatments (3). Infection after intramedullary nailing is a potential complication, especially in severe open fractures, that can delay wound healing and fracture repair (2, 4-6). If left untreated, an infection may lead to permanent loss of function of the affected limb (2, 4, 7). Open fractures are especially prone to infection (over 31% of cases based on a meta-analysis (6)) due to wound exposure to the environment with the risk of infection depending on the severity of soft tissue damage (5). Patients with cases of extreme and uncontrollable infection may require limb amputation to prevent deterioration and maintain guality of life (2). Infections following fracture fixation are subclassified according to the depth of the infection: superficial (subcutaneous region), deep (muscle/fascial region), or organ/space infections (8). However, there is debate over the usefulness of these terms, as they can be arbitrary depending on the location of an infection (7). A US study reported an infection rate of 2% after intramedullary nailing for closed fractures compared with 7.1% for open fractures (9). A Spanish

•

Page 7 of 67

1 2		
3 4 5 6 7 8 9 10 11 12 13	96	study reported an infection rate of 2.7% in closed fractures compared with 19% in open
	97	fractures (10). In a meta-analysis of studies investigating prophylactic antibiotic use in patients
	98	with open tibial fractures treated with intramedullary nailing, the risk of infection increased with
	99	severity of the fracture, rising to over 31% among patients with the most severe injury (and who
	100	received systemic antibiotics only) (6).
14 15	101	Patients who experience infection are more likely to require additional surgeries, extended
16 17	102	hospital stays, and extensive treatment for post-operative infection (2, 4, 5, 7). There are only a
 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 	103	limited number of studies, however, which compare healthcare resource utilisation and
	104	treatment costs for tibial shaft fractures with and without post-surgical infection across Europe.
	105	In a Belgian study, healthcare costs were five times higher and total length of hospital stay
	106	(LOS) six times longer for open tibial shaft fracture patients with deep infection versus those
	107	with no infection (11). In Denmark, the average direct cost of treating a severe open tibial shaft
	108	fracture was estimated to be €49,817, increasing to €81,155 when infection occurred. In
	109	patients treated within 7 days of their injury, infection increased the average direct cost and LOS
	110	by 124% and 135%, respectively (12).
	111	The aim of this study was to determine the impact of infections on healthcare costs and
	112	resource utilisation for patients undergoing intramedullary nailing for tibial shaft fractures from
	113	the perspective of National Health Service (NHS) England.
	114	Materials and methods
44 45 46	115	Study design and setting
47 48	116	This was a retrospective longitudinal cohort study of patients in England who underwent
49 50	117	intramedullary nailing for tibial shaft fracture (open or closed) followed-up for 2 years. Data
51 52	118	derived from the Clinical Practice Research Datalink (CPRD) linked to NHS Hospital Episode
53 54	119	Statistics (HES) and NHS Reference costs were used to calculate costs and healthcare
55 56	119	
57 58		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2		
3 4	120	resource utilisation associated with infections (superficial or deep) following intramedullary
5 6	121	nailing.
7 8 9	122	The CPRD database is an anonymised longitudinal dataset of over 11.3 million medical records
10 11	123	from over 600 primary care practices across the UK (13). It includes all visits to primary care
12 13	124	and other healthcare professionals, reasons for visits, diagnoses observations, medical history,
14 15	125	test results, referrals, and prescriptions (13). For this study, HES data relating to admissions to,
16 17	126	or attendances at, English NHS healthcare providers was used (HES Admitted Patient Care
18 19	127	data).
20 21 22	128	Patients
23 24	129	The study population included adults (aged ≥18 years) who were diagnosed with a tibial shaft
25 26 27 28 29 30 31	130	fracture (ICD-10 code: S82.2) between May 2003 and June 2017 and who subsequently
	131	underwent intramedullary nailing within 30 days of diagnosis. Inclusion and exclusion criteria
	132	and patient attrition flow are depicted in Figure 1.
32 33	133	Infections were identified using clinical diagnosis codes either from the inpatient setting (ICD-10,
34 35	134	OPCS codes) or the primary care setting (Read codes) (See Additional file 1). Only patients with
36 37	135	an infection occurring on (or after) Day 2 following the index date were considered eligible for
38 39 40	136	the infection cohort, as this would exclude infections that were present pre-operatively. For
40 41 42	137	subgroup analysis, diagnosis codes were categorised into either deep or superficial infections
43 44	138	and open or closed fractures based on medical knowledge.
45 46 47 48 49 50 51 52 53	139	Data collection
	140	The primary outcome of this study was total inpatient costs (Healthcare Resource Group [HRG],
	141	unbundled HRG and specialised care) accrued beginning from index stay admission through
	142	one-year of follow-up post-discharge from the index stay. Secondary endpoints included
54 55 56 57	143	cumulative total healthcare costs and resource utilisation for 30 days, 90 days, 1 year and
58 59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2		
3 4 5 6 7 8	144	2 years of follow-up post discharge of the index stay. Total healthcare costs comprised
	145	inpatient, hospital outpatient and primary care costs (consisting of consultations, prescriptions,
	146	and tests/investigations). Healthcare resource utilisation included LOS, readmissions,
9 10	147	reoperations, days in intensive care unit (ICU), hospital outpatient visits, diagnostic tests, and
11 12 12	148	primary care visits. Time to infection was an additional secondary outcome.
13 14 15	149	Resource use and costs
16 17	150	Healthcare cost data were estimated based on the healthcare resource utilisation reported in
18 19	151	CPRD/HES and the unit cost associated with each service.
20 21 22 23	152	Inpatient costs
24	153	The 2017/2018 HRG Reference Costs Grouper software was used to generate HRG codes for
25 26	154	each inpatient admission (14, 15). Each HRG code was assigned an appropriate cost from NHS
 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 	155	Reference Costs (16), using admission method, LOS, trim point and the patient classification to
	156	associate the relevant costs (14, 17, 18). Inpatient stays were considered as long-stays for
	157	admissions lasting ≥2 days in line with NHS reference costs (17, 19). Unbundled HRGs were
	158	automatically generated by the Grouper software and assigned relevant costs (16). Specialised
	159	care episodes were identified using the Prescribed Specialised Services Tool 2017/18 software
	160	and top-up costs were applied as a percentage increase to the HRG cost (20).
	161	Hospital outpatient costs
43 44	162	Outpatient costs were derived from the CPRD referral file where the referral type was classified
45 46 47	163	as "outpatient" and matched against NHS reference costs for the same or closest matching
47 48 49	164	specialty (16, 18).
50 51	165	Primary care costs
52 53 54		
55 56		
57 58		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14 15	
15	
16	
17	
18	
19 20	
20 21	
21 22	
22 23	
23 24	
24 25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49 50	
50 51	
52	
53	
55 54	
55	
56	
57	
58	
59	
60	

1 2 З

166 Consultations from the CPRD consultations file were categorised based on the setting (clinical, 167 surgery, home, telephone, administrative) and healthcare provider (doctor, nurse, other 168 professional). Costs were sourced from the Unit Costs of Health and Social Care (21). 169 Laboratory and diagnostic tests from the CPRD tests file were manually matched to the closest 170 NHS test category and assigned NHS Reference Costs (17). 171 Medication categories were based on British National Formulary classifications as recorded in 172 the CPRD therapy file, and unit costs were obtained using the Prescription Cost Analysis 2017 173 using the mean sub-paragraph cost associated with each medication (22). 174 Follow-up period and cohort definitions 175 Follow-up time was calculated as the difference between the index discharge date and the last 176 date of observation. Only patients with follow-up data at the relevant time point were included in 177 the analysis. 178 Statistical analyses 179 All analyses were conducted using R Studio v3.4.3. Statistical significance was set a priori at 180 p<0.05 (two-sided). Study variables were analysed descriptively. Time-to-infection was depicted 181 graphically using the Kaplan-Meier estimator. Unadjusted comparisons of patient demographics, 182 comorbidities, and medication use between groups were performed using t-tests for continuous 183 variables that were approximately normal, and Wilcoxon rank sum tests for continuous variables 184 that were not normally distributed. Pre-specified subgroup analyses allowed for stratification of 185 results according to type of fracture (open versus closed) or type of infection (superficial versus 186 deep). 187 Generalised Linear Models were used to adjust for confounding. Covariates were identified a 188 priori as risk factors for the study outcomes based on clinical knowledge. A backwards stepwise

1		
2 3 4	189	procedure was applied according to Akaike information criterion. Missing data were not imputed.
5 6 7	190	Except for in the sensitivity analyses, patients with missing data were excluded from analyses.
7 8 9	191	Sensitivity analyses at all time points were conducted using data from the subgroup of patients
10 11	192	who had complete two-year follow-up for total costs, LOS, readmission (rate and mean count),
12 13	193	and reoperation (rate and mean count).
14 15 16	194	Patient and public Involvement
17 18	195	Patients or the public were not involved in the design, or conduct, or reporting, or dissemination
19 20 21	196	plans of our research.
21 22 23	197	Results
24 25 26	198	Patient baseline characteristics
27 28	199	Of the 10,825 patients identified as having suffered a tibial shaft fracture, 3,005 received
29 30	200	intramedullary nailing. Of these, a total of 805 patients met the inclusion criteria and were
31 32	201	included in the study (Figure 1). The mean follow-up time was 4.8 years. The mean (standard
33 34 35	202	deviation [SD]) age was 40.8 (17.2) (See Table 1 for index stay; Additional file 2). A majority of
36	203	patients were male (n= 590; 73.3%) and most had suffered a closed (n=663; 82.4%) tibial shaft
37 38 39	204	fracture. Among patients with an open fracture, a significantly higher proportion of patients
40 41	205	(10.6%) experienced an infection compared with 2.3% of patients with a closed fracture
42 43	206	(p<0.001; Table 1).
44 45 46	207 208	Figure 1. Patient screening and enrolment according to the study inclusion/exclusion criteria
47 48	209	
49 50	210	
51 52		
53 54		
55		
56 57		
58 59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

		All enrolled		Index stay				
		patients (N=805)	No infection (N=775)	Infection (N=30)	p-value			
	Demographics							
	Age (years), mean (SD)	40.8 (17.2)	40.7 (16.8)	43.0 (23.9)	0.61			
	Gender, n (%)				0.84			
	Male	590 (73.3)	569 (73.4)	21 (70.0)				
	Clinical history/comorbidities							
	Charlson score, mean (SD)	0.04 (0.23)	0.04 (0.24)	0.00 (0.00)	<0.001			
	Smoker, n (%)	256 (31.8)	247 (31.9)	9 (30.0)	0.99			
	Diabetes, n (%)	27 (3.4)	27 (3.5)	0 (0.0)	0.62			
	COPD, n (%)	8 (1.0)	8 (1.0)	0 (0.0)	1.00			
	Congestive heart failure, n (%)	2 (0.3)	2 (0.3)	0 (0.0)	1.00			
	Hypertension, n (%)	12 (1.5)	12 (1.6)	0 (0.0)	1.00			
	Compartment syndrome, n (%)	27 (3.4)	22 (2.8)	5 (16.7)	<0.01			
	Index episode							
	Inpatient waiting time (days) for surgery, mean (SD)	1.4 (2.4)	1.4 (2.4)	0.70 (2.4)	0.14			
	Fracture type, n (%)				<0.001			
	Open fracture	142 (17.6)	127 (16.4)	15 (50.0)				
	Received ≥1 prescription for antibiotics in the 12 months prior to the index stay, n (%)	60 (7.5)	60 (7.7)	0 (0.00)	0.16			
	Received ≥1 prescription for opioids in the 12 months prior to the index stay, n (%)	16 (2.0)	15 (1.9)	1 (3.3)	0.46			
13	Abbreviations: COPD, chronic obstructive pulm	onary disease;	SD, standard de	eviation.				
214								
15	Infection rates							
16	During the index stay, 30 patients (3.7%) e	xperienced an	infection. Amo	ong patients v	vith 30-c			
17	90-day, 1-year, and 2-years post-discharge	e follow-up data	a, infection rate	es were respe	ectively:			
18	8.0%, 9.2%, 11.7%, and 13.4% (Figure 2).							
19	Figure 2. Cumulative percentage of infection events recorded post-index date							
20								
21	One-year inpatient costs							
22	Among patients with index stay plus 1-year post discharge data (N=686), the mean 1-year tota							
23	inpatient cost was significantly higher amor	ng patients wh	o experienced	an infection ((£15,580			

Table 1. Patient demographic and clinical characteristics (index stay and 1-year analysis 211 212 cohorte)

1 2 3

60

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 13 of 67

1

BMJ Open

		(N=606) Mean (95% CI)	N=80 Mean (95% CI)		
		No infection	Infection	p-value	
245	Table 2. 1-year healthcare resource us	-	variate analysis]	
244	(95% CI: 1.48, 4.09), respectively.				
243	reoperation due to infection was increased by 5.18 times (95% CI: 3.01, 9.13) and 2.47 times				
242	(95% CI: 62%, 169%) from 10.5 days to 21.9 days. The odds of being readmitted or requiring				
241	higher in patients with infections (all p<0.001). After adjustment, LOS was increased by 109%				
240	increased costs were LOS, readmission, and reoperation rates, which were all significantly				
239	statistically significant increase in resource use versus no infection (Table 2). Key drivers of				
238	For the majority of healthcare resource categories, presence of infection was associated with a				
237	7 One-year healthcare resource use				
236					
235	*** p<0.001				
233 234	Figure 3. Breakdown of 1-year total control Abbreviations: ns, not significant; CI, confide	-	itus (adjusted analy	vsis)	
232	78% increase in total costs as a result of	·			
231	an infection versus £8,279 (95% CI: £7,9	•	· ·		
230	Adjusted total costs were £14,756 (95%	CI: £13,123, £16,593	 among patients wh 	io experience	
229	One-year total costs				
228	p<0.001) (Figure 3).				
227	respectively (£13,672 [95% CI: £12,122,	, £15,420] versus £7,6	616 [95% CI: £7,301	, £7,944];	
226	surgery and compartment syndrome, me	ean costs were 80% (95% CI: 58%, 104%) higher,	
225	type (open/closed), age, smoking status	, index year, diabetes	s, COPD, inpatient w	aiting time fo	
224	n=80) compared with patients without in	liection (£7,746, p<0.0		ior fracture	

10.5 (9.7, 11.4)

21.9 (17.3, 27.7)

p<0.001

55

LOS, days

		BMJ Open						
		1						
			ivariate analysis					
		No infection (N=606)	Infection N=80	p-value				
		Mean (95% CI)	Mean (95% CI)	n=0.01				
	ICU LOS, days Number of readmissions	0.01 (0.01, 0.02) 0.5 (0.5, 0.6)	0.01 (0.00, 0.02) 1.5 (1.2, 1.8)	p=0.91 p<0.001				
	Readmission rate, %	35.9 (32.1, 39.9)	74.4 (63.4, 83.0)	p<0.001 p<0.001				
	Number of reoperations	0.2 (0.2, 0.3)	0.6 (0.5, 0.8)	p<0.001 p<0.001				
	Reoperations rate, %	20.3 (17.2, 23.8)	38.6 (28.3, 50.0)	p<0.001				
	Number of hospital outpatient referrals	1.8 (1.6, 2.1)	1.7 (1.2, 2.1)	p=0.44				
	Primary care resource use							
	Number of primary care events	30.9 (29.2, 32.7)	45.9 (39.0, 54.0)	p<0.001				
	Number of tests and examinations	14.0 (11.4, 16.6)	22.1 (13.9, 31.3)	p=0.052				
246	Abbreviations: CI, confidence interval; ICU,							
247	7 Total costs from index stay to two years follow-up							
248	At all time points mean total costs were statistically significantly higher for patients with an							
249	infection compared with those without (p<0.001) (Figure 4). Adjusted mean total costs of care in							
250	patients with infection versus no infection over time were: £11,257 versus £7,017 at 30 days;							
251	£11,949 versus £7,423 at 90 days; and £16,626 versus £9,439 at 2 years (all p<0.001).							
252	Figure 4. Total costs from index stay to 2 years follow-up							
253	Abbreviations: CI, confidence interval.							
254	*** p<0.001. Data plotted are means +/- 95	% CI.						
255								
256	Healthcare resource use from index stay to two years follow-up							
257	Multivariate analysis demonstrated that LOS, readmissions (rate and mean; Figure 5), and							
258	reoperations (rate and mean; Figure 6), were consistently higher at all timepoints among							
259	patients who experienced an infection compared with those who did not (p<0.001). At 30 days							
260	infection increased the adjusted LOS from 8.9 days to 15.0 days and at 2 years from 11.3 days							
261	to 24.6 days (both p<0.001). The adjusted readmission rate increased from 7.1% at 30 days to							
262	51.3% at 2 years follow-up in patients without infection compared with an increase from 44.1%							
	For peer review only - http:/	//hmionen.hmi.com/site//						

2		
3 4	263	to 77.6% in the infection group (Figure 5). The adjusted reoperation rate increased from 1.3% at
5 6	264	30 days to 31.2% at 2 years in the absence of infection, whereas in the infection group, the rate
7 8	265	increased from 11.5% to 49.0% (Figure 6).
9 10 11	266 267	Figure 5. Readmission (adjusted) according to follow-up time: (A) readmission rate and (B) mean number of readmissions per patient
12 13 14	268 269	Abbreviations: CI, confidence interval.
15 16	270	*** p<0.001. Data plotted are means +/- 95% CI.
17 18 19	271	
20 21 22	272 273	Figure 6. Reoperation (adjusted) according to follow-up time: (A) reoperation rate and (B) mean number of reoperations per patient
23 24 25	274 275	Abbreviations: CI, confidence interval.
25 26 27	276	** p<0.01, *** p<0.001. Data plotted are means +/- 95% CI.
28 29	277	
30 31 32	278	Subgroup analyses
33 34	279	Multivariate analysis by infection type resulted in mean 1-year inpatient costs of £7,614,
35 36	280	£12,814 and £15,513, respectively for no infection (n=606), superficial infection (n=54) and
37 38	281	deep infection (n=26) (Additional file 2). Analysis by fracture type showed a higher 1-year
39 40	282	infection rate among patients with open fractures (27.4%) versus closed fractures (8.6%). Mean
41 42	283	adjusted inpatient costs at 1 year for patients with and without infection were £19,542 versus
43 44	284	£9,495 for patients with open fractures and £12,178 versus £7,278 for patients with closed
45 46 47	285	fractures.
48 49 50 51	286	Sensitivity analyses
	287	A total of 588 patients (73%) out of the 805 patients at index had data for the full 2-year follow-
52 53 54 55	288	up period. Results for total costs, LOS, readmissions (rate and mean), and reoperations (rate
56 57 58 59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

and mean) at each time point were consistent with those of the primary analyses (Additional file290 2).

291 Discussion

This study used CPRD-linked HES data to determine the impact of infection on English healthcare costs and resource utilisation associated with patients undergoing intramedullary nailing for tibial fracture. Infection rates at 1-year and 2-years (11.7% and 13.4%, respectively) were comparable with the 10.5% rate reported in a 2014 meta-analysis (6). Mean inpatient costs measured after 1 year were predicted to be 80% higher (£6,056) for patients with infection compared with those without infection, while overall costs were 78% higher. The greatest cost drivers were hospital LOS (109% increase at 1 year), readmissions (odds of being readmitted increased by 5.18 times at 1 year), and reoperations (odds of reoperation increased by 2.47 times at 1 year). The 2-year follow-up in this study meant that we were able to capture changes in resource use over time associated with infection, such as readmission and reoperation. The findings of this study highlight the substantial impact on healthcare resource utilisation and costs to the English NHS, from both the hospital and primary care perspective.

This study is the first to quantify the additional healthcare resource burden of infections following tibial fractures treated with intramedullary nailing in England with a long-term perspective which includes inpatient, hospital outpatient and primary care parameters. Differences in healthcare systems, patient populations and treatment pathways make direct comparison with studies from other countries challenging; however, our findings are in line with results of studies from Belgium and Denmark (11, 12). Hoekstra et al demonstrated five times higher healthcare costs and six times longer LOS for open tibial shaft fracture patients with deep infection versus those without infection in Belgium (11). Although the magnitude of the increase in costs and LOS observed in our study is not as substantial, differences in patient populations may be a contributing factor, as Hoekstra et al. did not limit their study population to intramedullary nail

Page 17 of 67

BMJ Open

2	
3 4	314
5 6	315
7 8	316
9 10	317
11 12	318
13 14	319
15 16	320
17 18	321
19 20	-
21 22	322
23 24	323
25 26	324
27 28	325
29 30	326
31 32	327
33 34	328
34 35 36	329
30 37 38	330
38 39 40	331
40 41 42	000
42 43 44	332
44 45 46	333
47	334
48 49	335
50 51	336
52 53	337
54 55	338
56 57	
58 50	

314 fixation (11). In their Danish study, Olesen et al estimated a 60% increase in direct costs and an 315 80% increase in LOS resulting from infected open tibial fractures (12), consistent with the 316 magnitude of the increase observed in the current study; absolute LOS (74 days) and direct 317 healthcare costs (€81,155) in the presence of infection were substantially higher than in our 318 study, however, which may in part reflect the most severe types of wounds considered in the 319 Danish study, all of which were open fractures and 80% of which were Gustilo-Anderson 320 classification 3. 321 This study is subject to the following limitations: 1) potential bias in the patient population as we 322 only considered patients with complete follow-up, thus excluding very severe patients with short 323 life expectancy; 2) identification of relevant patients for inclusion in the study was based on

325 errors and misclassifications; 3) medication use was costed as recorded in CPRD, i.e.

averaged to the cost of the drug family/British National Formulary sub-paragraph; 4) dispensing

OPCS, ICD-10 and primary care-based read codes. The data may be susceptible to coding

327 costs were not included 5) outpatient specialties from CPRD did not always exactly match

328 outpatient specialty categories from NHS Reference Costs; when there was not an exact match,

329 the closest matching specialty was chosen; 6) costs were not directly available from the CPRD
 330 dataset and hence unit costs had to be sourced from published national sources for primary and
 331 secondary care and for drug prices.


Our study provides important evidence as to the short- to mid-term direct economic consequences of infection following tibial fractures. By increasing the sample size, the impact of infection type (superficial/deep) and fracture type (open/closed) could have been explored more robustly. Additional validation of clinical codes used to identify relevant data would have allowed us to account for any potential variation in clinical coding practice. Broadening the perspective to include indirect costs would allow the additional burden of infection to be established, such as rehabilitation and absenteeism.


1		
2 3 4	339	Conclusion
5 6	340	This study confirms that infection presents a substantial healthcare burden, leading to
7 8 9	341	significantly increased hospital LOS, need for hospital readmission and reoperation, and
9 10 11	342	increased use of GPs and other primary care resources. As such there exists an unmet need for
12 13	343	alternative medical technologies and infection prevention strategies that could help to reduce
14 15	344	infections in tibial shaft fractures and reduce costs. Our study indicates that the potential mid-
16 17	345	term (1–2 years) saving to the English NHS of is around £6,500 per patient.
18 19	346	
20 21 22	347	Declarations
22 23 24	348	Ethics approval and consent to participate
25 26	349	The study protocol was approved by the Independent Scientific Advisory Committee for
27 28	350	Medicines and Healthcare products Regulatory Agency database research (ISAC) on 27
29 30	351	November 2017 (ISAC Protocol: 17-132R). General ethical approval for observational research
31 32	352	using the CPRD with approval from the ISAC was granted by a Health Research Authority
33 34	353	Research Ethics Committee (East Midlands – Derby; reference number: 05/MRE04/87).
35 36 37	354	Consent for publication
37 38 39	355	Not applicable
40 41	356	Availability of data and material
42 43	357	The data that support the findings of this study are available from Clinical Practice Research
44 45	358	Datalink (CPRD) but restrictions apply to the availability of these data, which were used under
46 47	359	license for the current study, and so are not publicly available.
48 49	360	Competing interests
50 51 52	361	Peter Giannoudis received honoraria from Synthes GmbH for his involvement in this study.
52 53 54	362	Thibaut Galvain, Abhishek Chitnis, Cindy Tong, and Chantal Holy are employees of Johnson
55 56	363	and Johnson. Konstantina Paparouni is an employee of Synthes GmbH.
57 58		
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2		
2 3 4	364	Funding
5 6	365	This study was sponsored by Synthes GmbH.
7 8 9	366	Authors' contributions
10 11	367	All authors contributed to the study design, data analysis, and manuscript writing.
12 13	368	Acknowledgements:
14 15	369	We thank James Woolnough (Mtech Access) who provided medical writing services in the
16 17	370	preparation of the manuscript, funded by DePuy Synthes.
18 19 20	371	Abbreviations
20 21 22	372	CI, confidence interval; COPD, chronic obstructive pulmonary disease; CPRD, Clinical Practice
23 24	373	Research Datalink; GP, general practitioner; HES, Hospital Episode Statistics; HRG, Healthcare
25 26	374	Resource Group; ICU, intensive care unit; ISAC, Independent Scientific Advisory Committee;
27 28	375	LOS, length of stay; NA, not applicable; NHS, National Health Service; SD, standard deviation.
29 30 31	376	References
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57	377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400	 Duan X, Al-Qwbani M, Zeng Y, Zhang W, Xiang Z. Intramedullary nailing for tibial shaft fractures in adults. Cochrane Database Syst Rev. 2012;1:CD008241. Elniel AR, Giannoudis PV. Open fractures of the lower extremity: Current management and clinical outcomes. EFORT Open Rev. 2018;3(5):316-25. Reed LK, Mormino MA. Distal Tibia Nonunions and Malunions. Operative Techniques in Orthopaedics. 2008;18(2):128-35. Kanakaris NK, Tosounidis TH, Giannoudis PV. Surgical management of infected non- unions: An update. Injury. 2015;46 Suppl 5:S25-32. Smith EJ, Kuang X, Pandarinath R. Comparing hospital outcomes between open and closed tibia fractures treated with intramedullary fixation. Injury. 2017;48(7):1609-12. Craig J, Fuchs T, Jenks M, Fleetwood K, Franz D, Iff J, et al. Systematic review and meta-analysis of the additional benefit of local prophylactic antibiotic therapy for infection rates in open tibia fractures treated with intramedullary nailing. Int Orthop. 2014;38(5):1025-30. Morgenstern M, Moriarty TF, Kuehl R, Richards RG, McNally MA, Verhofstad MHJ, et al. International survey among orthopaedic trauma surgeons: Lack of a definition of fracture-related infection. Injury. 2018;49(3):491-6. Centre for Disease Control. National Healthcare Safety Network (NHSN) Patient Safety Component Manual. 2018. Auston DA, Meiss J, Serrano R, Sellers T, Carlson G, Hoggard T, et al. Percutaneous or Open Reduction of Closed Tibial Shaft Fractures During Intramedullary Nailing Does Not Increase Wound Complications, Infection or Nonunion Rates. J Orthop Trauma. 2017;31(4):215-9. Rubio-Suarez JC, Carbonell-Escobar R, Rodriguez-Merchan EC, Ibarzabal-Gil A, Gil- Garay E. Fractures of the tibial pilon treated by open reduction and internal fixation (locking
58 59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml


1		
2		
3	401	compression plate-less invasive stabilising system): Complications and sequelae. Injury.
4	402	2018;49 Suppl 2:S60-S4.
5 6	403	11. Hoekstra H, Smeets B, Metsemakers WJ, Spitz AC, Nijs S. Economics of open tibial
0 7	404	fractures: the pivotal role of length-of-stay and infection. Health Econ Rev. 2017;7(1):32.
8	405	12. Olesen UK, Pedersen NJ, Eckardt H, Lykke-Meyer L, Bonde CT, Singh UM, et al. The
9	406	cost of infection in severe open tibial fractures treated with a free flap. Int Orthop.
10	407	2017;41(5):1049-55.
11	408	13. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data
12	409	Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827-
13	410	36.
14	411	14. Canavan C, West J, Card T. Calculating Total Health Service Utilisation and Costs from
15	412	Routinely Collected Electronic Health Records Using the Example of Patients with Irritable
16	413	Bowel Syndrome Before and After Their First Gastroenterology Appointment.
17	414	Pharmacoeconomics. 2016;34(2):181-94.
18	415	15. National Health Service. Costing - HRG4+ 2017/18 Reference Costs Grouper 2017
19	416	[Available from: https://digital.nhs.uk/services/national-casemix-office/downloads-groupers-and-
20	417	tools/costing-hrg4-2017-18-reference-costs-grouper.
21	418	16. NHS Improvement. National schedule of reference costs 2016/17 2017 [Available from:
22 23	419	https://improvement.nhs.uk/resources/reference-costs/.
23 24	420	17. Achana FA, Fleming KM, Tata LJ, Sultan AA, Petrou S. Peripartum hysterectomy: an
2 4 25	421	economic analysis of direct healthcare costs using routinely collected data. BJOG.
26	422	2018;125(7):874-83.
27	423	18. Danese MD, Gleeson M, Griffiths RI, Catterick D, Kutikova L. Methods for estimating
28	424	costs in patients with hyperlipidemia experiencing their first cardiovascular event in the United
29	425	Kingdom. J Med Econ. 2017;20(9):931-7.
30	426	19. NHS Department of Health. A simple guide to Payment by Results. 2012.
31	427	20. NHS England and NHS Improvement. NHS National tariff payment system 2017/18 and
32	428	2018/19.
33	429	21. Curtis L, Burns A. Unit Costs of Health and Social Care 2017. Available at:
34	430	https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2017/ (Accessed: 9 Nov 2018). 22. NHS Digital. Prescription Cost Analysis - England, 2017 2018 [Available from:
35	431 432	22. NHS Digital. Prescription Cost Analysis - England, 2017 2018 [Available from: https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-
36 37	432	analysis/prescription-cost-analysis-england-2017.
37 38	433	analysis/prescription-cost-analysis-england-2017.
39	434	
40		
41	435	Additional files
42	400	
43	436	1. Additional file 1:
44	100	
45	437	a. Format: "Additional file1.docx"
46	107	
47	438	b. Title: Study protocol
48		
49	439	c. Description: this additional file includes the study protocol and its appendix
50		
51 52	440	composed of clinical and procedure codes
52 53		
55 54	441	2. Additional file 2:
55		
56	442	a. Format: "Additional file2.docx"
57		
58		
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml


1 2			
3 4	443	b.	Title: Baseline and results at all time points
5 6	444	C.	Description: this additional file includes the baseline demographics and results at
7 8	445		all time points that could not be integrated in the manuscript.
9 10			
11 12			
13 14			
14 15 16			
17			
18 19			
20 21			
22 23			
24 25			
26 27			
28 29			
30 31			
32 33			
34 35			
36 37			
38 39			
40 41			
42 43			
44 45			
46 47			
48 49			
50 51			
52 53			
54 55			
56 57			
58 59			
60			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml







74x105mm (600 x 600 DPI)











Abbreviations: CI, confidence interval. *** p<0.001. Data plotted are means +/- 95% CI. 152x101mm (300 x 300 DPI)



Follow-up time post-discharge of the index stay



Additional file 1: Study protocol

PROTOCOL INFORMATION REQUIRED

The following sections below <u>must</u> be included in the CPRD ISAC research protocol. Please refer to the guidance on 'Contents of CPRD ISAC Research Protocols' (<u>www.cprd.com/isac</u>) for more information on how to complete the sections below. Pages should be numbered. All abbreviations must be defined on first use.

Applicants must complete all sections listed below Sections which do not apply should be completed as '*Not Applicable*'

A. Study Title§

Please note: This information will be published on CPRD's website as part of its transparency policy

Healthcare Resource Utilization and Costs among Patients with and without Infection after Intramedullary Nailing for A Tibial Shaft Fracture

B. Lay Summary (Max. 200 words)§

Please note: This information will be published on CPRD's website as part of its transparency policy

Tibial shaft fractures are the most common long bone fracture of the lower limbs. Intramedullary nailing is the most frequent surgical treatment for tibial shaft fractures. In patients with tibial shaft fractures, infection is an important complication as about 15% of these fractures are open injuries. Such infections may lead to devastating consequences such as increase in length of hospital stay, readmissions, prolonged medication treatment and reoperations along with high use of medical resources and costs. However, the healthcare burden among patients developing an infection in tibial shaft fracture is not well documented. Consequently, this study seeks to understand the impact of infection after intramedullary nailing in patients with tibial shaft fractures on healthcare use and cost of care.

C. Technical Summary (Max. 200 words)§

Please note: This information will be published on CPRD's website as part of its transparency policy

The objective of this retrospective longitudinal cohort study is primarily designed to determine short (30day, 90-day) and mid-term (one-year, two-year) healthcare resource utilization (HRU) and costs among patients with deep and superficial infections versus those without following intramedullary nailing for a tibial shaft fracture. Patients with tibial shaft fracture treated with intramedullary nailing between 2011 and 2016 will be selected. The main exposure variable will include deep infection versus superficial surgical site infection or no infection. Analyses will be both descriptive and comparative using multivariable models. The multivariable models will include generalized linear models (GLMs) based on the outcome variable of interest for HRU and costs and will adjust for patient characteristics.

	Applicants must complete all sections listed below Sections which do not apply should be completed as ' <i>Not Applicable</i> '
	D. Objectives, Specific Aims and Rationale
,	Broad Research Objectives To evaluate the impact of developing infection in patients with intramedullary nailing for tibial shaft fractures on healthcare utilization and cost of care.
	 Specific Aims 1. To determine short (30-day, 90-day) and mid-term (one-year, two-year) Costs and HRU among patients with deep infection and superficial infections versus patients without an infection followi tibial shaft fracture treated with nailing.
,	Rationale This study seeks to understand the impact of post-surgical infection in patients with intramedullary na for tibial shaft fractures on cost of care and healthcare utilization.
	E. Study Background
• 1 1 1	Infections remains a feared complication in orthopaedic and trauma surgery due to its potentially devastating consequences for patients. It has also been associated with an increase in medical resource utilization and treatment costs due to increased length of hospital stay, readmissions, prolonged pharmacological treatment and reoperations. ¹⁻⁶ Deep infections defined as infections involving deeper tissues such as muscular fascia and bone ⁷ have been associated with a significant economic burden for healthcare systems. Data from long bone fracture reduction, hip replacement or hemiarthroplasty or so fixation for proximal humeral fractures and knee arthroplasty, consistently reported 2-3 times higher treatment costs for patients that developed an infection compared to those that did not. ¹⁻⁶
	Tibial shaft fractures are the most common long bone fracture of the lower limbs. ⁸ In patients with the shaft fractures, infection is an important complication as about 15% of these fractures are open injurie Infection may lead to prolonged treatment, compromised clinical outcomes and in some cases, even line amputation. ⁹⁻¹² In the European setting there is limited data available with respect to the actual cost of treatment. In a Danish study on patients with open tibia fractures treated with a free flap, the presence an infection increased the mean length of hospital stay from 28 to 63.8 days and the mean treatment cost from €49,301 to €67,958 for infected compared to uninfected fractures. ¹³ A study from the UK reporte the mean length of stay and treatment costs of patients with tibial osteomyelitis. For patients treated we limb salvage procedures alone, length of stay was 15 days (10-27) and corresponding treatment costs of 16,718 while for patients, whose treatment ended up in amputation length of stay was 13 days (8-17) and treatment costs were €18,441. ¹⁴
(1 1	Intramedullary nailing is the preferred surgical treatment in patients with tibial shaft fractures. The im of the development of an infection on short and mid-term post-operative medical resource utilization in not well documented. While literature from clinical trials provides some insight into infection incident rates, the treatment pathway and treatment success/failure rates, there is a lack of detailed patient-leve information particularly in relation to the actual costs of care.

Applicants must complete all sections listed below Sections which do not apply should be completed as '*Not Applicable*'

F. Study Type

Hypothesis generating

This study will generate the hypothesis for HRU and costs between patients with (deep and superficial) and without infection after intramedullary nailing for tibial shaft fractures

G. Study Design

This is a retrospective cohort study with a longitudinal follow-up for up to two years post intramedullary nailing for tibial shaft fractures.

H. Feasibility counts

Based on the preliminary feasibility study of Hospital Episode Statistics (HES) inpatient data for research grade patients with complete data, we identified a total of 11,329 patients with intramedullary nailing for a tibial shaft fracture between 2011 and 2013 of which 509 patients had an infection following intramedullary nailing for a tibial shaft fracture.

I. Sample size considerations

No prior real-world studies have been conducted to evaluate the health care resource use and costs of interest among patients with and without infection following intramedullary nailing for tibial shaft fracture. Therefore, it is not possible to estimate the sample size

J. Data Linkage Required (if applicable):§

[§]Please note that the data linkage/s requested in research protocols will be published by the CPRD as part of its transparency policy

The Clinical Practice Research Datalink (CPRD) with HES is required to identify the patients and outcomes that are based on diagnosis and procedures recorded in the inpatient setting.

K. Study population

Patients initially selected for tibial shaft fracture (ICD-10, S822) must meet all the following inclusion criteria:

- 1. Procedure for intramedullary nailing for tibial shaft fracture (appendix) between January 1, 2011 and February 30, 2016
 - Date of first intramedullary nailing for tibial shaft fracture between January 2011 and February 2016 will be the index date
- 2. Research grade patients with complete medical records for at least 12 months pre- and 30- day post index date. Patients with 90-day, 1- and 2- year follow-up or continuous enrollment will be further analysed.

Patients with the following criteria were excluded:

Records for intramedullary nailing for tibial shaft fracture during the 12-month pre-index period
 Records for treatment with internal fixation (appendix) during the 12-month pre-index period

	Applicants must complete all sections listed below Sections which do not apply should be completed as ' <i>Not Applicable'</i>
3.	Records for treatment with external fixation (appendix) from 12-month pre-index to 6 weeks pre-
-	index. Records for external fixation during 6 weeks pre-index will be included as external fixation
	often performed prior to intramedullary nailing.
4.	Records for severe multiple injuries to different parts of the body (polytrauma) (appendix) in the
	month pre-index period.
5.	Records for a fracture in neoplastic disease (appendix) in the 12-month pre-index period.
L. 3	Selection of comparison group(s) or controls
Pat	ients not developing an infection anytime during the study period will be selected as the control g
Μ.	Exposures, Health Outcomes [§] and Covariates
	ase note: Summary information on health outcomes (as included on the ISAC application form above)will be published on CPRD's v art of its transparency policy
Ext	posure
	ients developing infection during the 12-month post index period.
<u>Ou</u>	tcome(s)
Pri	mary Outcome
On	e- year inpatient costs
Sec	condary Outcomes
•	Number of hospital readmissions (in 30-days, 90-days, 1 year and 2 years)
•	Percent (yes/no) of patients with readmissions (in 30-days, 90-days, 1 year and 2 years)
•	Total cost of care at the different time points (in 30-days, 90-days, 1 year and 2 years)
•	a. Inpatient admissions
	b. Outpatient costs
	c. Pharmacy
Co	sts will be expressed in UK pounds and adjusted for inflation to 2015 index. Healthcare costs w
	ained from the Personal Social Services Research Unit (PSSRU) 2015 Cost of Care public doct
	Healthcare Resource Group (HRG) codes available in HES. Drug costs will be obtained from E
	tional Formulary 71 (March 2016-September 2016).
•	Number of procedures for introduction of therapeutic substance (Appendix) (30-days, 90-days, 1
	and 2 years)
•	Number of outpatient visits (all-cause) at the different time points (in 30-days, 90-days, 1 year an
	years)
•	Number of diagnostic tests and imaging (all-cause) at the different time points (in 30-days, 90-da
	year and 2 years)
•	Number of days in ICU (all-cause) at the different time points (in 30-days, 90-days, 1 year and 2
	years)
•	Time of infection and type of infection (bacterial vs other)
	/

• Percent (yes/no)	of patients with use of antibiotics at the different time points (in 30-days, 90-days, 1
year and 2 years)	
	ted amputation (Appendix) at the different time points (in 30-days, 90-days, 1 year
and 2 years) Covariates	
The covariates inform following:	nation will be captured during 12-month pre-index period and will include the
Patient Demographic	25
• Age	
• Gender	
Smoking status	
Procedural Characte	ristics
• Year of the index	date
Patient Clinical Chai	racteristics
Comorbidities (Appe	ndix)
• Diabetes	
 Dyspnea 	
 Ventilator require 	ement
Chronic obstructi	ve pulmonary disease (COPD)
• Congestive heart	failure (CHF)
• Renal failure	
• Hypertension	
Indices	
Charlson com using select d	norbidity index (CCI) - The CCI is an aggregate measure of comorbidity created by iagnoses associated with chronic disease (e.g., heart disease, cancer). The CCI nedical conditions and weights these conditions from $+1$ to $+6$.
Medications	
• Anti-hypertensive	e medications
 Opioids 	
N. Data/ Statistical A	laiysis
dichotomous and pol	ill be analyzed descriptively. Frequency counts and proportions will be provided for ychotomous variables. Means, medians, and standard deviations will be provided for Time to infection will be depicted graphically using Kaplan-Meier curve.
Unadiusted comparis	ons of patient demographics, comorbidities and medication use between groups (w
) will be performed with 2-sample t-tests for continuous variables and χ^2 tests for

Applicants must complete all sections listed below Sections which do not apply should be completed as '*Not Applicable*'

A sub-analysis will be conducted in which patients will be stratified by an open fracture and a closed tibial shaft fracture (appendix) to determine the outcomes.

All analyses will be conducted using SAS for Windows. Statistical significance will be set a-priori at p< 0.05 (two-sided).

In addition, a generalized Linear Model (GLM) will be utilized to get adjusted results after control for confounding. Details of this methods are mentioned in the section below:

O. Plan for addressing confounding

Multivariable models will be constructed to examine the impact of infection versus no infection and other patient characteristics for healthcare utilization and cost outcomes. A Generalized Linear Model (GLM) will be utilized and the appropriate error distribution and link function will be used based on the outcome variable of interest for utilization and costs.

Following standard procedures, for each model regression diagnostics will be performed to assess goodness of fit and violations of model assumptions. Appropriate modifications will be made as needed either through selection of alternative error distributions or link functions, or through transformations of either the independent or dependent variables. We will also examine the fitted and the observed data to uncover outliers, their effect on the analysis, and possible misspecification of the initial equation.

P. Plans for addressing missing data

Missing data will not be imputed for the analyses. Most variables (drugs, procedures, diagnosis) can have no missing values, as they are assumed not to have occurred unless a record is identified. To be included in the study, patients will need to have complete medical history for at least 12 months pre-index to 12 months post-index date.

Q. Patient or user group involvement (if applicable)

This is purely an observational study using CPRD with HES linkage data. This study does not involve requesting additional information from GPs. Also, the study does not require contacting patients to get any additional information.

R. Plans for disseminating and communicating study results, including the presence or absence of any restrictions on the extent and timing of publication

The study will be disseminated per the ICMJE guidelines. We plan on submitting the results to a peerreviewed journal and presenting the results at scientific conferences.

S. Limitations of the study design, data sources, and analytic methods

Applicants must complete all sections listed below Sections which do not apply should be completed as ' <i>Not Applicable</i> '
 Potential bias in patient population: only patients with complete medical history for 12 months post index will be included, thus excluding very severe patients with less than 12 month life expectancy Coding errors and misclassifications
 Under-reported or missing diagnoses, based on patients' choice (not to seek care) or access challenges Identify pharmacy cost in terms of medication prescribed in the primary care setting only
Cost evaluated using PSSRU, HRG and BNF codes as the costs are not directly available in the data T. References
 de Lissovoy G, Fraeman K, Hutchins V, et al. Surgical site infection: incidence and impact on hospital utilization and treatment costs. American journal of infection control 2009;37(5):387-97. Jenks PJ, Laurent M, McQuarry S, et al. Clinical and economic burden of surgical site infection (SSI) and predicted financial consequences of elimination of SSI from an English hospital. The Journal of hospital infection 2014;86(1):24-33. Pallard TC, Neuman JE, Parlaw NL et al. Deep wound infection offer provincel foregraph fronture.
3. Pollard TC, Newman JE, Barlow NJ, et al. Deep wound infection after proximal femoral fracture: consequences and costs. The Journal of hospital infection 2006; 63 (2):133-9.
 4. Schmidt A, Benard S, Cyr S. Hospital Cost of Staphylococcal Infection after Cardiothoracic or Orthopedic Operations in France: A Retrospective Database Analysis. Surgical infections 2015;16(4):428-35.
 5. Thakore RV, Greenberg SE, Shi H, et al. Surgical site infection in orthopedic trauma: A case-control study evaluating risk factors and cost. Journal of clinical orthopaedics and trauma 2015;6(4):220-6.
 6. Wijeratna MD, McRoberts J, Porteous MJ. Cost of infection after surgery for intracapsular fracture of the femoral neck. Annals of the Royal College of Surgeons of England 2015;97(4):283-6. 7. Metsemakers WJ, Handojo K, Reynders P, et al. Individual risk factors for deep infection and
compromised fracture healing after intramedullary nailing of tibial shaft fractures: a single centre experience of 480 patients. Injury 2015; 46 (4):740-5.
 8. Minhas SV, Ho BS, Switaj PJ, et al. A comparison of 30-day complications following plate fixation versus intramedullary nailing of closed extra-articular tibia fractures. Injury 2015;46(4):734-9. 9. Buckley RE, Colton C. Infection. Secondary Infection 2012.
https://www2.aofoundation.org/wps/portal/surgery?showPage=redfix&bone=Tibia&segment=Sha ft&classification=42-
Special%20considerations&treatment=&method=Special%20considerations&implantstype=Comp lications&approach=&redfix_url=1341319024234.
10. Hannigan GD, Pulos N, Grice EA, et al. Current Concepts and Ongoing Research in the Prevention and Treatment of Open Fracture Infections. Advances in wound care 2015; 4 (1):59-74.
11. Kanakaris NK, Tosounidis TH, Giannoudis PV. Surgical management of infected non-unions: An update. Injury 2015; 46 Suppl 5 :S25-32.
12. Mouzopoulos G, Kanakaris NK, Kontakis G, et al. Management of bone infections in adults: the surgeon's and microbiologist's perspectives. Injury 2011; 42 Suppl 5 :S18-23.
13. The cost of infection in severe open tibial fractures treated with a free flap. 34th Annual Meeting of the European Bone & Joint Infection Society; 2015; Lisbon, Portugal.
14. Kendall J, Jones, S., Mcnally, M. Income and costs of treating tibial osteomyelitis in the uk – a comparison of limb salvage versus amputation. 34th Annual Meeting of the European Bone & Joint Infection Society. Lisbon, Portugal, 2015.
List of Appendices (Submit all appendices as separate documents to this application)
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Applicants must complete all sections listed below Sections which do not apply should be completed as ' <i>Not Applicable</i> '
Appendix 1: OPCS-4 codes to identify intramedullary nailing for long bones Appendix 2 OPCS-4 codes to identify internal fixation Appendix 3 OPCS-4 codes to identify external fixation Appendix 4: ICD-10 codes to identify severe multiple injuries Appendix 5: Read codes to identify fracture due to neoplastic disease Appendix 6: ICD-10, OPCS and Read codes to identify infection Appendix 7: OPCS-4 codes to identify procedures for introduction of therapeutic substance Appendix 8: OPCS-4 codes to identify procedures amputation of tibia bone Appendix 9: Read codes to identify diabetes mellitus with and without complications Appendix 10: Read codes to identify ventilator requirement Appendix 11: Read codes to identify COPD Appendix 12: Read codes to identify renal failure Appendix 13: Read codes to identify renal failure Appendix 14: Read codes to identify heart failure Appendix 15: Read codes to identify hypertension Appendix 16: Read, ICD-10 and OPCS codes to identify open and closed tibial shaft fracture Appendix 17: Read codes to identify Charlson comorbidity index Appendix 18: OPCS codes to identify reoperations

1. OPCS-4 codes to identify intramedullary nailing for long bones

1. OPCS-4 codes to identify intramedulary naming for long bones		
OPCS-4	Description	
W192	Primary open reduction of fracture of long bone and fixation using rigid nail NEC	
W242	Closed reduction of fracture of long bone and rigid internal fixation NEC	
2. OPCS-4 codes to identify internal fixation		

OPCS-4	Description
0172	Remanipulation of fracture of long bone and rigid internal fixation NEC
O173	Remanipulation of fracture of long bone and flexible internal fixation HFQ
O175	Remanipulation of fragment of bone and fixation using screw
O178	Other specified secondary closed reduction of fracture of bone and internal fixation
O179	Unspecified secondary closed reduction of fracture of bone and internal fixation
W195	Primary open reduction of fragment of bone and fixation using screw
W196	Primary open reduction of fragment of bone and fixation using wire system
W198	Other specified primary open reduction of fracture of bone and intramedullary fixation
W199	Unspecified primary open reduction of fracture of bone and intramedullary fixation

1
2
3
4
5
6
0
/
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
47 48
49
50
51
52
53
54
54 55
56
57
58
59
60

1

Drimony open reduction of fracture of long bars and extremedullary fixetion using slat	
Primary open reduction of fracture of long bone and extramedullary fixation using NEC	
Primary open reduction of fracture of long bone and extramedullary fixation using cerclage	
Primary open reduction of fracture of long bone and extramedullary fixation using suture	
Primary open reduction of fracture of long bone and complex extramedullary fixation NEC	
Other specified primary open reduction of fracture of bone and extramedullary fixation	
Unspecified primary open reduction of fracture of bone and extramedullary fixation	
Secondary open reduction of fracture of bone and intramedullary fixation HFQ	
Secondary open reduction of fracture of bone and extramedullary fixation HFQ	
Secondary open reduction of fracture of bone and internal fixation HFQ	
Other specified closed reduction of fracture of bone and internal fixation	
Unspecified closed reduction of fracture of bone and internal fixation	
Application of internal fixation to bone NEC	
Adjustment to internal fixation of bone NEC	
Removal of internal fixation from bone NEC	
Other specified other internal fixation of bone	
Unspecified other internal fixation of bone	

3. OPCS-4 codes to identify external fixation

OPCS-4	Description
W222	Primary open reduction of fracture of bone and external fixation HFQ
W235	Secondary open reduction of fracture of bone and external fixation HFQ
W252	Closed reduction of fracture of bone and fixation using functional bracing system
W253	Remanipulation of fracture of bone and external fixation HFQ
W258	Other specified closed reduction of fracture of bone and external fixation
W259	Unspecified closed reduction of fracture of bone and external fixation
W301	Application of external fixation to bone NEC
W302	Adjustment to external fixation of bone NEC
W303	Removal of external fixation from bone NEC
W304	Application of external ring fixation to bone NEC
W308	Other specified other external fixation of bone
W309	Unspecified other external fixation of bone

ICD-10 codes Description	
S097	Multiple injuries of head
S197	Multiple injuries of neck
S277	Multiple injuries of intrathoracic organs
S297	Multiple injuries of thorax
S397	Other multiple injuries of abdomen, lower back and pelvis
S497	Multiple injuries of shoulder and upper arm
S597	Multiple injuries of forearm
S647	Injury of multiple nerves at wrist and hand level
S697	Multiple injuries of wrist and hand
S797	Multiple injuries of hip and thigh
S897	Multiple injuries of lower leg
S997	Multiple injuries of ankle and foot
T042	Crushing injuries involving multiple region of upper limb(s)
T043	Crushing injuries involving multiple region of lower limb(s)
T062	Injuries of nerves involving multiple body regions
T063	Injuries of blood vessels involving multiple body regions
T068	Other specified injuries involving multiple body regions
T07X	Unspecified multiple injuries

5. Read codes to identify fracture due to neoplastic disease

Medcode	Read_code	Description
54834	N331700	Fracture of bone in neoplastic disease

6. ICD-10, OPCS and Read codes to identify infection

ICD-10 codes	Description	Deep/Superficial
A498	Other bacterial infections of unspecified site	Deep
A499	Bacterial infection, unspecified	Deep
A544	Gonococcal infection of musculoskeletal system	Deep
L088	Other spec local infections of skin and subcutaneous tissue	Superficial
L089	Local infection of skin and subcutaneous tissue, unspecified	Superficial
T814	Infection following a procedure, not elsewhere classified	Deep

Medcode	Read_code	Description	Deep/Superficial
3128	M07z.00	Local infection skin/subcut tissue NOS	Superficial
6956	SK03.00	Post-traumatic wound infection NEC	Deep
7155	N302.11	Bone infection	Deep
51854	SP25600	Postoperative wound infection-deep	Deep
20342	N3000	Osteomyelitis, periostitis, other infections affecting bone	Deep
21073	M07y.00	Local infection of skin or subcutaneous tissue OS	Superficial
25363	SP06800	Infection and inflamm reac due inter ortho device	Deep
40293	SP06.00	Infection and inflammation due to internal prosthetic device	Deep
30381	SP05612	[X]Prosthetic infection	Deep
33381	A3Byz00	Other specified bacterial infection NOS	Superficial
43058	N30z.00	Bone infection NOS	Deep
39830	N300.12	Acute bone infection	Deep
40293	SP06.00	Infection and inflammation due to internal prosthetic device	Deep
52122	Myu0.00	[X]Infections of the skin and subcutaneous tissue	Superficial
69280	N30z600	Bone infection NOS, of the lower leg	Deep
69855	N30y600	Other infections involving bone, of the lower leg	Deep
4207	M03z000	Cellulitis NOS	Superficial

OPCS-4	Description	Deep/Superficial
S571	Debridement of skin NEC	Superficial
W332	Debridement of open fracture of bone	Deep
T963	Debridement of soft tissue NEC	Deep
W336	Debridement of bone NEC	Deep

7. OPCS-4 codes to identify procedures for debridement or introduction of therapeutic substance

OPCS-4	Description	
S571	Debridement of skin NEC	
W332	Debridement of open fracture of bone	
T963	Debridement of soft tissue NEC	

ן ר
2 3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
20 29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
54 55
55 56
58

59

60

	· · · ·
W336	Debridement of bone NEC
W283	Removal of internal fixation from bone NEC
X292	Continuous intravenous infusion of therapeutic substance NEC
S523	Insertion of therapeutic substance into subcutaneous tissue NEC
W351	Introduction of therapeutic substance into bone

8. OPCS-4 codes to identify procedures amputation of tibia bone

OPCS-4	Description
X094	Amputation of leg through knee
X095	Amputation of leg below knee
X098	Other specified amputation of leg
X099	Unspecified amputation of leg

9. Read codes to identify diabetes mellitus with and without complications

Medcodes	Read code	Description
231370	66AJ.11	Unstable diabetes
297735	C108600	Insulin dependent diabetes mellitus with gangrene
288454	C101100	Diabetes mellitus, adult onset, with ketoacidosis
344495	C10M.00	Lipoatrophic diabetes mellitus
224500	C103000	Diabetes mellitus, juvenile type, with ketoacidotic coma
233608	C109500	Non-insulin dependent diabetes mellitus with gangrene
251808	C109900	Non-insulin-dependent diabetes mellitus without complication
331810	C109412	Type 2 diabetes mellitus with ulcer
344028	C10FG00	Type 2 diabetes mellitus with arthropathy
279344	C109.11	NIDDM - Non-insulin dependent diabetes mellitus
343531	C109G11	Type II diabetes mellitus with arthropathy
279348	C10z.00	Diabetes mellitus with unspecified complication
342740	C10EM11	Type I diabetes mellitus with ketoacidosis
279343	C107200	Diabetes mellitus, adult with gangrene
210870	250 GA	Gangrene diabetic
339961	C10FJ00	Insulin treated Type 2 diabetes mellitus
308067	C108911	Type I diabetes mellitus maturity onset
297727	C102z00	Diabetes mellitus NOS with hyperosmolar coma
283820	250 HC	Hypoglycaemic Coma Diabetic
303253	250 AK	Maturity Onset Diabetes Mellitus Insulin
243302	G73y000	Diabetic Peripheral Angiopathy

Medcodes	Read code	Description
306131	250 E	Hypoglycaemia In Diabetes Mellitus
249566	66AJ.00	Diabetic - Poor Control
331925	C109J12	Insulin treated Type II diabetes mellitus
309010	C109F12	Type 2 diabetes mellitus with peripheral angiopathy
242649	C109300	Non-insulin-dependent diabetes mellitus with multiple comps
242646	C108400	Unstable insulin dependent diabetes mellitus
340367	C10F900	Type 2 diabetes mellitus without complication
206461	C10y.00	Diabetes mellitus with other specified manifestation
344412	C10F.11	Type II diabetes mellitus
341116	C10FL00	Type 2 diabetes mellitus with persistent proteinuria
306134	250 NT	UNSTABLE DIABETIC
309704	C109G00	Non-insulin dependent diabetes mellitus with arthropathy
343565	C109G12	Type 2 diabetes mellitus with arthropathy
249564	66A5.00	Diabetic on insulin
308094	C109511	Type II diabetes mellitus with gangrene
243795	L180600	Pre-existing diabetes mellitus, non-insulin-dependent
256384	250 PR	Pruritus Diabetic
341003	C10FN00	Type 2 diabetes mellitus with ketoacidosis
341356	C10E400	Unstable type 1 diabetes mellitus
270277	C10zy00	Other specified diabetes mellitus with unspecified comps
341680	C10D.00	Diabetes mellitus autosomal dominant type 2
288459	C107z00	Diabetes mellitus NOS with peripheral circulatory disorder
341002	C10EN00	Type 1 diabetes mellitus with ketoacidotic coma
303258	250 CT	Diabetic Cataract
215438	C101000	Diabetes mellitus, juvenile type, with ketoacidosis
206451	C100011	Insulin dependent diabetes mellitus
229069	250 JA	Diabetic Acidosis
309863	C108411	Unstable type I diabetes mellitus
303250	250 A	Sugar Diabetes
206452	C103.00	Diabetes mellitus with ketoacidotic coma
261004	C107.11	Diabetes mellitus with gangrene
303263	250 JL	Ketosis Diabetic
303256	250 AN	Diabetes
341598	C10E500	Type 1 diabetes mellitus with ulcer

Medcodes	Read code	Description
242650	C109400	Non-insulin dependent diabetes mellitus with ulcer
297739	C10yy00	Other specified diabetes mellitus with other spec comps
292948	250 AB	Abscess Diabetic
307957	C109711	Type II diabetes mellitus - poor control
261009	C10A000	Malnutrition-related diabetes mellitus with coma
339633	C10F.00	Type 2 diabetes mellitus
309658	C109J11	Insulin treated non-insulin dependent diabetes mellitus
223592	8A13.00	Diabetic stabilisation
233607	C108.00	Insulin dependent diabetes mellitus
347683	C10EG00	Type 1 diabetes mellitus with peripheral angiopathy
340865	C108E12	Type 1 diabetes mellitus with hypoglycaemic coma
302787	C108.13	Type I diabetes mellitus
270271	C107100	Diabetes mellitus, adult, peripheral circulatory disorder
233609	C10A100	Malnutrition-related diabetes mellitus with ketoacidosis
261001	C102000	Diabetes mellitus, juvenile type, with hyperosmolar coma
237987	250 AT	Diabetic Amyotrophy
308119	C109411	Type II diabetes mellitus with ulcer
341509	C10F500	Type 2 diabetes mellitus with gangrene
303262	250 JK	Ketoacidosis Diabetic
297726	C102100	Diabetes mellitus, adult onset, with hyperosmolar coma
308004	C108E11	Type I diabetes mellitus with hypoglycaemic coma
339527	С109К00	Hyperosmolar non-ketotic state in type 2 diabetes mellitus
247153	250 G	Ulcer Diabetic
258769	66AJz00	Diabetic - poor control NOS
347258	C10FJ11	Insulin treated Type II diabetes mellitus
297734	C108500	Insulin dependent diabetes mellitus with ulcer
309300	C109J00	Insulin treated Type 2 diabetes mellitus
341126	C10E800	Type 1 diabetes mellitus - poor control
309125	C108812	Type 1 diabetes mellitus - poor control
206454	C107400	NIDDM with peripheral circulatory disorder
343055	C10G.00	Secondary pancreatic diabetes mellitus
340580	C10EM00	Type 1 diabetes mellitus with ketoacidosis
331540	66AV.00	Diabetic on insulin and oral treatment
298869	L180500	Pre-existing diabetes mellitus, insulin-dependent

Medcodes	Read code	Description
342313	C10FP00	Type 2 diabetes mellitus with ketoacidotic coma
297725	C100.00	Diabetes mellitus with no mention of complication
344338	C10E600	Type 1 diabetes mellitus with gangrene
333576	C109D12	Type 2 diabetes mellitus with hypoglycaemic coma
341127	C10FF00	Type 2 diabetes mellitus with peripheral angiopathy
261005	C108.12	Type 1 diabetes mellitus
206457	C109.00	Non-insulin-dependent diabetes mellitus
331823	C109D00	Non-insulin dependent diabetes mellitus with hypoglyca coma
242656	C10zz00	Diabetes mellitus NOS with unspecified complication
340814	C10EE00	Type 1 diabetes mellitus with hypoglycaemic coma
295382	66AS.00	Diabetic annual review
233606	C107000	Diabetes mellitus, juvenile ??? circulatory disorder
347648	C10E412	Unstable insulin dependent diabetes mellitus
341139	C10E900	Type 1 diabetes mellitus maturity onset
242642	C101y00	Other specified diabetes mellitus with ketoacidosis
344989	C10FL11	Type II diabetes mellitus with persistent proteinuria
247152	250 DR	Diabetic Diarrhoea
283822	250 NH	Hyperosmolar Diabetic State
303259	250 DC	Dietary Control Diabetes
310005	C109712	Type 2 diabetes mellitus - poor control
270372	Cyu2.00	[X]Diabetes mellitus
270268	C1000	Diabetes mellitus
346131	C10EA00	Type 1 diabetes mellitus without complication
279341	C100z00	Diabetes mellitus NOS with no mention of complication
297729	C103z00	Diabetes mellitus NOS with ketoacidotic coma
331809	C108G00	Insulin dependent diab mell with peripheral angiopathy
308089	C108E00	Insulin dependent diabetes mellitus with hypoglycaemic coma
215437	C101.00	Diabetes mellitus with ketoacidosis
347882	C10E812	Insulin dependent diabetes mellitus - poor control
341302	C10F700	Type 2 diabetes mellitus - poor control
222266	66AK.00	Diabetic - cooperative patient
270276	C10B000	Steroid induced diabetes mellitus without complication
233603	C100111	Maturity onset diabetes
339632	C10E.00	Type 1 diabetes mellitus

1
2
3
4 5 6 7 8 9
5
6
/
0 9
10
10 11 12 13 14
12
13
14
15
16
1/ 10
10 10
14 15 16 17 18 19 20
21
22
23
24
25
26
24 25 26 27 28
28
29 30
31
32
33
34
34 35 36
36
37
38
39 40
40 41
42
43
44
45
46
47
48
49 50
50 51
52
53
54
55
56
57
58

Medcodes	Read code	Description
223655	8H2J.00	Admit diabetic emergency
283823	2500AH	Latent Diabetes
285267	1434	H/O: diabetes mellitus
308820	C108811	Type I diabetes mellitus - poor control
344076	C10E.12	Insulin dependent diabetes mellitus
270269	C100100	Diabetes mellitus, adult onset, no mention of complication
341357	C10F400	Type 2 diabetes mellitus with ulcer
242655	C10z100	Diabetes mellitus, adult onset, unspecified complication
280482	L180X00	Pre-existing diabetes mellitus, unspecified
341557	8BL2.00	Patient on maximal tolerated therapy for diabetes
242653	C10yz00	Diabetes mellitus NOS with other specified manifestation
288455	C102.00	Diabetes mellitus with hyperosmolar coma
270275	C10A.00	Malnutrition-related diabetes mellitus
270273	C108.11	IDDM-Insulin dependent diabetes mellitus
215439	C101z00	Diabetes mellitus NOS with ketoacidosis
342317	C10FD00	Type 2 diabetes mellitus with hypoglycaemic coma
261007	C108800	Insulin dependent diabetes mellitus - poor control
303261	250 HP	Precoma Diabetic
341856	C10EK00	Type 1 diabetes mellitus with persistent proteinuria
303252	250 AD	Diabetes Mellitus Insulin Dependant
347025	C10H.00	Diabetes mellitus induced by non-steroid drugs
270270	C107.00	Diabetes mellitus with peripheral circulatory disorder
332066	C10D.11	Maturity onset diabetes in youth type 2
224506	C107300	IDDM with peripheral circulatory disorder
340332	C109F11	Type II diabetes mellitus with peripheral angiopathy
309143	C109D11	Type II diabetes mellitus with hypoglycaemic coma
341409	C10EL00	Type 1 diabetes mellitus with persistent microalbuminuria
242641	C100112	Non-insulin dependent diabetes mellitus
340474	C10FM00	Type 2 diabetes mellitus with persistent microalbuminuria
261095	Cyu2000	[X]Other specified diabetes mellitus
288460	C109.12	Type 2 diabetes mellitus
224501	C103y00	Other specified diabetes mellitus with coma
302788	C109.13	Type II diabetes mellitus
332948	C108511	Type I diabetes mellitus with ulcer

Medcodes	Read code	Description
347834	C10EN11	Type I diabetes mellitus with ketoacidotic coma
297738	C109700	Non-insulin dependent diabetes mellitus - poor control
283819	250 H	Coma Diabetic
215444	C10y100	Diabetes mellitus, adult, other specified manifestation
346130	C10E.11	Type I diabetes mellitus
344745	C10N.00	Secondary diabetes mellitus
347629	C10F711	Type II diabetes mellitus - poor control
277055	66AI.00	Diabetic - good control
251805	C100000	Diabetes mellitus, juvenile type, no mention of complication
206900	F464000	Diabetic cataract
309738	C109212	Type 2 diabetes mellitus with neurological complications
224502	C104000	Diabetes mellitus, juvenile type, with renal manifestation
345097	C109111	Type II diabetes mellitus with ophthalmic complications
341813	2BBP.00	O/E - right eye background diabetic retinopathy
346841	C108C11	Type I diabetes mellitus with polyneuropathy
308934	C108H00	Insulin dependent diabetes mellitus with arthropathy
215442	C109C00	Non-insulin dependent diabetes mellitus with nephropathy
261008	C108B00	Insulin dependent diabetes mellitus with mononeuropathy
297732	C106100	Diabetes mellitus, adult onset, neurological manifestation
206455	C108000	Insulin-dependent diabetes mellitus with renal complications
309524	C109H00	Non-insulin dependent d m with neuropathic arthropathy
251806	C108200	Insulin-dependent diabetes mellitus with neurological comps
343081	C10F100	Type 2 diabetes mellitus with ophthalmic complications
341814	2BBQ.00	O/E - left eye background diabetic retinopathy
309275	C109011	Type II diabetes mellitus with renal complications
252191	F420200	Preproliferative diabetic retinopathy
288456	C105000	Diabetes mellitus, juvenile type, ophthalmic manifestation
347472	C10FR00	Type 2 diabetes mellitus with gastroparesis
288461	C109100	Non-insulin-dependent diabetes mellitus with ophthalm comps
306132	250 F	Neuropathy Diabetic
341286	C10FE00	Type 2 diabetes mellitus with diabetic cataract
308948	C108712	Type 1 diabetes mellitus with retinopathy
242643	C106.13	Diabetes mellitus with polyneuropathy
279760	F420.00	Diabetic retinopathy

1
2 3
4 5
6 7
8 9
10
11 12
13 14
15 16
17 18
19
20 21
22 23
24 25
26 27
28
29 30
31 32
33 34
35 36
37
38 39
40 41
42 43
44 45
46 47
48
49 50
51 52
53 54
55 56
57
58 50

60

Medcodes	Read code	Description
308463	C109612	Type 2 diabetes mellitus with retinopathy
270274	C109B00	Non-insulin dependent diabetes mellitus with polyneuropathy
309943	F420600	Non proliferative diabetic retinopathy
288457	C105y00	Other specified diabetes mellitus with ophthalmic complicatn
309614	C109E11	Type II diabetes mellitus with diabetic cataract
341801	C10FB00	Type 2 diabetes mellitus with polyneuropathy
340973	C10FA00	Type 2 diabetes mellitus with mononeuropathy
347417	C10F611	Type II diabetes mellitus with retinopathy
343003	C10E200	Type 1 diabetes mellitus with neurological complications
342681	C108B11	Type I diabetes mellitus with mononeuropathy
206459	C109600	Non-insulin-dependent diabetes mellitus with retinopathy
298103	F381300	Myasthenic syndrome due to diabetic amyotrophy
224505	C106z00	Diabetes mellitus NOS with neurological manifestation
224503	C104y00	Other specified diabetes mellitus with renal complications
342469	2BBV.00	O/E - left eye proliferative diabetic retinopathy
332953	C108711	Type I diabetes mellitus with retinopathy
279761	F420400	Diabetic maculopathy
201928	250 LG	Diabetic Glomerulosclerosis
309628	C109C12	Type 2 diabetes mellitus with nephropathy
224504	C106.11	Diabetic amyotrophy
207385	K01x111	Kimmelstiel - Wilson disease
206456	C108D00	Insulin dependent diabetes mellitus with nephropathy
341836	C108212	Type 1 diabetes mellitus with neurological complications
242645	C108100	Insulin-dependent diabetes mellitus with ophthalmic comps
288858	F3y0.00	Diabetic mononeuropathy
252174	F372.12	Diabetic neuropathy
234015	F420300	Advanced diabetic maculopathy
347410	C10F011	Type II diabetes mellitus with renal complications
344952	2BBI.00	O/E - left eye stable treated prolif diabetic retinopathy
339960	C10FC00	Type 2 diabetes mellitus with nephropathy
343345	C10EF00	Type 1 diabetes mellitus with diabetic cataract
308504	C109E12	Type 2 diabetes mellitus with diabetic cataract
309757	C108D11	Type I diabetes mellitus with nephropathy
308851	C109B11	Type II diabetes mellitus with polyneuropathy

Medcodes	Read code	Description
341264	C10F200	Type 2 diabetes mellitus with neurological complications
346403	C10EB00	Type 1 diabetes mellitus with mononeuropathy
309007	C109H12	Type 2 diabetes mellitus with neuropathic arthropathy
333002	F420800	High risk non proliferative diabetic retinopathy
242647	C108700	Insulin dependent diabetes mellitus with retinopathy
341800	C10EC00	Type 1 diabetes mellitus with polyneuropathy
219965	250 M	Charcot's Diabetic Arthropathy
261411	F374z00	Polyneuropathy in disease NOS
309758	C109112	Type 2 diabetes mellitus with ophthalmic complications
306133	250 N	Diabetic Nephropathy
309796	2BBL.00	O/E - diabetic maculopathy present both eyes
331538	C109012	Type 2 diabetes mellitus with renal complications
242648	C109000	Non-insulin-dependent diabetes mellitus with renal comps
206458	C109200	Non-insulin-dependent diabetes mellitus with neuro comps
341701	F420700	High risk proliferative diabetic retinopathy
215440	C106.12	Diabetes mellitus with neuropathy
342045	2BBS.00	O/E - left eye preproliferative diabetic retinopathy
340163	C109E00	Non-insulin depend diabetes mellitus with diabetic cataract
340357	C10F600	Type 2 diabetes mellitus with retinopathy
297737	C108C00	Insulin dependent diabetes mellitus with polyneuropathy
336008	C108211	Type I diabetes mellitus with neurological complications
340987	C10E000	Type 1 diabetes mellitus with renal complications
310061	C109H11	Type II diabetes mellitus with neuropathic arthropathy
297731	C106.00	Diabetes mellitus with neurological manifestation
308830	C109611	Type II diabetes mellitus with retinopathy
233989	F372.11	Diabetic polyneuropathy
344951	2BBk.00	O/E - right eye stable treated prolif diabetic retinopathy
243072	F420z00	Diabetic retinopathy NOS
288458	C105z00	Diabetes mellitus NOS with ophthalmic manifestation
233604	C105100	Diabetes mellitus, adult onset, ophthalmic manifestation
340333	C10ED00	Type 1 diabetes mellitus with nephropathy
308871	C108F11	Type I diabetes mellitus with diabetic cataract
331568	C108011	Type I diabetes mellitus with renal complications
346291	C10FC11	Type II diabetes mellitus with nephropathy

1	
1	
2	
2	
3	
4	
5	
6	
7	
8	
-	
9	
1	0
1	1
1	2
1	2 3
1	3
1	4
	4
1	5
1	6
_	7
1	/
1	8
1	9
2	0
2	0
2	1
~	
2	2
~	3
- 2	3
2	4
2	5
2	С
2	6
2	7
2	8
- 2	9
3	0
2	1
С	
3	2
J	2
3	3
3	4
- 3	5
2	6
3	o
2	7
٦	8
3	9
4	0
	1
-	
4	2
4	3
4	4
	F
4	5
л	6
4	7
4	8
4	9
F	0
5	1
5	2
5	3
5	4
5	5
-	-
5	6
5	7
5	8
F	0
С	9

340162 340507 252180	C108012 C109A11	Type 1 diabetes mellitus with renal complications
	C100A11	
252180	CIUSATI	Type II diabetes mellitus with mononeuropathy
	F381311	Diabetic amyotrophy
308872	C109C11	Type II diabetes mellitus with nephropathy
347405	C10EQ00	Type 1 diabetes mellitus with gastroparesis
279345	C109A00	Non-insulin dependent diabetes mellitus with mononeuropathy
308715	C108F00	Insulin dependent diabetes mellitus with diabetic cataract
206453	C104.11	Diabetic nephropathy
342033	2BBR.00	O/E - right eye preproliferative diabetic retinopathy
333621	C108J12	Type 1 diabetes mellitus with neuropathic arthropathy
347771	C10FB11	Type II diabetes mellitus with polyneuropathy
297733	C106y00	Other specified diabetes mellitus with neurological comps
256383	250 LK	Kimmelstiel- Wilson Disease/Syndrome
340257	C10FH00	Type 2 diabetes mellitus with neuropathic arthropathy
341459	C10F000	Type 2 diabetes mellitus with renal complications
297730	C105.00	Diabetes mellitus with ophthalmic manifestation
261428	F420100	Proliferative diabetic retinopathy
333249	C109211	Type II diabetes mellitus with neurological complications
261003	C104z00	Diabetes mellitis with nephropathy NOS
341221	C10E100	Type 1 diabetes mellitus with ophthalmic complications

10. Read codes to identify dyspnoea

Medcode	Read_code	Description
3092	R060A00	[D]Dyspnoea
6434	1736.00	Paroxysmal nocturnal dyspnoea
7000	2322.00	O/E - dyspnoea
18116	173D.00	Nocturnal dyspnoea
53771	173C.11	Dyspnoea on exertion

11. Read codes to identify ventilator requirement

Medcode	Read_code	Description
87337	7M36300	Ventilatory support

Medcode	Read code	Description
1001	H300	Chronic obstructive pulmonary disease
9520	66YB.00	Chronic obstructive pulmonary disease monitoring
9876	H3800	Severe chronic obstructive pulmonary disease
10802	H3700	Moderate chronic obstructive pulmonary disease
10863	H3600	Mild chronic obstructive pulmonary disease
11287	66YM.00	Chronic obstructive pulmonary disease annual review
18621	66YL.00	Chronic obstructive pulmonary disease follow-up
37247	H3z11	Chronic obstructive pulmonary disease NOS
45770	66Yg.00	Chronic obstructive pulmonary disease disturbs sleep
45771	66Yh.00	Chronic obstructive pulmonary disease does not disturb sleep
65733	Hyu3100	[X]Other specified chronic obstructive pulmonary disease
67040	H3y11	Other specified chronic obstructive pulmonary disease
93568	H3900	Very severe chronic obstructive pulmonary disease
102685	66YB000	Chronic obstructive pulmonary disease 3 monthly review
103007	66YB100	Chronic obstructive pulmonary disease 6 monthly review
103494	14B3.12	History of chronic obstructive pulmonary disease
104985	9NgP.00	On chronic obstructive pulmonary disease supprtv cre pathway
105457	8CMW500	Chronic obstructive pulmonary disease care pathway

12. Read codes to identify COPD

13. Read codes to identify heart failure

Medcode	Read_code	Description
398	G580.00	Congestive heart failure
2062	G5800	Heart failure
4024	G58z.00	Heart failure NOS
9913	10100	Heart failure confirmed
10079	G580.12	Right heart failure
15058	14A6.00	H/O: heart failure
17851	8HBE.00	Heart failure follow-up
21837	G232.00	Hypertensive heart&renal dis wth (congestive) heart failure
23707	G580000	Acute congestive heart failure
27964	G582.00	Acute heart failure
28684	G233.00	Hypertensive heart and renal disease with renal failure
30779	662W.00	Heart failure annual review
32671	G580100	Chronic congestive heart failure

4
5
6
7
8
9
10 11
12
13
14
15
16
16 17 18
18
19 20
20
21
20 21 22 23 24 25 26 27 28 29 30
25
24 25 26 27 28
26
27
28
29 30
30
31
32 33
33 34
35
30
38
39
35 36 37 38 39 40
41
42
43
44
45
46
47
48 49
49 50
51
52
53
54
55
56
57
58 59
59 60
00

Medcode	Read_code	Description
32898	8H2S.00	Admit heart failure emergency
32911	9Or00	Heart failure monitoring administration
32945	8CL3.00	Heart failure care plan discussed with patient
46912	14AM.00	H/O: Heart failure in last year
60099	67D4.00	Heart failure information given to patient
66306	SP11111	Heart failure as a complication of care
69062	9N6T.00	Referred by heart failure nurse specialist
71235	8Hk0.00	Referred to heart failure education group
83502	662p.00	Heart failure 6 month review
94870	G580400	Congestive heart failure due to valvular disease
96799	G5y4z00	Post cardiac operation heart failure NOS
101137	G583.11	HFNEF - heart failure with normal ejection fraction
101138	G583.00	Heart failure with normal ejection fraction
103732	8CMK.00	Has heart failure management plan
105002	679W100	Education about deteriorating heart failure
105542	8CeC.00	Preferred place of care for next exacerbation heart failure
106198	661M500	Heart failure self-management plan agreed
4. Read codes	s to identify renal fail	lure
Medcode	Read_code	Description
350	K0600	Renal failure unspecified

Medcode	Read_code	Description
350	K0600	Renal failure unspecified
512	K0500	Chronic renal failure
2266	K0400	Acute renal failure
6712	K050.00	End stage renal failure
11554	SP15400	Renal failure as a complication of care
11773	7L1A.11	Dialysis for renal failure
15945	SK05.00	Renal failure following crush syndrome
16929	D215.00	Anaemia secondary to renal failure
24292	SP15412	Post operative renal failure
24676	SK08.00	Acute renal failure due to rhabdomyolysis
25394	D215000	Anaemia secondary to chronic renal failure
25582	K04z.00	Acute renal failure NOS
28684	G233.00	Hypertensive heart and renal disease with renal failure
31549	7L1A.00	Compensation for renal failure
32423	G222.00	Hypertensive renal disease with renal failure

Medcode	Read_code	Description
35235	K04y.00	Other acute renal failure
48022	7L1Ay00	Other specified compensation for renal failure
53852	K0512	End stage renal failure
53940	Kyu2100	[X]Other chronic renal failure
53945	Kyu2000	[X]Other acute renal failure
56760	7L1B.00	Placement ambulatory apparatus compensation renal failure
57919	K043.00	Acute drug-induced renal failure
59194	7L1By00	Placement ambulatory apparatus- compensate renal failure OS
61930	Kyu2.00	[X]Renal failure
63277	L393.00	Acute renal failure following labour and delivery
63760	SK05.11	Renal failure after crushing
64636	7L1Az00	Compensation for renal failure NOS
65089	7L1Cz00	Placement other apparatus- compensate for renal failure NOS
71314	L093.00	Renal failure following abortive pregnancy
72458	L393000	Post-delivery acute renal failure unspecified
83513	7L1C.00	Placement other apparatus for compensation for renal failure
96179	L393100	Post-delivery acute renal failure - delivered with p/n prob
97198	K044.00	Acute renal failure due to urinary obstruction
100205	K0E00	Acute-on-chronic renal failure
101666	L070300	Unspecified abortion with renal failure
104857	K043000	Acute renal failure due to ACE inhibitor
105209	K045.00	Acute renal failure due to non-traumatic rhabdomyolysis
105267	K04B.00	Acute renal failure due to traumatic rhabdomyolysis
105739	K0411	ARF - Acute renal failure
106860	C353600	Renal failure-associated hyperphosphataemia
107241	K043400	Acute renal failure induced by non-steroid anti-inflamm drug

15. Read codes to identify hypertension

Medcode	Read_code	Description
799	G2000	Essential hypertension
1894	G201.00	Benign essential hypertension
2666	14A2.00	H/O: hypertension
3425	6620.00	On treatment for hypertension
3712	G20z.11	Hypertension NOS
4372	G202.00	Systolic hypertension

Medcode	Read_code	Description
7329	G2400	Secondary hypertension
10818	G20z.00	Essential hypertension NOS
12680	8CR4.00	Hypertension clinical management plan
15377	G200.00	Malignant essential hypertension
16059	G24z.00	Secondary hypertension NOS
16565	6627	Good hypertension control
18482	662c.00	Hypertension six month review
18590	662b.00	Moderate hypertension control
19070	662d.00	Hypertension annual review
21826	662F.00	Hypertension treatm. started
25371	G241000	Secondary benign renovascular hypertension
27511	6628	Poor hypertension control
30776	6629	Hypertension:follow-up default
31387	G24z000	Secondary renovascular hypertension NOS
31755	G240.00	Secondary malignant hypertension
34744	G244.00	Hypertension secondary to endocrine disorders
42229	G24zz00	Secondary hypertension NOS
44549	L128.00	Pre-exist hypertension compl preg childbirth and puerperium
51635	G241z00	Secondary benign hypertension NOS
57288	G241.00	Secondary benign hypertension
59383	G240000	Secondary malignant renovascular hypertension
73293	G240z00	Secondary malignant hypertension NOS
83473	G203.00	Diastolic hypertension
85944	7Q01.00	High cost hypertension drugs
97533	Gyu2100	[X]Hypertension secondary to other renal disorders
98230	67H8.00	Lifestyle advice regarding hypertension
101649	7Q01y00	Other specified high cost hypertension drugs
102406	662P000	Hypertension 9 month review
102458	Gyu2000	[X]Other secondary hypertension
105274	G2800	Stage 2 hypertension (NICE - Nat Ins for Hth Clin Excl 2011)
105316	G2511	Stage 1 hypertension
105371	G2500	Stage 1 hypertension (NICE - Nat Ins for Hth Clin Excl 2011
105480	G2700	Hypertension resistant to drug therapy
105487	G2611	Severe hypertension

Medcode	Read_code	Description
105989	G2600	Severe hypertension (Nat Inst for Health Clinical Ex 2011)
61166	G21z000	Hypertensive heart disease NOS without CCF
61660	G211000	Benign hypertensive heart disease without CCF
95334	G210000	Malignant hypertensive heart disease without CCF

0.000		
95334	G210000	Malignant hypertensive heart disease without CCF
16. Codoo to i	dentify onen and ala	
To. Codes to I	dentity open and clos	sed tibial shaft fracture
Medcode	Read_code	Description
20678	S333200	Open fracture of tibia and fibula, shaft
28068	S333.00	Open fracture of tibia/fibula, shaft
28118	S333000	Open fracture shaft of tibia
28198	S333z00	Open fracture of tibia and fibula, shaft, NOS
28233	S33y.00	Open fracture of tibia and fibula, unspecified part, NOS
29084	S33y200	Open fracture of tibia and fibula, unspecified part
29164	S33y000	Open fracture of tibia, unspecified part, NOS
Medcode	Read_code	Description
971	S33x000	Closed fracture of tibia, unspecified part, NOS
4572	S33x200	Closed fracture of tibia and fibula, unspecified part
29109	S33x.00	Closed fracture of tibia and fibula, unspecified part, NOS

Medcode	Read_code	Description
971	S33x000	Closed fracture of tibia, unspecified part, NOS
4572	S33x200	Closed fracture of tibia and fibula, unspecified part
29109	S33x.00	Closed fracture of tibia and fibula, unspecified part, NOS
29121	S332.00	Closed fracture of tibia/fibula, shaft
33520	S332200	Closed fracture of tibia and fibula, shaft
34021	S332000	Closed fracture shaft of tibia
41971	S33xz00	Closed fracture of tibia and fibula, unspecified part, NOS
55464	S332z00	Closed fracture of tibia and fibula, shaft, NOS
	·	

OPCS-4	Description	Open/closed fracture
S571	Debridement of skin NEC	Open
W332	Debridement of open fracture of bone	Open
Т963	Debridement of soft tissue NEC	Open
W336	Debridement of bone NEC	Open

ICD-10	Description	Open/closed fracture
T14.1	Open wound of unspecified body region	Open
T01.3	Open wounds involving multiple regions of lower limb(s)	Open
S81.7	Multiple open wounds of lower leg	Open

ICD-10	Description	Open/closed fracture
S81.8	Open wound of other parts of lower leg	Open
S81.9	Open wound of lower leg, part unspecified	Open
T93.0	Sequelae of open wound of lower limb	Open
T93.2	Sequelae of other fractures of lower limb	Open
T01.9	Multiple open wounds, unspecified	Open
T13.1	Open wound of lower limb, level unspecified	Open
T01.8	Open wounds involving other combinations of body regions	Open
T94.0	Sequelae of injuries involving multiple body regions	Open
T94.1	Sequelae of injuries, not specified by body region	Open
T12.1	Fracture of lower limb, level unspecified, open	Open

17. Read codes to identify Charlson comorbidity index



Microsoft Excel 2003 Worksheet

18. OPCS Codes to identify reoperations

OPCS-4	Description
W242	Closed reduction of fracture of long bone and rigid internal fixation NEC
0172	Remanipulation of fracture of long bone and rigid internal fixation NEC
0173	Remanipulation of fracture of long bone and flexible internal fixation HFQ
O175	Remanipulation of fragment of bone and fixation using screw
O178	Other specified secondary closed reduction of fracture of bone and internal fixation
O179	Unspecified secondary closed reduction of fracture of bone and internal fixation
W231	Secondary open reduction of fracture of bone and intramedullary fixation HFQ
W232	Secondary open reduction of fracture of bone and extramedullary fixation HFQ
W236	Secondary open reduction of fracture of bone and internal fixation HFQ
W248	Other specified closed reduction of fracture of bone and internal fixation
W249	Unspecified closed reduction of fracture of bone and internal fixation
W281	Application of internal fixation to bone NEC
W282	Adjustment to internal fixation of bone NEC
W283	Removal of internal fixation from bone NEC
W288	Other specified other internal fixation of bone
W289	Unspecified other internal fixation of bone

W253Remanipulation of fracture of bone and external fixation HFQW258Other specified closed reduction of fracture of bone and external fixationW259Unspecified closed reduction of fracture of bone and external fixationW301Application of external fixation to bone NECW302Adjustment to external fixation of bone NECW303Removal of external fixation from bone NECW304Application of external ring fixation to bone NECW308Other specified other external fixation of boneW309Unspecified other external fixation of boneW309Unspecified other external fixation of boneW32Other graft of bone
W253Remanipulation of fracture of bone and external fixation HFQW258Other specified closed reduction of fracture of bone and external fixationW259Unspecified closed reduction of fracture of bone and external fixationW301Application of external fixation to bone NECW302Adjustment to external fixation of bone NECW303Removal of external fixation from bone NECW304Application of external ring fixation to bone NECW308Other specified other external fixation of boneW309Unspecified other external fixation of boneW303Removal of implanted substance from boneW32Other graft of bone
W258Other specified closed reduction of fracture of bone and external fixationW259Unspecified closed reduction of fracture of bone and external fixationW301Application of external fixation to bone NECW302Adjustment to external fixation of bone NECW303Removal of external fixation from bone NECW304Application of external ring fixation to bone NECW308Other specified other external fixation of boneW309Unspecified other external fixation of boneW303Removal of implanted substance from boneW32Other graft of bone
W259Unspecified closed reduction of fracture of bone and external fixationW301Application of external fixation to bone NECW302Adjustment to external fixation of bone NECW303Removal of external fixation from bone NECW304Application of external ring fixation to bone NECW308Other specified other external fixation of boneW309Unspecified other external fixation of boneW35.3Removal of implanted substance from boneW32Other graft of bone
W301Application of external fixation to bone NECW302Adjustment to external fixation of bone NECW303Removal of external fixation from bone NECW304Application of external ring fixation to bone NECW308Other specified other external fixation of boneW309Unspecified other external fixation of boneW35.3Removal of implanted substance from boneW32Other graft of bone
W302Adjustment to external fixation of bone NECW303Removal of external fixation from bone NECW304Application of external ring fixation to bone NECW308Other specified other external fixation of boneW309Unspecified other external fixation of boneW35.3Removal of implanted substance from boneW32Other graft of bone
W303Removal of external fixation from bone NECW304Application of external ring fixation to bone NECW308Other specified other external fixation of boneW309Unspecified other external fixation of boneW35.3Removal of implanted substance from boneW32Other graft of bone
W304Application of external ring fixation to bone NECW308Other specified other external fixation of boneW309Unspecified other external fixation of boneW35.3Removal of implanted substance from boneW32Other graft of bone
W308Other specified other external fixation of boneW309Unspecified other external fixation of boneW35.3Removal of implanted substance from boneW32Other graft of bone
W309Unspecified other external fixation of boneW35.3Removal of implanted substance from boneW32Other graft of bone
W35.3 Removal of implanted substance from bone W32 Other graft of bone
W32 Other graft of bone
W32.1 Prepared graft of bone
W32.2 Allograft of bone NEC
W32.3 Xenograft of bone
W32.4 Synthetic graft of bone
W32.5 Cancellous chip allograft of bone
W32.8 Other specified other graft of bone
W32.9 Unspecified other graft of bone
S31.3 Revision of flap of skin NEC

Additional file 2: Baseline and results at all time points

Table C1. Patient demographic and clinical characteristics at all time points

	All	Ir	ndex stay			30 days			90 days			1 year			2 years	
	enrolled patients (N=805)	No infection (N=775)	Infection (N=30)	p- value ^a	No infection (N=736)	Infection (N=64)	p- value ^a	No infection (N=699)	Infection (N=71)	p- value ^a	No infection (N=606)	Infection (N=80)	p- value ^a	No infection (N=509)	Infection (N=79)	p- value ^a
0 Demographics																
Age (years), mean (SD)	40.8 (17.2)	40.7 (16.8)	43.0 (23.9)	0.61	40.5 (16.9)	44.0 (19.1)	0.17	40.7 (16.9)	43.8 (19.1)	0.20	40.7 (16.8)	45.1 (19.1)	0.06	40.5 (16.4)	46.4 (20.0)	0.02
³ Gender, n (%) 4 Male	590 (73.3)	569 (73.4)	21 (70.0)	0.84	539 (73.2)	47 (73.4)	1.00	508 (72.7)	52 (73.2)	1.00	438 (72.3)	59 (73.8)	0.89	368 (72.3)	57 (72.2)	1.00
⁵ Clinical history/	comorbiditi	es														1
6 Charlson score, 7 mean (SD)	0.04 (0.23)	0.04 (0.24)	0.00 (0.00)	<0.001	0.04 (0.24)	0.02 (0.12)	0.22	0.04 (0.3)	0.01 (0.12)	0.13	0.04 (0.24)	0.01 (0.11)	0.11	0.03 (0.22)	0.01 (0.11)	0.25
8 9 Smoker, n (%)	256 (31.8)	247 (31.9)	9 (30.0)	0.99	239 (32.5)	17 (26.6)	0.41	233 (33.3)	18 (25.4)	0.22	202 (33.3)	20 (25.0)	0.17	160 (31.4)	19 (24.1)	0.23
Diabetes, n (%)	27 (3.4)	27 (3.5)	0 (0.0)	0.62	26 (3.5)	1 (1.6)	0.72	26 (3.7)	1 (1.4)	0.50	21 (3.5)	3 (3.8)	0.75	15 (3.0)	3 (3.8)	0.72
1 COPD, n (%)	8 (1.0)	8 (1.0)	0 (0.0)	1.00	8 (1.1)	0 (0.0)	1.00	7 (1.0)	0 (0.0)	1.00	6 (1.0)	1 (1.3)	0.58	3 (0.6)	1 (1.3)	0.44
Congestive heart failure, n	2 (0.3)	2 (0.3)	0 (0.0)	1.00	2 (0.3)	0 (0.0)	1.00	1 (0.1)	0 (0.0)	1.00	0 (0.0)	0 (0.0)	NA	0 (0.0)	0 (0.0)	NA
Hypertension, n (%)	12 (1.5)	12 (1.6)	0 (0.0)	1.00	12 (1.6)	0 (0.0)	0.61	12 (1.7)	0 (0.0)	0.62	10 (1.7)	0 (0.0)	0.62	7 (1.4)	0 (0.0)	0.60
Compartment syndrome, n (%)	27 (3.4)	22 (2.8)	5 (16.7)	0.00	19 (2.6)	8 (12.5)	<0.05	18 (2.6)	8 (11.3)	<0.05	17 (2.8)	9 (11.2)	0.00	15 (3.0)	8 (10.1)	<0.05
⁸ Index episode											6					
29 Year of 60 intramedullary 11 nailing, mean 52 (SD)	2009 (3.6)	2009 (3.6)	2009 (3.6)	0.72	2009 (3.6)	2009 (3.6)	0.99	2009 (3.6)	2009 (3.6)	0.74	2008 (3.4)	2008 (3.4)	0.99	2008 (3.1)	2008 (3.1)	0.85
3 Inpatient waiting 4 time (days) for 5 surgery, mean 6 (SD)	1.4 (2.4)	1.4 (2.4)	0.7 (2.4)	0.14	1.4 (2.4)	0.7 (1.7)	<0.05	1.4 (2.5)	0.8 (1.7)	<0.05	1.4 (2.4)	0.6 (1.0)	<0.001	1.4 (2.2)	0.6 (1.0)	<0.001
Fracture type, n				<0.001			<0.001			<0.001			<0.001			<0.001
Closed fracture	663 (82.4)	648 (83.6)	15 (50.0)		624 (84.8)	35 (54.7)		595 (85.1)	42 (59.2)		524 (86.5)	49 (61.3)		438 (86.1)	52 (65.8)	

preserved ±1 incution (N=75) infection (N=75)	2 years				1 year			90 days			30 days			dex stay	In		
prescription for antibilities in the 12 months prior by charge of the stay, n (%) 1 (2.0) 15 (1.9) 1 (3.3) 0.46 15 (2.0) 1 (1.6) 1.00 15 (2.2) 1 (1.4) 1.00 11 (1.8) 2 (2.5) 0.66 8 (1.6) Prescription for proteins in the 12 months prior (%) Abbreviations: COPD, chronic obstructive pulmonary disease; NA, not applicable; SD, standard deviation. * No infection versus infection, t-tests were performed for companison of continuous variables and chi-squared (or Fisher exact tests when r <5) for comparison of categorical variables.	Infection p- (N=79) value	ection				infection			infection			infection	•		infection	patients	
Received 21 16 (2.0) 15 (1.9) 1 (3.3) 0.46 15 (2.0) 1 (1.5) 1.00 15 (2.2) 1 (1.4) 1.00 11 (1.8) 2 (2.5) 0.66 8 (1.6) poloids in the 12 months pior to in the 12 months pior to in the 2 in the 3 in the 2 in the 3 in the	5 (6.3) 1.00	; (6.9)	3	0.51	4 (5.0)	47 (7.8)	0.36	3 (4.2)	56 (8.0)	0.47	3 (4.7)	57 (7.7)	0.16	0 (0.0)	60 (7.7)	60 (7.5)	prescription for antibiotics in the 12 months prior to the index stay, n (%)
 ^a No infection versus infection, t-tests were performed for comparison of continuous variables and chi-squared (or Fisher exact tests when r (5) for comparison of categorical variables. 	2 (2.5) 0.63	(1.6)	3	0.66	2 (2.5)	11 (1.8)	1.00	1 (1.4)	15 (2.2)	1.00	1 (1.6)	15 (2.0)	0.46	1 (3.3)	15 (1.9)	16 (2.0)	Received ≥1 prescription for opioids in the 12 months prior to the index stay, n
^a No infection versus infection, t-tests were performed for comparison of continuous variables and chi-squared (or Fisher exact tests when r <5) for comparison of categorical variables.	I	I				ion.	d devia	SD, standai	pplicable; S	A, not a	disease; N	oulmonary	ructive p	ronic obst	COPD, chi	eviations:	
	las	/hen n v	sts v	xact tes	or Fisher ex	squared (c	and chi-	variables	continuous	rison of	for compa	nerformed	ts were	ction t-tes	ersus infer	infection v	^a No
			, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			Squaroa (e		Valiabioo			lor compa	•					
													ariables.	egorical va	son of cate	or compari	<5) fe
For poor review only http://braisman.http://braism						c vlateral	uidalia	ito /obout/	o broi corci	la na i a ra -		or routour -	Former				
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml						s.xntml	juideline	site/about/g	n.omj.com/	omjope	niy - http://	er review o	For pe				

1 2 3	Tab
4	
5	Tim
6	
7	
8 9	Inde
9 10	
11	
12	(N il infe
13	"""
14	
15	
16 17	
17	
19	
20	
21	
22	
23	
24	
25 26	
20 27	
28	
29	
30	
31	
32	
33 34	
34 35	
36	
37	
38	
39	
40	
41	
42 43	
43 44	
44 45	
46	
47	

Table D1. Comparative results at all time points

Time period	Endpoint	Bivariate ana	alysis, mean (SD)		analysis, mean % Cl)	Absolute difference (multivariate analysis)
		Infection	No infection	Infection	No infection	
Index stay	Total costs (£)	11,695 (6,553)	6,669 (3,133; p<0.001)	10,384 (8,900, 12,116)	6,603 (6,411, 6,802)	3,781 p<0.001
(N infection = 30; N no infection = 775)	Inpatient costs (£)	11,695 (6,553)	6,669 (3,133; p<0.001)	10,384 (8,900, 12,116)	6,603 (6,411, 6,802)	3,781 p<0.001
	LOS (days)	22.6 (20.0)	9.7 (12.1; p<0.001)	17.6 (13.0, 23.7)	8.5 (8.0, 9.0)	9.05 p<0.001
	ICU LOS (days)	1.5 (8.2)	0.1 (1.1; p=0.53)	0.1 (0.1, 0.2)	0.0 (0.0, 0.01)	0.115 p<0.001
	Reoperations (number)	0.3 (0.8)	0.0 (0.1; p<0.001)	0.1 (0.0, 0.2)	0.0 (0.0, 0.0)	0.070 p<0.001
	Reoperations (rate, %)	13.3	1.3 (p<0.001)	9.7 (3.1, 26.3)	1.1 (0.5, 2.1)	8.6 p<0.001

Time period	Endpoint	Bivariate ana	llysis, mean (SD)	Multivariate a (95%	Absolute difference (multivariate analysis)	
		Infection	No infection	Infection	No infection	-
Index stay + 30 days post-discharge	Total costs (£)	12,673 (7,345)	7,089 (3,588; p<0.001)	11,257 (10,045, 12,615)	7,017 (6,792, 7,248)	4,241 p<0.001
(N infection = 64; N no	Inpatient costs (£)	12,367 (7,290)	6,829 (3,397; p<0.001)	11,008 (9,818, 12,343)	6,768 (6,551, 6,993)	4,240 p<0.001
infection = 736)	Hospital outpatient/ambulatory costs (£)	215 (116)	155 (94; p=0.4)	245 (145, 345)	152 (125, 179)	93 p=0.07
	Primary care costs (£)	289 (555)	254 (673, p=0.24)	243 (139, 426)	205 (175, 241)	38 p=0.57
	LOS (days)	19.3 (19.2)	10.1 (12.2; p<0.001)	15.0 (12.1, 18.6)	8.9 (8.4, 9.5)	6.1 p<0.001
	ICU LOS (days)	0.7 (5.6)	0.1 (1.1; p=0.4)	0.1 (0.0, 0.1)	0.0 (0.0, 0.0)	0.0 p<0.001
	Readmissions (number)	0.6 (0.6)	0.1 (0.3; p<0.001)	0.5 (0.4, 0.7)	0.1 (0.1, 0.1)	0.4 p<0.001
	Readmissions (rate, %)	48.4	7.6 (p<0.001)	44.1 (31.5, 57.5)	7.1 (5.4, 9.2)	37.0 p<0.001
	Reoperations (number)	0.2 (0.7)	0.0 (0.1; p<0.001)	0.1 (0.1, 0.2)	0.0 (0.0, 0.0)	0.1 p<0.001
	Reoperations (rate, %)	14.1	1.6 (p<0.001)	11.5 (5.4, 22.9)	1.3 (0.7, 2.5)	10.2 p<0.001
	Amputation (rate, %)	3.1	0.1 (p<0.01)	-	Not feasibl	e
	Hospital outpatient/ambulatory referrals (number)	1.6 (0.9)	1.2 (0.5; p=0.28)	1.6 (1.1, 2.2)	1.21 (1.0, 1.4)	0.45 p=0.13
Index stay + 90 days post-discharge	Total costs (£)	13,621 (7,827)	7,527 (4,326; p<0.001)	11,949 (10,634,13,427)	7,423 (7,160, 7,696)	4,526 p<0.001
(N infection = 71; N no	Inpatient costs (£)	13,154 (7,673)	7,157 (4,111; p<0.001)	11,532 (10,246,12,979)	7,072 (6,818, 7,336)	4,459 p<0.001

Page 59 of 67

Time period	Endpoint	Bivariate ana	alysis, mean (SD)	Multivariate analysis, mean (95% CI)		Absolute difference (multivariate analysis)	
		Infection	No infection	Infection	No infection		
infection = 699)	Hospital outpatient/ambulatory costs (£)	183 (87)	171 (135; p=0.53)	194 (125, 264)	170 (141, 198)	25 p=0.515	
	Primary care costs (£)	436 (637)	353 (737; p<0.05)	428 (290, 630)	299 (264, 338)	129 p=0.084	
	LOS (days)	21.7 (21.5)	11.1 (14.6 p<0.001)	16.4 (13.2, 20.4)	9.6 (9.0, 10.3)	6.8 p<0.001	
	ICU LOS (days)	0.7 (5.3)	0.1 (1.2; p=0.576)	0.0 (0.0, 0.1)	0.0 (0.0, 0.0)	0.0 p<0.001	
	Readmissions (number)	0.8 (0.8)	0.2 (0.6; p<0.001)	0.7 (0.5, 0.9)	0.2 (0.2, 0.2)	0.5 p<0.001	
	Readmissions (rate, %)	57.7	17.2 (p<0.001)	5.4 (41.5, 65.9)	16.5 (13.9, 19.5)	37.4 p<0.001	
	Reoperations (number)	0.3 (0.7)	0.1 (0.3; p<0.001)	0.2 (0.1, 0.3)	0.1 (0.0, 0.1)	0.1 p=0.001	
	Reoperations (rate, %)	18.3	6.0 (p<0.001)	14.3 (7.7, 25.0)	5.4 (3.9, 7.4)	9.0 p<0.05	
	Amputation (rate, %)	2.8	0.1 (p<0.05)	4	Not feasible	e	
	Hospital outpatient/ambulatory referrals (number)	1.2 (0.6)	1.4 (0.9; p=0.92)	1.3 (0.9, 1.7)	1.4 (1.2, 1.5)	0.0 p=0.835	
Index stay + 1 year post-discharge	Total costs (£)	16,800 (12,663)	8,435 (5,330; p<0.001)	14,756 (13,123, 16,593)	8,279 (7,946, 8,626)	6,478 p<0.001	
(N infection = 80; N no infection = 606)	Inpatient costs (£)	15,580 (11,872)	7,746 (5,060; p<0.001)	13,672 (12,122, 15,420)	7,616 (7,301, 7,944)	6,056 p<0.001	
	Hospital outpatient/ambulatory costs (£)	250 (251)	239 (218; p=0.77)	220 (151, 288)	244 (211, 277)	25 p=0.516	
	Primary care costs (£)	1,139 (1,657)	630 (903; p<0.001)	1,017 (769, 1,344)	551 (498, 609)	466 p<0.001	

Time period	Endpoint	Bivariate ana	alysis, mean (SD)		analysis, mean % Cl)	Absolute difference (multivariate analysis)	
		Infection	No infection	Infection	No infection		
	LOS (days)	28.5 (33.3)	12.6 (21.3; p<0.001)	21.9 (17.3, 27.7)	10.5 (9.7, 11.4)	11.4 p<0.001	
	ICU LOS (days)	0.2 (1.5)	0.1 (1.1; p=0.758)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 p=0.914	
	Readmissions (number)	1.5 (1.5)	0.5 (0.9; p<0.001)	1.5 (1.2, 1.8)	0.5 (0.4, 0.6)	1.0 p<0.001	
	Readmissions (rate, %)	75	36 (p<0.001)	74.4 (63.4, 83.0)	35.9 (32.1, 39.9)	38.5 p<0.001	
	Reoperations (number)	0.6 (1.0)	0.2 (0.5; p<0.001)	0.6 (0.5, 0.8)	0.2 (0.2, 0.3)	0.4 p<0.001	
	Reoperations (rate, %)	37.5	21.3 (p<0.01)	38.6 (28.3, 50.0)	20.3 (17.2, 23.8)	18.2 p<0.001	
	Amputation (rate, %)	2.5	0.2 (p<0.05)		Not feasible	e	
	Hospital outpatient/ambulatory referrals (number)	1.8 (1.6)	1.8 (1.5; p=0.66)	1.7 (1.2, 2.1)	1.8 (1.6, 2.1)	0.2 p=0.44	
Index stay + 2 years post-discharge	Total costs (£)	18,779 (14,929)	9,611 (6,284; p<0.001)	16,626 (14,664, 18,849)	9,439 (8,998, 9,901)	7,187 p<0.001	
(N infection = 79; N no	Inpatient costs (£)	16,900 (13,720)	8,573 (5,729; p<0.001)	14,898 (13,106, 16,935)	8,447 (8,044, 8,871)	6,451 p<0.001	
infection = 509)	Hospital outpatient/ambulatory costs (£)	282 (296)	275 (265; p=0.893)	264 (189, 338)	277 (243, 310)	13 p=0.747	
	Primary care costs (£)	1,758 (2,437)	929 (1,179; p<0.01)	1,487 (1,149, 1,924)	821 (742, 907)	666 p<0.001	
	LOS (days)	31.5 (38.1)	13.4 (22.6; p<0.001)	24.6 (19.6, 30.8)	11.3 (10.4, 12.3)	13.3 p<0.001	
	ICU LOS (days)	0.2 (1.5)	0.1 (1.2; p=0.24)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 p=0.20	

Page 61 of 67

Time period Endpoint	Endpoint	Bivariate analysis, mean (SD)		Multivariate analysis, mean (95% Cl)		Absolute difference (multivariate analysis)	
		Infection	No infection	Infection	No infection		
	Readmissions (number)	2.1 (2.3)	1.0 (1.5; p<0.001)	2.2 (1.9, 2.6)	0.9 (0.8, 1.0)	1.3 p<0.001	
	Readmissions (rate, %)	77.2	51.1 (p<0.001)	77.6 (67.0, 85.6)	51.4 (46.9, 56.8)	26.3 p<0.001	
	Reoperations (number)	0.8 (1.1)	0.4 (0.7; p<0.01)	0.8 (0.6, 1.0)	0.4 (0.3, 0.4)	0.4 p<0.001	
	Reoperations (rate, %)	46.8	32.4 (p<0.05)	49.0 (37.7, 60.3)	31.2 (27.2, 35.5)	17.7 p<0.05	
	Amputation (rate, %)	3.8	0.2 (p<0.01)		Not feasible	e	
	Hospital outpatient/ambulatory referrals (number)	2.0 (2.0)	2.1 (1.9; p=0.55)	2.0 (1.5, 2.5)	2.1 (1.8, 2.3)	0.1 p=0.82	

Abbreviations: CI, confidence interval; ICU, intensive care unit; LOS, length of stay; NA, not applicable; SD, standard deviation.

Table D2. 1 year cost breakdown (£) - inpatient setting

Endpoint	Bivariate analysis	s, mean (SD)
	Infection	No infection
Total inpatient costs	15,580 (11,872)	7,746 (5,060)
HRG costs	15,488 (11,743)	7,702 (4,985)
Unbundled HRG costs	36 (116)	16 (72)
Critical care costs	56 (381)	26 (208)
Specialised care costs	0 (0)	2 (42)

Abbreviations: HRG, Healthcare Resource Group; SD, standard deviation.

Table D3. 1 year healthcare resource use and cost breakdown – primary care

Endpoint	Bivariate analysis, mean (SD)					
	Infection	No infection				
Costs (£)	· · ·					
Total primary care costs	1,139 (1,657)	630 (903)				
Total drug costs	368 (1,031)	198 (681)				
Total test costs	147 (247)	95 (186)				
Imaging test costs	27 (71)	25 (72)				
Total consultation costs	625 (721)	338 (334)				
GP	322 (317)	212 (225)				
Nurse	140 (362)	36 (75)				
Other healthcare professional	120 (243)	55 (121)				
Administrative	42 (36)	35 (30)				
Healthcare resource use (number)	Vi					
Total tests	25 (52)	14 (30)				
Imaging tests	0.4 (0.8)	0.5 (1.5)				
Total consultations	52 (51)	33 (25)				
GP	14 (13)	9 (9)				
Nurse	10 (21)	3 (5)				
Other healthcare professional	9 (17)	4 (8)				
Administrative	22 (18)	18 (15)				

Abbreviations: GP, General Practitioner; SD, standard deviation.

Table D4. Subgroup analyses of 1 year inpatient costs – infection type (deep versus superficial)

	No infection (N=606)	Superficial infection (N=54)	Deep infection (N=26)
Bivariate analysis, mean (SD)	£7,746 (£5,060)	£14,232 (£8,633)	£18,378 (£16,592)
Multivariate analysis, mean (95% CI) ^a	£7,614 (£7,301, £7,941)	£12,814 (£11,093, £14,803)	£15,513 (£12,640, £19,040)

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; SD, standard deviation.

^a Adjusted for open/closed fracture, age, smoker, year at index, diabetes, COPD, days prior nailing and compartment syndrome.

Table D5. Subgroup analyses of 1 year inpatient costs – fracture type (open versus closed)

		ection 606)	Infection (N=80)		
Fracture type	Closed	Open	Closed	Open	
	(N=524)	(N=82)	(N=49)	(N=31)	
Bivariate analysis, mean (SD)	£7,433 (£3,957)	£9,741 (£9,247)	£12,291 (£7,366)	£20,778 (£15,451)	
Multivariate analysis,	£7,278 (£6,956,	£9,495 (£8,469,	£12,178 (£10,492,	£19,542 (£16,166,	
mean (95% CI) ^a	£7,614)	£10,645)	£14,136)	£23,623)	

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; SD, standard deviation.

^a Adjusted for age, smoker, year at index, diabetes, COPD, days prior nailing and compartment syndrome.

BMJ Open

Table D6. Sensitivity analyses

Time period	Endpoint	Bivariate anal	ysis, mean (SD)	Multivariate a	Absolute difference	
		Infection	No infection	Infection	No infection	(multivariate analysis)
Index stay	Total costs (£)	12,554 (6,832)	6,580 (3,123; p<0.001)	11,110 (9,328, 13,232)	6,517 (6,295, 6,747)	4,593 p<0.001
(N infection = 24; N no infection = 564)	LOS (days)	24.2 (20.9)	9.4 (11.7; p<0.001)	18.6 (13.1, 26.4)	8.5 (7.9, 9.1)	10.1 p<0.001
	Reoperations (number)	0.3 (0.9)	0.0 (0.1; p<0.001)	0.1 (0.0, 0.3)	0.0 (0.0, 0.0)	0.1 p<0.001
	Reoperations (rate)	12.5	1.6 (p<0.01)	9.9 (2.7, 30.6)	1.4 (0.7, 2.8)	8.5 p<0.05
Index stay + 30 days post-discharge	Total costs (£)	12,957 (7,385)	7,077 (3,747; p<0.001)	11,453 (10,016, 13,096)	7,010 (6,739, 7,292)	4,444 p<0.001
(N infection = 51; N	LOS (days)	20.2 (19.4)	10.0 (12.4; p<0.001)	15.6 (12.1, 20.0)	9.1 (8.4, 9.8)	6.5 p<0.001
no infection = 537)	Readmissions (number)	0.6 (0.6)	0.1 (0.3; p<0.001)	0.5 (0.3, 0.7)	0.1 (0.1, 0.1)	0.4 p<0.001
	Readmissions (rate)	47.1	8.4 (p<0.001)	45.7 (32.0, 60.0)	7.9 (5.9, 10.5)	37.8 p<0.001
	Reoperations (number)	0.3 (0.7)	0.0 (0.2; p<0.001)	0.1 (0.1, 0.3)	0.0 (0.0, 0.0)	0.1 p<0.001
	Reoperations (rate)	13.7	2.2 (p<0.001)	11.7 (5.0, 25.3)	1.8 (1.0, 3.4)	9.9 p<0.001
Index stay + 90 days post-discharge	Total costs (£)	13,620 (7,762)	7,584 (4,622; p<0.001)	11,869 (10,364, 13,593)	7,480 (7,160, 7,813)	4,389 p<0.001
(N infection = 59; N	LOS (days)	21.9 (21.8)	11.2 (15.2; p<0.001)	16.3 (12.7, 21.0)	9.8 (9.1, 10.7)	6.5 p<0.001
no infection = 529)	Readmissions (number)	0.8 (0.8)	0.2 (0.5; p<0.001)	0.7 (0.5, 0.9)	0.2 (0.2, 0.2)	0.5 p<0.001

Page 65 of 67

Time period	Endpoint	Bivariate anal	ysis, mean (SD)	Multivariate analysis, mean (95% Cl)		Absolute difference
		Infection	No infection	Infection	No infection	(multivariate analysis)
	Readmissions (rate)	57.6	18.1 (p<0.001)	54.9 (41.1, 68.0)	17.2 (14.1, 20.8)	37.7 p<0.001
	Reoperations (number)	0.3 (0.7)	0.1 (0.3; p<0.05)	0.2 (0.1, 0.3)	0.1 (0.0, 0.1)	0.1 p<0.05
	Reoperations (rate)	15.3	7.0 (p<0.05)	11.1 (5.2, 22.0)	6.1 (4.3, 8.7)	5.0 p=0.1438
Index stay + 1 year post-discharge	Total costs (£)	16,788 (12,914)	8,449 (5,525; p<0.001)	14,597 (12,841, 16,593)	8,294 (7,920, 8,686)	6,303 p<0.001
(N infection = 72; N	LOS (days)	29.2 (34.6)	12.3 (21.1; p<0.001)	22.5 (17.7, 28.5)	10.3 (9.4, 11.2)	12.2 p<0.001
no infection = 516)	Readmissions (number)	1.5 (1.6)	0.5 (0.9; p<0.001)	1.5 (1.2, 1.8)	0.5 (0.4, 0.6)	1.0 p<0.001
	Readmissions (rate)	75.0	35.5 (p<0.001)	75.0 (63.6, 83.8)	35.3 (31.2, 39.6)	39.7 p<0.001
	Reoperations (number)	0.6 (0.9)	0.2 (0.5; p<0.01)	0.5 (0.4, 0.7)	0.2 (0.2, 0.3)	0.3 p<0.001
	Reoperations (rate)	36.1	21.7 (p<0.05)	37.4 (26.7, 49.5)	20.7 (17.3, 24.5)	16.8 p<0.05
Index stay + 2 years post-discharge	Total costs (£)	18,779 (14,929)	9,611 (6,284; p<0.001)	16,626 (14,664, 18,849)	9,439 (8,998, 9,901),	7,187 p<0.00 ²
(N infection = 79; N	LOS (days)	31.5 (38.1)	13.4 (22.6; p<0.001)	24.6 (19.6, 30.8)	11.3 (10.4, 12.3)	13.3 p<0.001
no infection = 509)	Readmissions (number)	2.1 (2.3)	1.0 (1.5; p<0.001)	2.2 (1.9, 2.5)	0.9 (0.8, 1.0)	1.3 p<0.001
	Readmissions (rate)	77.2	51.1 (p<0.001)	77.6 (67.0, 85.6)	51.4 (46.9, 55.8)	26.3 p<0.001
	Reoperations (number)	0.8 (1.1)	0.4 (0.7; p<0.01)	0.8 (0.6, 1.0)	0.4 (0.3, 0.5)	0.4 p<0.001

Time period	Endpoint	Bivariate analysis, mean (SD)		Multivariate analysis, mean (95% CI)		Absolute difference
		Infection	No infection	Infection	No infection	(multivariate analysis)
	Reoperations (rate)	46.8	32.4 (p<0.05)	49.0 (37.7, 60.3)	31.2 (27.2, 35.5)	17.7 p<0.05

For beer review only

Abbreviations: CI, confidence interval; LOS, length of stay; NA, not applicable; SD, standard deviation.

 BMJ Open

Section/Topic	ltem #	Recommendation	Reported on page
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9-10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	9-10
		(c) Explain how missing data were addressed	9
		(d) If applicable, explain how loss to follow-up was addressed	10
		(e) Describe any sensitivity analyses	9-10

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed	10:14
		eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	10
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10-11
		(b) Indicate number of participants with missing data for each variable of interest	10:14
		(c) Summarise follow-up time (eg, average and total amount)	10
Outcome data	15*	Report numbers of outcome events or summary measures over time	10:14
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence	11:14
		interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	10:14
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14-15
Discussion			
Key results	18	Summarise key results with reference to study objectives	15
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	15-16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

BMJ Open

A nonconcurrent cohort study to estimate the economic burden of infections following intramedullary nailing for a tibial shaft fracture in England

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-035404.R1
Article Type:	Original research
Date Submitted by the Author:	11-Jun-2020
Complete List of Authors:	Galvain, Thibaut; Johnson and Johnson Medical Devices, Health Economics and Market Access Chitnis, Abhishek ; Johnson and Johnson Medical Devices, Real World Analytics and Research Paparouni, Konstantina; DePuy Synthes, Health Economics and Market Access Tong, Cindy; Johnson and Johnson Medical Devices, Health Economics and Market Access Holy, Chantal; Johnson and Johnson Medical Devices, Real World Analytics and Research Giannoudis, Peter; Leeds Teaching Hospitals NHS Trust, Academic Department of Trauma and Orthopaedics; University of Leeds, School of Medicine
Primary Subject Heading :	Surgery
Secondary Subject Heading:	Epidemiology, Emergency medicine, Health economics, Infectious diseases
Keywords:	ACCIDENT & EMERGENCY MEDICINE, WOUND MANAGEMENT, TRAUMA MANAGEMENT, EPIDEMIOLOGY, HEALTH ECONOMICS, Infection control < INFECTIOUS DISEASES

SCHOLARONE[™] Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

reliez oni

1 2		
2 3 4	1	Title: A nonconcurrent cohort study to estimate the economic burden of infections
5 6	2	following intramedullary nailing for a tibial shaft fracture in England
7 8	3	Thibaut Galvain, ^{1†} Abhishek Chitnis, ² Konstantina Paparouni, ³ Cindy Tong, ⁴ Chantal E Holy, ²
9 10	4	Peter V Giannoudis ⁵
11 12	5	1. Johnson and Johnson Medical Devices, Health Economics and Market Access,
13 14 15	6	Issy-les-Moulineaux, FR. tgalvain@its.jnj.com
16 17 19	7	2. Johnson and Johnson Medical Devices, Real World Analytics and Research, New Brunswick,
18 19 20	8	NJ, USA. achitni@its.jnj.com, CHoly1@its.jnj.com
20 21 22	9	3. DePuy Synthes, Health Economics and Market Access, Zuchwil, CH. kpaparouni@gmail.com
23 24	10	4. Johnson and Johnson Medical Devices, Health Economics and Market Access, Somerville,
25 26	11	NJ, USA. stong2@its.jnj.com
27 28	12	5. Leeds Teaching Hospitals NHS Trust, Academic Department of Trauma and Orthopaedics,
29 30	13	Leeds, West Yorkshire, UK; University of Leeds, School of Medicine, Leeds, West Yorkshire,
31 32	14	UK. pgiannoudi@aol.com
33 34 35	15	+Corresponding author
36 37	16	Running head:
38 39	17	Resource use and costs in patients with and without infection after tibial fracture nailing
40 41	18	Key words:
42 43	19	Tibial shaft fracture
44 45 46	20	CPRD
40 47 48	21	HES
49 50	22	Infection
51 52	23	• Cost
53 54	24	England
55 56 57	27	
58 59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2		
3 4	25	• Trauma
3 4 5 6	26	Burden of disease
7 8	27	
9 10	-	
11		
12 13		
14 15		
16		
17 18		
19 20		
21		
22 23		
24 25		
26		
27 28		
29 30		
31		
32 33		
34 35		
36 37		
38		
39 40		
41 42		
43		
44 45		
46 47		
48		
49 50		
51 52		
53 54		
55		
56 57		
58 59		
59 60		For peer review only - http://bmjopen.bmj.com/site/abour

1 2		
2 3 4	28	Abstract
5 6 7	29	Objectives
, 8 9	30	Determine the impact of infections on direct costs and healthcare resource use in England for
10 11 12	31	patients undergoing intramedullary nailing (IMN) for tibial shaft fractures.
13 14	32	Design
15 16 17	33	Nonconcurrent cohort based on retrospectively collected data with 2 years follow-up.
17 18 19	34	Setting
20 21 22	35	England.
23 24	36	Participants
25 26 27	37	The study population included adult patients (≥18 years) in England with a diagnosis of tibial
28 29	38	shaft fracture (ICD-10, S822) in the inpatient setting between May 2003 and June 2017 followed
30 31	39	by a procedure for IMN for tibial shaft fracture within 30 days. Patient data were derived from
32 33	40	the Clinical Practice Research Datalink (CPRD) linked to NHS Hospital Episode Statistics
34 35 36	41	datasets.
37 38	42	Primary independent variable
39 40 41	43	Infection.
42 43	44	Primary and secondary outcome measures
44 45 46	45	The primary outcome was total inpatient costs from index stay admission through one-year of
47 48	46	follow-up. Secondary outcome included cumulative total healthcare costs, and resource
 49 50 51 52 53 54 55 56 57 58 	47	utilisation at 30 days, 90 days, 1 year and 2 years.

2	
3 4	48
5 6 7	49
8	50
9 10	51
11 12 13	52
13 14 15	53
16 17	54
18 19	55
20 21	56
22 23	57
24 25 26	58
27 28	59
29 30	60
31 32 33	61
34 35 36	62
37 38	63
39 40	64
41 42	65
43 44	66
45 46	67
47 48 49	68
49 50 51	69
52 53	70
54 55	
56 57	
58 59	
60	

48	Results
49	Overall, 805 patients met the inclusion criteria. At index inpatient stay, 3.7% had a post IMN
50	infection, rising to 11.7% at 1-year. One-year inpatient costs were 80% higher for patients with
51	infection (p<0.001). Total costs were estimated to be £14,756 (95% confidence interval [CI];
52	£13,123, £16,593) for patients with infection versus £8,279 (95% CI; £7,946, £8,626). Length of
53	stay (LOS), readmission, and reoperation were the key drivers of healthcare costs (all p<0.001).
54	After adjustment, LOS was higher by 109% (95% CI: 62%, 169%), from 10.5 days to 21.9 days,
55	for patients with infection. The odds of being readmitted or requiring reoperation were higher by
56	5.18 times (95% CI: 3.01, 9.13) and 2.47 times (95% CI: 1.48, 4.09), respectively, for patients
57	with infection versus those without infection.
58	Conclusions
59	Post IMN infection significantly increases inpatient costs, LOS, readmissions, and reoperations
60	associated with tibial fracture fixation. Healthcare burden could be reduced through novel
61	surgical site infection prevention strategies.
62	Strengths and limitations of this study
63	This is the first study to quantify the healthcare resource burden of infections following
64	tibial shaft fractures treated with intramedullary nailing in England.
65	The study had a long term and cross-sector perspective that included inpatient, hospital
66	outpatient and primary care parameters.
67	This study only considered patients with complete follow-up, thus excluding very severe
68	patients with short life expectancy.
69	Some costs were not directly available from the CPRD dataset and were sourced from
70	published national sources.

The study relied on clinical codes to identify superficial and deep infections which may • be subject to coding errors and misclassifications. Introduction Tibial shaft fractures are the most common type of long-bone fracture. They can be either closed fractures, where the skin remains intact, or open fractures (accounting for 25% of all tibial shaft fractures) where the skin is broken (1). Intramedullary nailing is a common surgical treatment for this type of injury. Infection after intramedullary nailing is a potential complication, especially in severe open fractures, that can delay wound healing and fracture repair (2-5). If left untreated, an infection may lead to permanent loss of function of the affected limb (2, 3, 6). Open fractures are especially prone to infection due to wound exposure to the environment with the risk of infection depending on the severity of soft tissue damage (4). Patients with cases of extreme and uncontrollable infection may require limb amputation to prevent deterioration and maintain quality of life (2). Infections following fracture fixation are subclassified according to the depth of the infection: superficial (subcutaneous region), deep (muscle/fascial region), or organ/space infections (7). However, there is debate over the usefulness of these terms, as they can be arbitrary depending on the location of an infection (6). A US study reported an infection rate of 2% after intramedullary nailing for closed fractures compared with 7.1% for open fractures (8). A Belgian study reported an infection rate of 4.3% in patients with open or closed fractures, of which 1.4% were deep (9). In a meta-analysis of studies investigating prophylactic antibiotic use in patients with open tibial fractures treated with intramedullary nailing, the risk of infection increased with severity of the fracture, rising to over 31% among patients with the most severe injury (and who received systemic antibiotics only) (5).

Page 7 of 68

1 2

2 3 4	94	Patients who experience infection are more likely to require additional surgeries, extended
5	95	hospital stays, and extensive treatment for post-operative infection (2-4, 6). There are only a
7 8	96	limited number of studies, however, which compare healthcare resource utilisation and
9 10	97	treatment costs for tibial shaft fractures with and without post-surgical infection across Europe.
11 12	98	In a Belgian study, healthcare costs were five times higher and total length of hospital stay
13 14	99	(LOS) six times longer for open tibial shaft fracture patients with deep infection versus those
15 16	100	with no infection (10). In Denmark, the average direct cost of treating a severe open tibial shaft
17 18 19	101	fracture was estimated to be €49,817, increasing to €81,155 when infection occurred. In
20 21	102	patients treated within 7 days of their injury, infection increased the average direct cost and LOS
22 23	103	by 124% and 135%, respectively (11).
24 25 26	104	The aim of this nonconcurrent cohort study was to determine the impact of infections on
26 27 28	105	healthcare costs and resource utilisation for patients undergoing intramedullary nailing for tibial
20 29 30	106	shaft fractures from the perspective of National Health Service (NHS) England.
31		
32	107	Materials and methods
32 33 34 35	107 108	Materials and methods Study design and setting
32 33 34 35 36 37		
32 33 34 35 36 37 38 39	108	
32 33 34 35 36 37 38 39 40 41	108 109	This was a nonconcurrent cohort study based on retrospectively collected data of patients in
32 33 34 35 36 37 38 39 40 41 42 43	108 109 110	This was a nonconcurrent cohort study based on retrospectively collected data of patients in England who underwent intramedullary nailing for tibial shaft fracture (open or closed) and were
32 33 34 35 36 37 38 39 40 41 42 43 44 45	108 109 110 111	This was a nonconcurrent cohort study based on retrospectively collected data of patients in England who underwent intramedullary nailing for tibial shaft fracture (open or closed) and were followed-up for 2 years. Data derived from the Clinical Practice Research Datalink (CPRD)
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48	108 109 110 111 112	This was a nonconcurrent cohort study based on retrospectively collected data of patients in England who underwent intramedullary nailing for tibial shaft fracture (open or closed) and were followed-up for 2 years. Data derived from the Clinical Practice Research Datalink (CPRD) linked to NHS Hospital Episode Statistics (HES) and NHS Reference costs were used to
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50	108 109 110 111 112 113	This was a nonconcurrent cohort study based on retrospectively collected data of patients in England who underwent intramedullary nailing for tibial shaft fracture (open or closed) and were followed-up for 2 years. Data derived from the Clinical Practice Research Datalink (CPRD) linked to NHS Hospital Episode Statistics (HES) and NHS Reference costs were used to calculate costs and healthcare resource utilisation associated with infections (superficial or
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52	108 109 110 111 112 113 114	This was a nonconcurrent cohort study based on retrospectively collected data of patients in England who underwent intramedullary nailing for tibial shaft fracture (open or closed) and were followed-up for 2 years. Data derived from the Clinical Practice Research Datalink (CPRD) linked to NHS Hospital Episode Statistics (HES) and NHS Reference costs were used to calculate costs and healthcare resource utilisation associated with infections (superficial or deep) following intramedullary nailing.
$\begin{array}{c} 32\\ 33\\ 34\\ 35\\ 36\\ 37\\ 38\\ 39\\ 40\\ 41\\ 42\\ 43\\ 44\\ 45\\ 46\\ 47\\ 48\\ 49\\ 50\\ 51\\ 52\\ 53\\ 54\\ 55\\ 56\end{array}$	108 109 110 111 112 113 114 115	This was a nonconcurrent cohort study based on retrospectively collected data of patients in England who underwent intramedullary nailing for tibial shaft fracture (open or closed) and were followed-up for 2 years. Data derived from the Clinical Practice Research Datalink (CPRD) linked to NHS Hospital Episode Statistics (HES) and NHS Reference costs were used to calculate costs and healthcare resource utilisation associated with infections (superficial or deep) following intramedullary nailing. The CPRD database is an anonymised longitudinal dataset of over 11.3 million medical records
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 3 54 55	108 109 110 111 112 113 114 115 116	This was a nonconcurrent cohort study based on retrospectively collected data of patients in England who underwent intramedullary nailing for tibial shaft fracture (open or closed) and were followed-up for 2 years. Data derived from the Clinical Practice Research Datalink (CPRD) linked to NHS Hospital Episode Statistics (HES) and NHS Reference costs were used to calculate costs and healthcare resource utilisation associated with infections (superficial or deep) following intramedullary nailing. The CPRD database is an anonymised longitudinal dataset of over 11.3 million medical records from over 600 primary care practices across the UK (12). It includes all visits to primary care

test results, referrals, and prescriptions (12). For this study, HES data relating to admissions to, or attendances at, English NHS healthcare providers was used (HES Admitted Patient Care data). Patients The study population included adults (aged ≥18 years) who were diagnosed with an isolated or not tibial shaft fracture (ICD-10 code: S82.2) between May 2003 and June 2017 and who subsequently underwent intramedullary nailing within 30 days of diagnosis. Inclusion and exclusion criteria and patient attrition flow are depicted in Figure 1. Infections were identified using clinical diagnosis codes either from the inpatient setting (ICD-10, OPCS codes) or the primary care setting (Read codes) (See Additional file 1). Only patients with an infection occurring on (or after) Day 2 following the index date were considered eligible for the infection cohort, as this would exclude infections that were present pre-operatively. For subgroup analysis, diagnosis codes were categorised into either deep or superficial infections and open or closed fractures based on medical knowledge. Data collection The primary outcome of this study was total inpatient costs (Healthcare Resource Group [HRG], unbundled HRG and specialised care) accrued beginning from index stay admission through one-year of follow-up post-discharge from the index stay. Secondary endpoints included cumulative total healthcare costs and resource utilisation for 30 days, 90 days, 1 year and 2 years of follow-up post discharge of the index stay. Total healthcare costs comprised inpatient, hospital outpatient and primary care costs (consisting of consultations, prescriptions, and tests/investigations). Healthcare resource utilisation included LOS, readmissions, reoperations, days in intensive care unit (ICU), hospital outpatient visits, diagnostic tests, and primary care visits. Time to infection was an additional secondary outcome.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2		
3 4	142	Resource use and costs
5 6	143	Healthcare cost data were estimated based on the healthcare resource utilisation reported in
7 8	144	CPRD/HES and the unit cost associated with each service from an NHS perspective. In
9 10	145	England, NHS provides preventive medicine, primary care and hospital services to 88% of the
11 12 13	146	citizens. Responsibility for publicly funded health care remains with the Secretary of State for
13 14 15	147	Health, supported by the Department of Health (13). Hospitals are reimbursed by NHS
16 17	148	according to the amount and type of activity that they perform using Healthcare Resource
18 19	149	Groups (HRGs) (14).
20 21 22	150	Inpatient costs
23 24	151	The 2017/2018 HRG Reference Costs Grouper software was used to generate HRG codes for
25 26	152	each inpatient admission (15, 16). Each HRG code was assigned an appropriate cost from NHS
27 28	153	Reference Costs (17), using admission method, LOS, trim point and the patient classification to
29 30	154	associate the relevant costs (15, 18, 19). Inpatient stays were considered as long-stays for
31 32	155	admissions lasting ≥2 days in line with NHS reference costs (18, 20). Unbundled HRGs were
33 34 35	156	automatically generated by the Grouper software and assigned relevant costs (17). Specialised
36 37	157	care episodes were identified using the Prescribed Specialised Services Tool 2017/18 software
38 39	158	and top-up costs were applied as a percentage increase to the HRG cost (21).
40 41	159	Hospital outpatient costs
42 43	160	Outpatient costs were derived from the CPRD referral file where the referral type was classified
44 45	161	as "outpatient" and matched against NHS reference costs for the same or closest matching
46 47		
48 49	162	specialty (17, 19).
50 51 52 53 54 55 56 57 58	163	Primary care costs
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1

58 59

2		
3 4	164	Consultations from the CPRD consultations file were categorised based on the setting (clinical,
5 6	165	surgery, home, telephone, administrative) and healthcare provider (doctor, nurse, other
7 8	166	professional). Costs were sourced from the Unit Costs of Health and Social Care (22).
9 10	167	Laboratory and diagnostic tests from the CPRD tests file were manually matched to the closest
11 12	168	NHS test category and assigned NHS Reference Costs (18).
13 14 15	169	Medication categories were based on British National Formulary classifications as recorded in
16		
17 18	170	the CPRD therapy file, and unit costs were obtained using the Prescription Cost Analysis 2017
19 20	171	using the mean sub-paragraph cost associated with each medication (23).
21 22	172	Follow-up period and cohort definitions
23		
24 25	173	Follow-up time was calculated as the difference between the index discharge date and the last
26 27	174	date of observation. Only patients with follow-up data at the relevant time point were included in
28 29	175	the analysis.
30 31	176	Statistical analyses
32 33 34	177	All analyses were conducted using R Studio v3.4.3. Statistical significance was set a priori at
35 36	178	p<0.05 (two-sided). Study variables were analysed descriptively. Time-to-infection was depicted
37 38	179	graphically using the Kaplan-Meier estimator. Unadjusted comparisons of patient demographics,
39 40	180	comorbidities, and medication use between groups were performed using t-tests for continuous
41 42 42	181	variables that were approximately normal, and Wilcoxon rank sum tests for continuous variables
43 44 45	182	that were not normally distributed. Pre-specified subgroup analyses allowed for stratification of
46 47	183	results according to type of fracture (open versus closed) or type of infection (superficial versus
48 49	184	deep).
50 51	185	Generalised Linear Models were used to adjust for confounding, to isolate the association
52 53	186	between surgical site infection and the outcomes. Covariates were identified a priori as risk
54 55 56 57	187	factors for the study outcomes based on clinical knowledge. A backwards stepwise procedure

1		
2 3	188	was applied according to Akaike information criterion. Missing data were not imputed. Except for
4		
5 6 7	189	in the sensitivity analyses, patients with missing data were excluded from analyses.
, 8 9	190	Sensitivity analyses at all time points were conducted using data from the subgroup of patients
10 11	191	who had complete two-year follow-up for total costs, LOS, readmission (rate and mean count),
12 13	192	and reoperation (rate and mean count).
14 15 16	193	Patient and public Involvement
17 18	194	Patients or the public were not involved in the design, or conduct, or reporting, or dissemination
19 20	195	plans of our research.
21 22 23	196	Results
24	197	Patient baseline characteristics
25 26	107	
27 28	198	Of the 10,825 patients identified as having suffered a tibial shaft fracture, 3,005 received
29 30 31	199	intramedullary nailing. Of these, a total of 805 patients met the inclusion criteria and were
31 32 33	200	included in the study (Figure 1). The mean follow-up time was 4.8 years. The mean (standard
34 35	201	deviation [SD]) age was 40.8 (17.2) (See Table 1 for index stay; Additional file 2). A majority of
36 37	202	patients were male (n= 590; 73.3%) and most had suffered a closed (n=663; 82.4%) tibial shaft
38 39	203	fracture. Among patients with an open fracture, a significantly higher proportion of patients
40 41	204	(10.6%) experienced an infection compared with 2.3% of patients with a closed fracture
42 43	205	(p<0.001; Table 1).
44 45 46	206 207	Figure 1. Patient screening and enrolment according to the study inclusion/exclusion criteria
47 48	208	
49 50	209	
51 52		
53		
54 55		
55 56		
57		
58 59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

		All enrolled	Index stay		
		patients (N=805)	No infection (N=775)	Infection (N=30)	p-value
	Demographics		(,	(
	Age (years), mean (SD)	40.8 (17.2)	40.7 (16.8)	43.0 (23.9)	0.61
	Gender, n (%)	. ,			0.84
	Male	590 (73.3)	569 (73.4)	21 (70.0)	
	Clinical history/comorbidities	. ,			1
	Charlson score, median (range)	0.00 (3.00)	0.00 (2.00)	0.00 (3.00)	<0.00
	Smoker, n (%)	256 (31.8)	247 (31.9)	9 (30.0)	0.99
	Diabetes, n (%)	27 (3.4)	27 (3.5)	0 (0.0)	0.62
	COPD, n (%)	8 (1.0)	8 (1.0)	0 (0.0)	1.00
	Congestive heart failure, n (%)	2 (0.3)	2 (0.3)	0 (0.0)	1.00
	Hypertension, n (%)	12 (1.5)	12 (1.6)	0 (0.0)	1.00
	Compartment syndrome, n (%)	27 (3.4)	22 (2.8)	5 (16.7)	<0.01
	Index episode		•		
	Inpatient waiting time (days) for surgery, mean (SD)	1.4 (2.4)	1.4 (2.4)	0.70 (2.4)	0.14
	Fracture type, n (%)				<0.00
	Open fracture	142 (17.6)	127 (16.4)	15 (50.0)	
	Received ≥1 prescription for antibiotics in the 12 months prior to the index stay, n (%)	60 (7.5)	60 (7.7)	0 (0.00)	0.16
	Received ≥1 prescription for opioids in the 12 months prior to the index stay, n (%)	16 (2.0)	15 (1.9)	1 (3.3)	0.46
1	Abbreviations: COPD, chronic obstructive pulm	onary disease;	SD, standard de	eviation.	1
12					
13	Infection rates				
4	During the index stay, 30 patients (3.7%) e.	xperienced an	infection. Amo	ong patients v	vith 30-o
5	90-day, 1-year, and 2-years post-discharge	e follow-up data	a, infection rate	es were respe	ectively:
6	8.0%, 9.2%, 11.7%, and 13.4%, (Figure 2).				
7	Figure 2. Cumulative percentage of infed	ction events r	ecorded post	-index date	
8					
9	One-year inpatient costs				
0	Among patients with index stay plus 1-year	post discharg	e data (N=686), the mean 1	l-year to
1	inpatient cost was significantly higher amor	ng patients who	o experienced	an infection (£15,58
			·		

Table 1. Patient demographic and clinical characteristics at index 210

Page 13 of 68

60

LOS, days

BMJ Open

1						
2 3 4	222	n=80) compared with patients withou	ut infection (£7,746; p<0.	001). After adjusting	for fracture	
5 6	223	type (open/closed), age, smoking status, index year, diabetes, COPD, inpatient waiting time for				
7 8	224	surgery and compartment syndrome, mean costs were 80% (95% CI: 58%, 104%) higher,				
9 10	225	respectively (£13,672 [95% CI: £12,7	122, £15,420] versus £7,	616 [95% CI: £7,301	, £7,944];	
11 12	226	p<0.001), (Figure 3).				
13 14 15	227	One-year total costs				
16 17	228	Adjusted total costs were £14,756 (9	95% CI: £13,123, £16,593	3) among patients wl	no experienced	
18 19	229	an infection versus £8,279 (95% CI: £7,946, £8,626; p<0.001) in patients without infection – a				
20 21 22	230	78% increase in total costs as a result of infection (95% CI: 57%, 102%) (Figure 3).				
23	231	Figure 3. Breakdown of 1-year tota	al costs by infection sta	atus (adjusted analy	/sis)	
24 25	232	Abbreviations: ns, not significant; CI, cor				
26 27	233	*** p<0.001				
28 29	234					
30 31	235	One-year healthcare resource use				
32 33 34	236	For the majority of healthcare resour	ce categories, presence	of infection was asse	ociated with a	
35 36	237	statistically significant increase in res	source use versus no infe	ection (Table 2). Key	drivers of	
37 38	238	increased costs were LOS, readmiss	sion, and reoperation rate	es, which were all sig	nificantly	
39 40	239	higher in patients with infections (all	p<0.001). After adjustme	ent, LOS was increas	ed by 109%	
41 42	240	(95% CI: 62%, 169%) from 10.5 day	s to 21.9 days. The odds	of being readmitted	or requiring	
43 44	241	reoperation due to infection was increased by 5.18 times (95% CI: 3.01, 9.13) and 2.47 times				
45 46 47	242	(95% CI: 1.48, 4.09), respectively.				
47 48 49	243	Table 2. 1-year healthcare resource use by infection status				
50	Multivariate analysis					
51No infectionInfectionp-val52(N=606)N=8053Mean (95% Cl)Mean (95% Cl)					p-value	
54				210(172.077)	n<0.001	

10.5 (9.7, 11.4)

21.9 (17.3, 27.7)

p<0.001

	No infection	Infection			
	(N=606)	Infection N=80	p-value		
	Mean (95% CI)	Mean (95% CI)			
ICU LOS, days	0.01 (0.01, 0.02)	0.01 (0.00, 0.02)	p=0.91		
Number of readmissions	0.5 (0.5, 0.6)	1.5 (1.2, 1.8)	p<0.001		
Readmission rate, %	35.9 (32.1, 39.9)	74.4 (63.4, 83.0)	p<0.001		
Number of reoperations	0.2 (0.2, 0.3)	0.6 (0.5, 0.8)	p<0.001		
Reoperations rate, %	20.3 (17.2, 23.8)	38.6 (28.3, 50.0)	p<0.001		
Number of hospital outpatient referrals	1.8 (1.6, 2.1)	1.7 (1.2, 2.1)	p=0.44		
Primary care resource use					
Number of primary care events	30.9 (29.2, 32.7)	45.9 (39.0, 54.0)	p<0.001		
Number of tests and examinations	14.0 (11.4, 16.6)	22.1 (13.9, 31.3)	p=0.052		
Abbreviations: CI, confidence interval; ICU,	intensive care unit; LOS	S, length of stay			
<u> </u>	A 11				
Total costs from index stay to two ye	ars follow-up				
At all-time points mean total costs were	statistically significan	tly higher for patients	with an		
infection compared with those without (p	o<0.001), (Figure 4). /	Adjusted mean total o	costs of ca		
in patients with infection versus no infec	tion over time were: £	£11,257 versus £7,01	7 at 30 da		
£11,949 versus £7,423 at 90 days; and	£16,626 versus £9,43	39 at 2 years (all p<0.	.001).		
Figure 4. Total costs from index stav	to 2 years follow-up				
•					
*** p<0.001. Data plotted are means +/- 95%	% CI.				
Healthcare resource use from index s	stay to two years fol	low-up			
Multivariate analysis demonstrated that	LOS, readmissions (r	rate and mean; Figure	e 5), and		
responsibles (rate and mean: Figure 6)	wore consistently hig	bor at all timopointe d	amona		
reoperations (rate and mean, Figure 6),	were consistently hig		among		
patients who experienced an infection c	ompared with those v	vho did not (p<0.001)	. At 30 day		
infection increased the adjusted LOS fro	om 8.9 days to 15.0 d	ays and at 2 years fro	om 11.3 da		
to 24.6 days (both p<0.001). The adjust	ed readmission rate in	ncreased from 7.1%	at 30 days		
51.3% at 2 years follow-up in patients w	vithout infection compa	ared with an increase	e from 44.1		
	Readmission rate, % Number of reoperations Reoperations rate, % Number of hospital outpatient referrals Primary care resource use Number of primary care events Number of tests and examinations Abbreviations: CI, confidence interval; ICU, Total costs from index stay to two yee At all-time points mean total costs were infection compared with those without (p in patients with infection versus no infect £11,949 versus £7,423 at 90 days; and Figure 4. Total costs from index stay Abbreviations: CI, confidence interval. **** p<0.001. Data plotted are means +/- 959	Readmission rate, %35.9 (32.1, 39.9)Number of reoperations0.2 (0.2, 0.3)Reoperations rate, %20.3 (17.2, 23.8)Number of hospital outpatient1.8 (1.6, 2.1)referrals1.8 (1.6, 2.1)Primary care resource use30.9 (29.2, 32.7)Number of primary care events30.9 (29.2, 32.7)Number of tests and examinations14.0 (11.4, 16.6)Abbreviations: CI, confidence interval; ICU, intensive care unit; LOSTotal costs from index stay to two years follow-upAt all-time points mean total costs were statistically significantinfection compared with those without (p<0.001), (Figure 4). A	Readmission rate, %35.9 (32.1, 39.9)74.4 (63.4, 83.0)Number of reoperations0.2 (0.2, 0.3)0.6 (0.5, 0.8)Reoperations rate, %20.3 (17.2, 23.8)38.6 (28.3, 50.0)Number of hospital outpatient1.8 (1.6, 2.1)1.7 (1.2, 2.1)referrals1.7 (1.2, 2.1)1.7 (1.2, 2.1)Primary care resource use30.9 (29.2, 32.7)45.9 (39.0, 54.0)Number of primary care events30.9 (29.2, 32.7)45.9 (39.0, 54.0)Number of tests and examinations14.0 (11.4, 16.6)22.1 (13.9, 31.3)Abbreviations: CI, confidence interval; ICU, intensive care unit; LOS, length of stayTotal costs from index stay to two years follow-upAt all-time points mean total costs were statistically significantly higher for patientsin patients with infection versus no infection over time were: £11,257 versus £7,01£11,949 versus £7,423 at 90 days; and £16,626 versus £9,439 at 2 years (all p<0		

1 2		
- 3 4	261	to 77.6% in the infection group (Figure 5). The adjusted reoperation rate increased from 1.3% at
5 6	262	30 days to 31.2% at 2 years in the absence of infection, whereas in the infection group, the rate
7 8	263	increased from 11.5% to 49.0% (Figure 6).
9 10 11 12	264 265	Figure 5. Readmission (adjusted) according to follow-up time: (A) readmission rate and (B) mean number of readmissions per patient
12 13 14	266 267	Abbreviations: CI, confidence interval.
15 16	268	*** p<0.001. Data plotted are means +/- 95% Cl.
17 18 19	269	
20 21 22	270 271	Figure 6. Reoperation (adjusted) according to follow-up time: (A) reoperation rate and (B) mean number of reoperations per patient
23 24 25	272 273	Abbreviations: CI, confidence interval.
25 26 27	274	** p<0.01, *** p<0.001. Data plotted are means +/- 95% CI.
28 29	275	
30 31	276	Subgroup analyses
32 33 34	277	Multivariate analysis by infection type resulted in mean 1-year inpatient costs of £7,614,
35 36	278	£12,814 and £15,513, respectively for no infection (n=606), superficial infection (n=54) and
37 38	279	deep infection (n=26) (Additional file 2). Analysis by fracture type showed a higher 1-year
39 40	280	infection rate among patients with open fractures (27.4%) versus closed fractures (8.6%). Mean
41 42	281	adjusted inpatient costs at 1 year for patients with and without infection were £19,542 versus
43 44	282	\pounds 9,495 for patients with open fractures and \pounds 12,178 versus \pounds 7,278 for patients with closed
45 46 47	283	fractures.
48 49	284	Sensitivity analyses
50 51	285	A total of 588 patients (73%) out of the 805 patients at index had data for the full 2-year follow-
52 53 54 55 56 57	286	up period. Results for total costs, LOS, readmissions (rate and mean), and reoperations (rate
58 59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

and mean) at each time point were consistent with those of the primary analyses (Additional file288 2).

289 Discussion

This study used CPRD-linked HES data to determine the impact of infection on English healthcare costs and resource utilisation associated with patients undergoing intramedullary nailing for tibial fracture. Infection rates at 1-year and 2-years (11.7% and 13.4%, respectively) were comparable with the 10.5% rate reported in a 2014 meta-analysis (5). Mean inpatient costs measured after 1 year were predicted to be 80% higher (£6,056) for patients with infection compared with those without infection, while overall costs were 78% higher. The greatest cost drivers were hospital LOS (109% increase at 1 year), readmissions (odds of being readmitted increased by 5.18 times at 1 year), and reoperations (odds of reoperation increased by 2.47 times at 1 year). The 2-year follow-up in this study meant that we were able to capture changes in resource use over time associated with infection, such as readmission and reoperation. The findings of this study highlight the substantial impact on healthcare resource utilisation and costs to the English NHS, from both the hospital and primary care perspective. This study is the first to quantify the additional healthcare resource burden of infections following

tibial fractures treated with intramedullary nailing in England with a long-term perspective which includes inpatient, hospital outpatient and primary care parameters. Differences in healthcare systems, patient populations and treatment pathways make direct comparison with studies from other countries challenging; however, our findings are in line with results of studies from Belgium and Denmark (10, 11). Hoekstra et al. demonstrated five times higher healthcare costs and six times longer LOS for open tibial shaft fracture patients with deep infection versus those without infection in Belgium (10). Although the magnitude of the increase in costs and LOS observed in our study is not as substantial, differences in patient populations may be a contributing factor, as Hoekstra et al. did not limit their study population to intramedullary nail

Page 17 of 68

1

BMJ Open

2	
3	3
4	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	3
7	
8	3
9	,
10	Ċ
11	2
12	
13 14	3
15	
16	3
17	
18	3
19 20	
20	3
22	
23	3
24	
25	Ċ
18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	<i>.</i>
27	
29	3
30	
31	3
32	
33 34	3
35	,
36	Ċ
37	
38	
39 40	3
40 41	
42	3
43	
44	3
45	
46 47	3
47 48	
49	3
50	
51	Ċ
52	<i>.</i>
53 54	
54 55	3
56	
57	
58	
59	
60	

312 fixation (10). In their Danish study, Olesen et al. estimated a 60% increase in direct costs and 313 an 80% increase in LOS resulting from infected open tibial fractures (11), consistent with the 314 magnitude of the increase observed in the current study; absolute LOS (74 days) and direct 315 healthcare costs (€81,155) in the presence of infection were substantially higher than in our 316 study, however, which may in part reflect the most severe types of wounds considered in the 317 Danish study, all of which were open fractures and 80% of which were Gustilo-Anderson 318 classification 3. Furthermore, a US-study found that surgical site infections nearly doubled 319 inpatient costs to \$109,000 in patients with isolated fractures (24).

320 Surgical site infections remain one of the most challenging complications in trauma surgery (25). 321 Over the past decades, surgical site infection incidence has decreased, especially deep 322 infections in patients with open tibial fractures (26). The question remained whether these rates 323 could be decreased further. Still, no infections occurred in two studies in complex tibial fracture 324 patients treated with antibiotic coated intramedullary tibia nails (27, 28). Based on consensus 325 opinions, they may be a promising option for prevention of surgical site infections in open 326 fractures or revision cases (29). Other approaches to prevent infections through local delivery of 327 antibacterials were based on specialized biomaterials formulated as additives in bone void fillers 328 such as bone cement or bacteriostatic bone substitute materials (25, 30, 31). Moreover, in order 329 to prevent infections, open fractures should be managed according to the UK NICE guideline 330 and the Open fracture BOAST (32, 33).

This study is subject to the following limitations: 1) potential bias in the patient population as we only considered patients with complete follow-up, thus excluding very severe patients with short life expectancy or with few comorbidities, limiting the generalizability of the findings to this subgroup; 2) identification of relevant patients for inclusion in the study was based on OPCS, ICD-10 and primary care-based read codes. The data may be susceptible to coding errors and misclassifications. Surgical site infections were defined following the CDC criteria (34, 35).

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Recently it became clear that the CDC definition for infection probably is not sufficient to define fracture-related infections. One important reason is the fact that the subdivision of infection into superficial and deep infection is arbitrary (36). However, the use of the CDC definition was standard during our study period (2003 – 2017); 3) medication use was costed as recorded in CPRD, i.e. averaged to the cost of the drug family/British National Formulary sub-paragraph; 4) dispensing costs were not included 5) outpatient specialties from CPRD did not always exactly match outpatient specialty categories from NHS Reference Costs; when there was not an exact match, the closest matching specialty was chosen; 6) costs were not directly available from the CPRD dataset and hence unit costs had to be sourced from published national sources for primary and secondary care and for drug prices; 7) economic assessment was limited to direct healthcare costs while infections could lead to permanent functional loss and potentially increase in secondary costs (25); 8) all potential confounders could not be adjusted for, limiting the association between increased healthcare resource utilizations and costs with surgical site infections. Our study provides important evidence as to the short- to mid-term direct economic consequences of infection following tibial fractures. By increasing the sample size, the impact of infection type (superficial/deep) and fracture type (open/closed) could have been explored more robustly. Additional validation of clinical codes used to identify relevant data would have allowed us to account for any potential variation in clinical coding practice. Broadening the perspective to include indirect costs would allow the additional burden of infection to be established, such as rehabilitation and absenteeism. Conclusion This study confirms that infection presents a substantial healthcare burden, leading to significantly increased hospital LOS, need for hospital readmission and reoperation, and increased use of GPs and other primary care resources. As such there exists an unmet need for

Page 19 of 68

1 2		
- 3 4	362	alternative medical technologies and infection prevention strategies that could help to reduce
5 6	363	infections in tibial shaft fractures and reduce costs. Our study indicates that the potential mid-
7 8 9	364	term (1–2 years) saving to the English NHS of is around \pounds 6,500 per patient.
) 10 11	365	
12 13	366	Declarations
14 15	367	Ethics approval and consent to participate
16 17	368	The study protocol was approved by the Independent Scientific Advisory Committee for
18 19	369	Medicines and Healthcare products Regulatory Agency database research (ISAC) on 27
20 21	370	November 2017 (ISAC Protocol: 17-132R). General ethical approval for observational research
22 23	371	using the CPRD with approval from the ISAC was granted by a Health Research Authority
24 25 26	372	Research Ethics Committee (East Midlands – Derby; reference number: 05/MRE04/87).
27 28	373	Consent for publication
29 30	374	Not applicable
31 32	375	Availability of data and material
33 34	376	The data that support the findings of this study are available from Clinical Practice Research
35 36	377	Datalink (CPRD), but restrictions apply to the availability of these data, which were used under
37 38	378	license for the current study, and so are not publicly available.
39 40 41	379	Competing interests
41 42 43	380	Peter Giannoudis received honoraria from DePuy Synthes for his involvement in this study.
44 45	381	Thibaut Galvain, Abhishek Chitnis, Cindy Tong, and Chantal Holy are employees of Johnson
46 47	382	and Johnson Medical Devices. Konstantina Paparouni is an employee of DePuy Synthes. The
48 49	383	funding corporations could have affected the study design, analysis and manuscript writing; but
50 51 52	384	authors owned final decisions.
53 54	385	Funding
55 56 57 58	386	This study was sponsored by DePuy Synthes.
59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml


1		
2 3 4	387	Authors' contributions
5 6	388	Study conception and design: TG, PVG, CEH, KP, CT and AC. Acquisition of data: TG, PVG,
7 8	389	CT and AC. Data analysis: TG, CT and AC. Interpretation of data and results: TG, PVG, CEH,
9 10	390	KP, CT and AC. Drafting of manuscript: TG, PVG, CEH, KP, CT and AC. Critical revision: TG,
11 12	391	PVG, CEH, KP, CT and AC. Project management: KP.
13 14	392	Acknowledgements:
15 16 17	393	We thank James Woolnough (Mtech Access) who provided medical writing services in the
17 18 19	394	preparation of the manuscript, funded by DePuy Synthes.
20 21	395	Abbreviations
22 23	396	BOAST, British Orthopaedic Association Standards for Trauma & Orthopaedic; CI, confidence
24 25	397	interval; COPD, chronic obstructive pulmonary disease; CPRD, Clinical Practice Research
26 27	398	Datalink; GP, general practitioner; HES, Hospital Episode Statistics; HRG, Healthcare Resource
28 29	399	Group; ICU, intensive care unit; ISAC, Independent Scientific Advisory Committee; LOS, length
30 31	400	of stay; NA, not applicable; NICE, National Institute for Health and Care Excellence; NHS,
32 33	401	National Health Service; SD, standard deviation.
34 35 36	402	References
 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 	403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420	 Duan X, Al-Qwbani M, Zeng Y, Zhang W, Xiang Z. Intramedullary nailing for tibial shaft fractures in adults. Cochrane Database Syst Rev. 2012;1:CD008241. Elniel AR, Giannoudis PV. Open fractures of the lower extremity: Current management and clinical outcomes. EFORT Open Rev. 2018;3(5):316-25. Kanakaris NK, Tosounidis TH, Giannoudis PV. Surgical management of infected non- unions: An update. Injury. 2015;46 Suppl 5:S25-32. Smith EJ, Kuang X, Pandarinath R. Comparing hospital outcomes between open and closed tibia fractures treated with intramedullary fixation. Injury. 2017;48(7):1609-12. Craig J, Fuchs T, Jenks M, Fleetwood K, Franz D, Iff J, et al. Systematic review and meta-analysis of the additional benefit of local prophylactic antibiotic therapy for infection rates in open tibia fractures treated with intramedullary nailing. Int Orthop. 2014;38(5):1025-30. Metsemakers WJ, Kortram K, Morgenstern M, Moriarty TF, Meex I, Kuehl R, et al. Definition of infection after fracture fixation: A systematic review of randomized controlled trials to evaluate current practice. Injury. 2018;49(3):497-504. Centre for Disease Control. National Healthcare Safety Network (NHSN) Patient Safety Component Manual, 2018. Auston DA, Meiss J, Serrano R, Sellers T, Carlson G, Hoggard T, et al. Percutaneous or Open Reduction of Closed Tibial Shaft Fractures During Intramedullary Nailing Does Not
58 59 60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml


1		
2		
3	421	Increase Wound Complications, Infection or Nonunion Rates. J Orthop Trauma.
4	422	2017;31(4):215-9.
5	423	9. Metsemakers WJ, Handojo K, Reynders P, Sermon A, Vanderschot P, Nijs S. Individual
6 7	424	risk factors for deep infection and compromised fracture healing after intramedullary nailing of
8	425	tibial shaft fractures: a single centre experience of 480 patients. Injury. 2015;46(4):740-5.
9	426	10. Hoekstra H, Smeets B, Metsemakers WJ, Spitz AC, Nijs S. Economics of open tibial
10	427	fractures: the pivotal role of length-of-stay and infection. Health Econ Rev. 2017;7(1):32.
11	428 429	11. Olesen UK, Pedersen NJ, Eckardt H, Lykke-Meyer L, Bonde CT, Singh UM, et al. The cost of infection in severe open tibial fractures treated with a free flap. Int Orthop.
12	429	2017;41(5):1049-55.
13 14	431	12. Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data
14	432	Resource Profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol. 2015;44(3):827-
16	433	36.
17	434	13. Boyle S. United Kingdom (England): Health system review. Health Syst Transit.
18	435	2011;13(1):1-483, xix-xx.
19	436	14. Bojke C, Grasic K, Street A. How should hospital reimbursement be refined to support
20 21	437	concentration of complex care services? Health Econ. 2018;27(1):e26-e38.
21	438	15. Canavan C, West J, Card T. Calculating Total Health Service Utilisation and Costs from
23	439 440	Routinely Collected Electronic Health Records Using the Example of Patients with Irritable Bowel Syndrome Before and After Their First Gastroenterology Appointment.
24	440 441	Pharmacoeconomics. 2016;34(2):181-94.
25	442	16. National Health Service. Costing - HRG4+ 2017/18 Reference Costs Grouper 2017
26	443	[Available from: https://digital.nhs.uk/services/national-casemix-office/downloads-groupers-and-
27	444	tools/costing-hrg4-2017-18-reference-costs-grouper
28 29	445	17. NHS Improvement. National schedule of reference costs 2016/17 2017 [Available from:
30	446	https://improvement.nhs.uk/resources/reference-costs/.
31	447	18. Achana FA, Fleming KM, Tata LJ, Sultan AA, Petrou S. Peripartum hysterectomy: an
32	448	economic analysis of direct healthcare costs using routinely collected data. BJOG.
33	449	2018;125(7):874-83.
34 35	450 451	19. Danese MD, Gleeson M, Griffiths RI, Catterick D, Kutikova L. Methods for estimating costs in patients with hyperlipidemia experiencing their first cardiovascular event in the United
35 36	452	Kingdom. J Med Econ. 2017;20(9):931-7.
37	453	20. NHS Department of Health. A simple guide to Payment by Results. 2012.
38	454	21. NHS England and NHS Improvement. NHS National tariff payment system 2017/18 and
39	455	2018/19.
40	456	22. Curtis L, Burns A. Unit Costs of Health and Social Care 2017. Available at:
41	457	https://www.pssru.ac.uk/project-pages/unit-costs/unit-costs-2017/ (Accessed: 9 Nov 2018).
42 43	458	23. NHS Digital. Prescription Cost Analysis - England, 2017 2018 [Available from:
44	459	https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-
45	460 461	analysis/prescription-cost-analysis-england-2017. 24. Thakore RV, Greenberg SE, Shi H, Foxx AM, Francois EL, Prablek MA, et al. Surgical
46	461 462	24. Thakore RV, Greenberg SE, Shi H, Foxx AM, Francois EL, Prablek MA, et al. Surgical site infection in orthopedic trauma: A case-control study evaluating risk factors and cost. J Clin
47	463	Orthop Trauma. 2015;6(4):220-6.
48	464	25. Metsemakers WJ, Kuehl R, Moriarty TF, Richards RG, Verhofstad MHJ, Borens O, et al.
49 50	465	Infection after fracture fixation: Current surgical and microbiological concepts. Injury.
51	466	2018;49(3):511-22.
52	467	26. Ktistakis I, Giannoudi M, Giannoudis PV. Infection rates after open tibial fractures: are
53	468	they decreasing? Injury. 2014;45(7):1025-7.
54	469	27. Metsemakers WJ, Reul M, Nijs S. The use of gentamicin-coated nails in complex open tible fracture and revision ecces: A retreapactive analysis of a single contra case series and
55 56	470 471	tibia fracture and revision cases: A retrospective analysis of a single centre case series and review of the literature. Injury. 2015;46(12):2433-7.
50 57	7/1	10^{10} working interature. Injury. 2010,40(12).2400-7.
58		
59		
60		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1		
2 3	470	20 Even T. Change D. Cohmidmeier C. Deschke MJ. The use of contemicin costed poils in
4	472	28. Fuchs T, Stange R, Schmidmaier G, Raschke MJ. The use of gentamicin-coated nails in
5	473 474	the tibia: preliminary results of a prospective study. Arch Orthop Trauma Surg. 2011;131(10):1419-25.
6		
7	475	29. Metsemakers WJ, Fragomen AT, Moriarty TF, Morgenstern M, Egol KA, Zalavras C, et
8	476	al. Evidence-Based Recommendations for Local Antimicrobial Strategies and Dead Space
9	477	Management in Fracture-Related Infection. J Orthop Trauma. 2020;34(1):18-29.
10	478	30. Buchholz HW, Engelbrecht H. [Depot effects of various antibiotics mixed with Palacos
11	479	resins]. Chirurg. 1970;41(11):511-5.
12	480	31. van Gestel NA, Geurts J, Hulsen DJ, van Rietbergen B, Hofmann S, Arts JJ. Clinical
13	481	Applications of S53P4 Bioactive Glass in Bone Healing and Osteomyelitic Treatment: A
14	482	Literature Review. Biomed Res Int. 2015;2015:684826.
15	483	32. Fractures (complex): assessment and management. NICE guideline. National Institute
16	484	for Health and Care Excellence. 2017.
17	485	33. BOAST - Open Fractures. British Orthopaedic Association. 2017.
18	486	34. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of
19	487	Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital
20	488	Infection Control Practices Advisory Committee. Am J Infect Control. 1999;27(2):97-132; quiz 3-
21	489	4: discussion 96.
22	490	35. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of
23	491	nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound
24	492	infections. Infect Control Hosp Epidemiol. 1992;13(10):606-8.
25	493	36. Metsemakers WJ, Morgenstern M, McNally MA, Moriarty TF, McFadyen I, Scarborough
26	494	M, et al. Fracture-related infection: A consensus on definition from an international expert group.
27	494	Injury. 2018;49(3):505-10.
28	490	
29	496	
30		
31	497	Additional files 1. Additional file 1: a. Format: "Additional file1.pdf"
32	497	Additional mes
33	498	1. Additional file 1:
34	490	
35	499	a. Format: "Additional file1.pdf"
36	499	a. Format. Auditional me r.put
37	500	h Title: Study protocol
38	500	b. Title: Study protocol
39	504	Descriptions this additional file is also be at the study on the study of the second its
40 41	501	c. Description: this additional file includes the study protocol and its appendix
41 42		
42	502	composed of clinical and procedure codes
43		
45	503	2. Additional file 2:
46		
47	504	a. Format: "Additional file2.pdf"
48		
49	505	 b. Title: Baseline and results at all time points
50		
51	506	c. Description: this additional file includes the baseline demographics and results at
52		
53	507	all time points that could not be integrated in the manuscript.
54		
55		
56		
57		
58		
59		
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
60		

Page 23 of 68


1






Page 25 of 68









Abbreviations: CI, confidence interval. *** p<0.001. Data plotted are means +/- 95% CI.

152x101mm (600 x 600 DPI)

Page 27 of 68



- 54 55
- 55



For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Additional file 1: Study protocol

PROTOCOL INFORMATION REQUIRED

The following sections below <u>must</u> be included in the CPRD ISAC research protocol. Please refer to the guidance on '*Contents of CPRD ISAC Research Protocols*' (<u>www.cprd.com/isac</u>) for more information on how to complete the sections below. Pages should be numbered. All abbreviations must be defined on first use.

Applicants must complete all sections listed below Sections which do not apply should be completed as '*Not Applicable*'

A. Study Title[§]

[§]Please note: This information will be published on CPRD's website as part of its transparency policy

Healthcare Resource Utilization and Costs among Patients with and without Infection after Intramedullary Nailing for A Tibial Shaft Fracture

B. Lay Summary (Max. 200 words)§

[§]Please note: This information will be published on CPRD's website as part of its transparency policy

Tibial shaft fractures are the most common long bone fracture of the lower limbs. Intramedullary nailing is the most frequent surgical treatment for tibial shaft fractures. In patients with tibial shaft fractures, infection is an important complication as about 15% of these fractures are open injuries. Such infections may lead to devastating consequences such as increase in length of hospital stay, readmissions, prolonged medication treatment and reoperations along with high use of medical resources and costs. However, the healthcare burden among patients developing an infection in tibial shaft fracture is not well documented. Consequently, this study seeks to understand the impact of infection after intramedullary nailing in patients with tibial shaft fractures on healthcare use and cost of care.

C. Technical Summary (Max. 200 words)§

Please note: This information will be published on CPRD's website as part of its transparency policy

The objective of this retrospective longitudinal cohort study is primarily designed to determine short (30day, 90-day) and mid-term (one-year, two-year) healthcare resource utilization (HRU) and costs among patients with deep and superficial infections versus those without following intramedullary nailing for a tibial shaft fracture. Patients with tibial shaft fracture treated with intramedullary nailing between 2011 and 2016 will be selected. The main exposure variable will include deep infection versus superficial surgical site infection or no infection. Analyses will be both descriptive and comparative using multivariable models. The multivariable models will include generalized linear models (GLMs) based on the outcome variable of interest for HRU and costs and will adjust for patient characteristics.

Applicants must complete all sections listed below Sections which do not apply should be completed as '*Not Applicable*'

D. Objectives, Specific Aims and Rationale

Broad Research Objectives

To evaluate the impact of developing infection in patients with intramedullary nailing for tibial shaft fractures on healthcare utilization and cost of care.

Specific Aims

1. To determine short (30-day, 90-day) and mid-term (one-year, two-year) Costs and HRU among patients with deep infection and superficial infections versus patients without an infection following tibial shaft fracture treated with nailing.

Rationale

This study seeks to understand the impact of post-surgical infection in patients with intramedullary nailing for tibial shaft fractures on cost of care and healthcare utilization.

E. Study Background

Infections remains a feared complication in orthopaedic and trauma surgery due to its potentially devastating consequences for patients. It has also been associated with an increase in medical resource utilization and treatment costs due to increased length of hospital stay, readmissions, prolonged pharmacological treatment and reoperations. ¹⁻⁶ Deep infections defined as infections involving deeper tissues such as muscular fascia and bone⁷ have been associated with a significant economic burden for healthcare systems. Data from long bone fracture reduction, hip replacement or hemiarthroplasty or screw fixation for proximal humeral fractures and knee arthroplasty, consistently reported 2-3 times higher treatment costs for patients that developed an infection compared to those that did not. ¹⁻⁶

Tibial shaft fractures are the most common long bone fracture of the lower limbs.⁸ In patients with tibial shaft fractures, infection is an important complication as about 15% of these fractures are open injuries. Infection may lead to prolonged treatment, compromised clinical outcomes and in some cases, even limb amputation. ⁹⁻¹² In the European setting there is limited data available with respect to the actual cost of treatment. In a Danish study on patients with open tibia fractures treated with a free flap, the presence of an infection increased the mean length of hospital stay from 28 to 63.8 days and the mean treatment costs from €49,301 to €67,958 for infected compared to uninfected fractures.¹³A study from the UK reported the mean length of stay and treatment costs of patients with tibial osteomyelitis. For patients treated with limb salvage procedures alone, length of stay was 15 days (10-27) and corresponding treatment costs were €16,718 while for patients, whose treatment ended up in amputation length of stay was 13 days (8-17) and treatment costs were €18,441.¹⁴

Intramedullary nailing is the preferred surgical treatment in patients with tibial shaft fractures. The impact of the development of an infection on short and mid-term post-operative medical resource utilization is not well documented. While literature from clinical trials provides some insight into infection incidence rates, the treatment pathway and treatment success/failure rates, there is a lack of detailed patient-level information particularly in relation to the actual costs of care.

	Applicants must complete all sections listed below
	Sections which do not apply should be completed as ' <i>Not Applicable</i> '
F. \$	Study Type
Hv	oothesis generating
-	s study will generate the hypothesis for HRU and costs between patients with (deep and superficia
	without infection after intramedullary nailing for tibial shaft fractures
G	Study Design
0. (
ть:	a is a nation and two appoints attractively with a longitudinal fallow, up for up to two years post intromedull
	s is a retrospective cohort study with a longitudinal follow-up for up to two years post intramedull ing for tibial shaft fractures.
H. I	Feasibility counts
Dee	ed on the preliminary feasibility study of Hospital Episode Statistics (HES) inpatient data for rese
	le patients with complete data, we identified a total of 11,329 patients with intramedullary nailing
	al shaft fracture between 2011 and 2013 of which 509 patients had an infection following
	amedullary nailing for a tibial shaft fracture.
mu	
I.Sa	ample size considerations
No	prior real-world studies have been conducted to evaluate the health care resource use and costs of
inte	rest among patients with and without infection following intramedullary nailing for tibial shaft
frac	cture. Therefore, it is not possible to estimate the sample size
	Data Linkage Required (if applicable): [§]
Plea	ase note that the data linkage/s requested in research protocols will be published by the CPRD as part of its transparency policy
	Clinical Practice Research Datalink (CPRD) with HES is required to identify the patients and
	comes that are based on diagnosis and procedures recorded in the inpatient setting.
K. \$	Study population
Pati	ents initially selected for tibial shaft fracture (ICD-10, S822) must meet all the following inclusion
crit	eria:
1	Procedure for intramedullary nailing for tibial shaft fracture (appendix) between January 1, 2011 a
	February 30, 2016
	• Date of first intramedullary nailing for tibial shaft fracture between January 2011 and Februar
•	2016 will be the index date
2.	Research grade patients with complete medical records for at least 12 months pre- and 30- day po
	index date. Patients with 90-day, 1- and 2- year follow-up or continuous enrollment will be further
	analysed.
Pat	ients with the following criteria were excluded:
1.	Records for intramedullary nailing for tibial shaft fracture during the 12-month pre-index period
2.	Records for treatment with internal fixation (appendix) during the 12-month pre-index period
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	Applicants must complete all sections listed below Sections which do not apply should be completed as ' <i>Not Applicable</i> '
	Records for treatment with external fixation (appendix) from 12-month pre-index to 6 weeks pre- index. Records for external fixation during 6 weeks pre-index will be included as external fixation often performed prior to intramedullary nailing. Records for severe multiple injuries to different parts of the body (polytrauma) (appendix) in the 12 month pre-index period.
5.	Records for a fracture in neoplastic disease (appendix) in the 12-month pre-index period.
L.	Selection of comparison group(s) or controls
Pat	ients not developing an infection anytime during the study period will be selected as the control gro
	Exposures, Health Outcomes [§] and Covariates
[§] Pl∉ as p	ase note: Summary information on health outcomes (as included on the ISAC application form above)will be published on CPRD's we art of its transparency policy
Бv	
	posure ients developing infection during the 12-month post index period.
<u>Ou</u>	tcome(s)
Pri	mary Outcome
On	e- year inpatient costs
See	condary Outcomes
•	Number of hospital readmissions (in 30-days, 90-days, 1 year and 2 years)
•	Percent (yes/no) of patients with readmissions (in 30-days, 90-days, 1 year and 2 years)
•	Total cost of care at the different time points (in 30-days, 90-days, 1 year and 2 years)
	a. Inpatient admissions
	b. Outpatient costs
C.	c. Pharmacy
	sts will be expressed in UK pounds and adjusted for inflation to 2015 index. Healthcare costs wil tained from the Personal Social Services Research Unit (PSSRU) 2015 Cost of Care public docur
	Healthcare Resource Group (HRG) codes available in HES. Drug costs will be obtained from Br
	tional Formulary 71 (March 2016-September 2016).
1	
•	Number of procedures for introduction of therapeutic substance (Appendix) (30-days, 90-days, 1 y and 2 years)
•	Number of outpatient visits (all-cause) at the different time points (in 30-days, 90-days, 1 year and years)
•	Number of diagnostic tests and imaging (all-cause) at the different time points (in 30-days, 90-day year and 2 years)
•	Number of days in ICU (all-cause) at the different time points (in 30-days, 90-days, 1 year and 2 years)
•	Time of infection and type of infection (bacterial vs other)
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	Applicants must complete all sections listed below Sections which do not apply should be completed as ' <i>Not Applicabl</i> e'
•	Percent (yes/no) of patients with use of antibiotics at the different time points (in 30-days, 90-day
	year and 2 years)
	Patients necessitated amputation (Appendix) at the different time points (in 30-days, 90-days, 1 y
Cor	and 2 years) variates
	e covariates information will be captured during 12-month pre-index period and will include the
foll	owing:
Pat	ient Demographics
•	Age
•	Gender
•	Smoking status
Dre	ocedural Characteristics
170	
•	Year of the index date
Pat	ient Clinical Characteristics
Соі	morbidities (Appendix)
_	Distance
	Diabetes
	Dyspnea Ventilator requirement
	Chronic obstructive pulmonary disease (COPD)
•	Congestive heart failure (CHF)
•	Renal failure
•	Hypertension
Ind	ices Charles a semantidity in day (CCI). The CCL is an approach a semantidity exacted
	• Charlson comorbidity index (CCI) - The CCI is an aggregate measure of comorbidity created using select diagnoses associated with chronic disease (e.g., heart disease, cancer). The CCI
	includes 17 medical conditions and weights these conditions from $+1$ to $+6$.
Me	dications
	Anti-hypertensive medications
	Opioids
-	opiolas
N. 1	Data/ Statistical Analysis
All	study variables will be analyzed descriptively. Frequency counts and proportions will be provide
	hotomous and polychotomous variables. Means, medians, and standard deviations will be provide
	tinuous variables. Time to infection will be depicted graphically using Kaplan-Meier curve.
	adjusted comparisons of patient demographics, comorbidities and medication use between groups
	without infection) will be performed with 2-sample t-tests for continuous variables and χ^2 tests f
cate	egorical variables and Wilcoxon rank sum tests for cost variables.

Applicants must complete all sections listed below Sections which do not apply should be completed as '*Not Applicable*'

A sub-analysis will be conducted in which patients will be stratified by an open fracture and a closed tibial shaft fracture (appendix) to determine the outcomes.

All analyses will be conducted using SAS for Windows. Statistical significance will be set a-priori at p< 0.05 (two-sided).

In addition, a generalized Linear Model (GLM) will be utilized to get adjusted results after control for confounding. Details of this methods are mentioned in the section below:

O. Plan for addressing confounding

Multivariable models will be constructed to examine the impact of infection versus no infection and other patient characteristics for healthcare utilization and cost outcomes. A Generalized Linear Model (GLM) will be utilized and the appropriate error distribution and link function will be used based on the outcome variable of interest for utilization and costs.

Following standard procedures, for each model regression diagnostics will be performed to assess goodness of fit and violations of model assumptions. Appropriate modifications will be made as needed either through selection of alternative error distributions or link functions, or through transformations of either the independent or dependent variables. We will also examine the fitted and the observed data to uncover outliers, their effect on the analysis, and possible misspecification of the initial equation.

P. Plans for addressing missing data

Missing data will not be imputed for the analyses. Most variables (drugs, procedures, diagnosis) can have no missing values, as they are assumed not to have occurred unless a record is identified. To be included in the study, patients will need to have complete medical history for at least 12 months pre-index to 12 months post-index date.

Q. Patient or user group involvement (if applicable)

This is purely an observational study using CPRD with HES linkage data. This study does not involve requesting additional information from GPs. Also, the study does not require contacting patients to get any additional information.

R. Plans for disseminating and communicating study results, including the presence or absence of any restrictions on the extent and timing of publication

The study will be disseminated per the ICMJE guidelines. We plan on submitting the results to a peer-reviewed journal and presenting the results at scientific conferences.

S. Limitations of the study design, data sources, and analytic methods

	Applicants must complete all sections listed below Sections which do not apply should be completed as ' <i>Not Applicable</i> '
•	Potential bias in patient population: only patients with complete medical history for 12 months po
	index will be included, thus excluding very severe patients with less than 12 month life expectar
•	Coding errors and misclassifications
•	Under-reported or missing diagnoses, based on patients' choice (not to seek care) or access challes
•	Identify pharmacy cost in terms of medication prescribed in the primary care setting only
•	Cost evaluated using PSSRU, HRG and BNF codes as the costs are not directly available in the da
Τ.	References
1	de Lissovoy G, Fraeman K, Hutchins V, et al. Surgical site infection: incidence and impact on hos utilization and treatment costs. American journal of infection control 2009; 37 (5):387-97.
2	Jenks PJ, Laurent M, McQuarry S, et al. Clinical and economic burden of surgical site infection (S
	and predicted financial consequences of elimination of SSI from an English hospital. The Jou of hospital infection 2014; 86 (1):24-33.
3	Pollard TC, Newman JE, Barlow NJ, et al. Deep wound infection after proximal femoral fracture:
	consequences and costs. The Journal of hospital infection 2006;63(2):133-9.
4	Schmidt A, Benard S, Cyr S. Hospital Cost of Staphylococcal Infection after Cardiothoracic or
	Orthopedic Operations in France: A Retrospective Database Analysis. Surgical infections
	2015; 16 (4):428-35.
5	Thakore RV, Greenberg SE, Shi H, et al. Surgical site infection in orthopedic trauma: A case-cont
	study evaluating risk factors and cost. Journal of clinical orthopaedics and trauma 2015;6(4):
	6.
6	Wijeratna MD, McRoberts J, Porteous MJ. Cost of infection after surgery for intracapsular fracture
	the femoral neck. Annals of the Royal College of Surgeons of England 2015;97(4):283-6.
7.	Metsemakers WJ, Handojo K, Reynders P, et al. Individual risk factors for deep infection and
	compromised fracture healing after intramedullary nailing of tibial shaft fractures: a single ce
0	experience of 480 patients. Injury 2015; 46 (4):740-5.
8	Minhas SV, Ho BS, Switaj PJ, et al. A comparison of 30-day complications following plate fixation
0	versus intramedullary nailing of closed extra-articular tibia fractures. Injury 2015; 46 (4):734-9
9.	Buckley RE, Colton C. Infection. Secondary Infection 2012. https://www2.aofoundation.org/wps/portal/surgery?showPage=redfix&bone=Tibia&segment
	ft&classification=42-
	Special% 20considerations&treatment=&method=Special% 20considerations&implantstype=
	lications&approach=&redfix_url=1341319024234.
1(D. Hannigan GD, Pulos N, Grice EA, et al. Current Concepts and Ongoing Research in the Prevention
1	and Treatment of Open Fracture Infections. Advances in wound care 2015;4(1):59-74.
1	1. Kanakaris NK, Tosounidis TH, Giannoudis PV. Surgical management of infected non-unions: Ai
-	update. Injury 2015; 46 Suppl 5 :S25-32.
12	2. Mouzopoulos G, Kanakaris NK, Kontakis G, et al. Management of bone infections in adults: the
	surgeon's and microbiologist's perspectives. Injury 2011;42 Suppl 5:S18-23.
1	3. The cost of infection in severe open tibial fractures treated with a free flap. 34th Annual Meeting
	the European Bone & Joint Infection Society; 2015; Lisbon, Portugal.
14	4. Kendall J, Jones, S., Mcnally, M. Income and costs of treating tibial osteomyelitis in the uk – a
	comparison of limb salvage versus amputation. 34th Annual Meeting of the European Bone &
	Joint Infection Society. Lisbon, Portugal, 2015.
Li	st of Appendices (Submit all appendices as separate documents to this application)
	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

2	
-	
2	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
10	
עו סכ	
20	
21	
3 4 5 6 7 8 9 10 11 23 4 5 6 7 8 9 10 11 23 24 25 26 27 28 9 30 31 23 34 35 6 37 38	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
32	
37	
25	
22	
30	
3/	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
5 0	
53	
54	
55	
56	
57	
58	
59	
60	

Applicants must complete all sections listed below Sections which do not apply should be completed as '*Not Applicable*'

Appendix 1: OPCS-4 codes to identify intramedullary nailing for long bones
Appendix 2 OPCS-4 codes to identify internal fixation
Appendix 3 OPCS-4 codes to identify external fixation
Appendix 4: ICD-10 codes to identify severe multiple injuries
Appendix 5: Read codes to identify fracture due to neoplastic disease
Appendix 6: ICD-10, OPCS and Read codes to identify infection
Appendix 7: OPCS-4 codes to identify procedures for introduction of therapeutic substance
Appendix 8: OPCS-4 codes to identify procedures amputation of tibia bone
Appendix 9: Read codes to identify diabetes mellitus with and without complications
Appendix 10: Read codes to identify dyspnoea
Appendix 11: Read codes to identify ventilator requirement
Appendix 12: Read codes to identify COPD
Appendix 13: Read codes to identify heart failure
Appendix 14: Read codes to identify renal failure
Appendix 15: Read codes to identify hypertension
Appendix 16: Read, ICD-10 and OPCS codes to identify open and closed tibial shaft fracture
Appendix 17: Read codes to identify Charlson comorbidity index
Appendix 18: OPCS codes to identify reoperations

1. OPCS-4 codes to identify intramedullary nailing for long bones

OPCS-4	Description	
W192	Primary open reduction of fracture of long bone and fixation using rigid nail NEC	
W242	Closed reduction of fracture of long bone and rigid internal fixation NEC	
2 OPCS-4 codes to identify internal fixation		

2. OPCS-4 codes to identify internal fixation

OPCS-4	Description
0172	Remanipulation of fracture of long bone and rigid internal fixation NEC
0173	Remanipulation of fracture of long bone and flexible internal fixation HFQ
O175	Remanipulation of fragment of bone and fixation using screw
O178	Other specified secondary closed reduction of fracture of bone and internal fixation
O179	Unspecified secondary closed reduction of fracture of bone and internal fixation
W195	Primary open reduction of fragment of bone and fixation using screw
W196	Primary open reduction of fragment of bone and fixation using wire system
W198	Other specified primary open reduction of fracture of bone and intramedullary fixation
W199	Unspecified primary open reduction of fracture of bone and intramedullary fixation

1
2
3 4
5
6
7 8
9
10
11 12
13
14
15 16
17
17 18
19 20
20 21
21 22
23
24 25
26
27
28 29
30
31 32
32
33 34
34 35
36
37 38
39
40
41 42
42 43
44
45
46 47
48
49
50 51
52
53
54 55
55 56
57
58
59

OPCS-4	Description
W201	Primary open reduction of fracture of long bone and extramedullary fixation using plate NEC
W202	Primary open reduction of fracture of long bone and extramedullary fixation using cerclage
W203	Primary open reduction of fracture of long bone and extramedullary fixation using suture
W204	Primary open reduction of fracture of long bone and complex extramedullary fixation NEC
W208	Other specified primary open reduction of fracture of bone and extramedullary fixation
W209	Unspecified primary open reduction of fracture of bone and extramedullary fixation
W231	Secondary open reduction of fracture of bone and intramedullary fixation HFQ
W232	Secondary open reduction of fracture of bone and extramedullary fixation HFQ
W236	Secondary open reduction of fracture of bone and internal fixation HFQ
W248	Other specified closed reduction of fracture of bone and internal fixation
W249	Unspecified closed reduction of fracture of bone and internal fixation
W281	Application of internal fixation to bone NEC
W282	Adjustment to internal fixation of bone NEC
W283	Removal of internal fixation from bone NEC
W288	Other specified other internal fixation of bone
W289	Unspecified other internal fixation of bone
	Unspecified other internal fixation of bone codes to identify external fixation

3. OPCS-4 codes to identify external fixation

OPCS-4	Description
W222	Primary open reduction of fracture of bone and external fixation HFQ
W235	Secondary open reduction of fracture of bone and external fixation HFQ
W252	Closed reduction of fracture of bone and fixation using functional bracing system
W253	Remanipulation of fracture of bone and external fixation HFQ
W258	Other specified closed reduction of fracture of bone and external fixation
W259	Unspecified closed reduction of fracture of bone and external fixation
W301	Application of external fixation to bone NEC
W302	Adjustment to external fixation of bone NEC
W303	Removal of external fixation from bone NEC
W304	Application of external ring fixation to bone NEC
W308	Other specified other external fixation of bone
W309	Unspecified other external fixation of bone

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

ICD-10 codes	Description
S097	Multiple injuries of head
S197	Multiple injuries of neck
S277	Multiple injuries of intrathoracic organs
S297	Multiple injuries of thorax
S397	Other multiple injuries of abdomen, lower back and pelvis
S497	Multiple injuries of shoulder and upper arm
S597	Multiple injuries of forearm
S647	Injury of multiple nerves at wrist and hand level
S697	Multiple injuries of wrist and hand
S797	Multiple injuries of hip and thigh
S897	Multiple injuries of lower leg
S997	Multiple injuries of ankle and foot
T042	Crushing injuries involving multiple region of upper limb(s)
T043	Crushing injuries involving multiple region of lower limb(s)
T062	Injuries of nerves involving multiple body regions
T063	Injuries of blood vessels involving multiple body regions
T068	Other specified injuries involving multiple body regions
T07X	Unspecified multiple injuries

ICD-10 codes to identify severe multiple injuries

5. Read codes to identify fracture due to neoplastic disease

Medcode	Read_code	Description
54834	N331700	Fracture of bone in neoplastic disease
6. ICD-10, OP	CS and Read	codes to identify infection

6. ICD-10, OPCS and Read codes to identify infection

ICD-10 codes	Description	Deep/Superficial
A498	Other bacterial infections of unspecified site	Deep
A499	Bacterial infection, unspecified	Deep
A544	Gonococcal infection of musculoskeletal system	Deep
L088	Other spec local infections of skin and subcutaneous tissue	Superficial
L089	Local infection of skin and subcutaneous tissue, unspecified	Superficial
T814	Infection following a procedure, not elsewhere classified	Deep

1 2
2 3 4
5
6 7
8 9
10
11 12
13
14 15
16 17
18
19 20
21
22 23
24 25
26
27 28
29 30
31
32 33
34 35
36
37 38
39
40 41
42 43
44
45 46
47
48 49
50 51
52
53 54
55 56
57
58 59
60

Medcode	Read_code	Description	Deep/Superficia
3128	M07z.00	Local infection skin/subcut tissue NOS	Superficial
6956	SK03.00	Post-traumatic wound infection NEC	Deep
7155	N302.11	Bone infection	Deep
51854	SP25600	Postoperative wound infection-deep	Deep
20342	N3000	Osteomyelitis, periostitis, other infections affecting bone	Deep
21073	M07y.00	Local infection of skin or subcutaneous tissue OS	Superficial
25363	SP06800	Infection and inflamm reac due inter ortho device	Deep
40293	SP06.00	Infection and inflammation due to internal prosthetic device	Deep
30381	SP05612	[X]Prosthetic infection	Deep
33381	A3Byz00	Other specified bacterial infection NOS	Superficial
43058	N30z.00	Bone infection NOS	Deep
39830	N300.12	Acute bone infection	Deep
40293	SP06.00	Infection and inflammation due to internal prosthetic device	Deep
52122	Myu0.00	[X]Infections of the skin and subcutaneous tissue	Superficial
69280	N30z600	Bone infection NOS, of the lower leg	Deep
69855	N30y600	Other infections involving bone, of the lower leg	Deep
4207	M03z000	Cellulitis NOS	Superficial

OPCS-4	Description	Deep/Superficial
S571	Debridement of skin NEC	Superficial
W332	Debridement of open fracture of bone	Deep
T963	Debridement of soft tissue NEC	Deep
W336	Debridement of bone NEC	Deep

7. OPCS-4 codes to identify procedures for debridement or introduction of therapeutic substance

OPCS-4	Description	
S571	Debridement of skin NEC	
W332	Debridement of open fracture of bone	
T963	Debridement of soft tissue NEC	

W336	Debridement of bone NEC	
W283	Removal of internal fixation from bone NEC	
X292	Continuous intravenous infusion of therapeutic substance NEC	
S523	Insertion of therapeutic substance into subcutaneous tissue NEC	
W351	Introduction of therapeutic substance into bone	

8. OPCS-4 codes to identify procedures amputation of tibia bone

OPCS-4	Description	
X094	Amputation of leg through knee	
X095	Amputation of leg below knee	
X098	Other specified amputation of leg	
X099	Unspecified amputation of leg	

9. Read codes to identify diabetes mellitus with and without complications

Medcodes	Read code	Description
231370	66AJ.11	Unstable diabetes
297735	C108600	Insulin dependent diabetes mellitus with gangrene
288454	C101100	Diabetes mellitus, adult onset, with ketoacidosis
344495	C10M.00	Lipoatrophic diabetes mellitus
224500	C103000	Diabetes mellitus, juvenile type, with ketoacidotic coma
233608	C109500	Non-insulin dependent diabetes mellitus with gangrene
251808	C109900	Non-insulin-dependent diabetes mellitus without complication
331810	C109412	Type 2 diabetes mellitus with ulcer
344028	C10FG00	Type 2 diabetes mellitus with arthropathy
279344	C109.11	NIDDM - Non-insulin dependent diabetes mellitus
343531	C109G11	Type II diabetes mellitus with arthropathy
279348	C10z.00	Diabetes mellitus with unspecified complication
342740	C10EM11	Type I diabetes mellitus with ketoacidosis
279343	C107200	Diabetes mellitus, adult with gangrene
210870	250 GA	Gangrene diabetic
339961	C10FJ00	Insulin treated Type 2 diabetes mellitus
308067	C108911	Type I diabetes mellitus maturity onset
297727	C102z00	Diabetes mellitus NOS with hyperosmolar coma
283820	250 HC	Hypoglycaemic Coma Diabetic
303253	250 AK	Maturity Onset Diabetes Mellitus Insulin
243302	G73y000	Diabetic Peripheral Angiopathy

1
2
3
4
4
5
6
7
8
9
10
11
12
13
14
15
16
16 17
10
18
19
20
21
22
22 23
23
24
25
26
26 27
27
28
29
30
21
31 32
32
33
34
34 35 36 37
22
36
37
38
39
40
41
42
43
44
45
46
47
48
49
49
50
51
52
53
54
56
57
58
50

Medcodes	Read code	Description
306131	250 E	Hypoglycaemia In Diabetes Mellitus
249566	66AJ.00	Diabetic - Poor Control
331925	C109J12	Insulin treated Type II diabetes mellitus
309010	C109F12	Type 2 diabetes mellitus with peripheral angiopathy
242649	C109300	Non-insulin-dependent diabetes mellitus with multiple comps
242646	C108400	Unstable insulin dependent diabetes mellitus
340367	C10F900	Type 2 diabetes mellitus without complication
206461	C10y.00	Diabetes mellitus with other specified manifestation
344412	C10F.11	Type II diabetes mellitus
341116	C10FL00	Type 2 diabetes mellitus with persistent proteinuria
306134	250 NT	UNSTABLE DIABETIC
309704	C109G00	Non-insulin dependent diabetes mellitus with arthropathy
343565	C109G12	Type 2 diabetes mellitus with arthropathy
249564	66A5.00	Diabetic on insulin
308094	C109511	Type II diabetes mellitus with gangrene
243795	L180600	Pre-existing diabetes mellitus, non-insulin-dependent
256384	250 PR	Pruritus Diabetic
341003	C10FN00	Type 2 diabetes mellitus with ketoacidosis
341356	C10E400	Unstable type 1 diabetes mellitus
270277	C10zy00	Other specified diabetes mellitus with unspecified comps
341680	C10D.00	Diabetes mellitus autosomal dominant type 2
288459	C107z00	Diabetes mellitus NOS with peripheral circulatory disorder
341002	C10EN00	Type 1 diabetes mellitus with ketoacidotic coma
303258	250 CT	Diabetic Cataract
215438	C101000	Diabetes mellitus, juvenile type, with ketoacidosis
206451	C100011	Insulin dependent diabetes mellitus
229069	250 JA	Diabetic Acidosis
309863	C108411	Unstable type I diabetes mellitus
303250	250 A	Sugar Diabetes
206452	C103.00	Diabetes mellitus with ketoacidotic coma
261004	C107.11	Diabetes mellitus with gangrene
303263	250 JL	Ketosis Diabetic
303256	250 AN	Diabetes
341598	C10E500	Type 1 diabetes mellitus with ulcer

Medcodes	Read code	Description
242650	C109400	Non-insulin dependent diabetes mellitus with ulcer
297739	C10yy00	Other specified diabetes mellitus with other spec comps
292948	250 AB	Abscess Diabetic
307957	C109711	Type II diabetes mellitus - poor control
261009	C10A000	Malnutrition-related diabetes mellitus with coma
339633	C10F.00	Type 2 diabetes mellitus
309658	C109J11	Insulin treated non-insulin dependent diabetes mellitus
223592	8A13.00	Diabetic stabilisation
233607	C108.00	Insulin dependent diabetes mellitus
347683	C10EG00	Type 1 diabetes mellitus with peripheral angiopathy
340865	C108E12	Type 1 diabetes mellitus with hypoglycaemic coma
302787	C108.13	Type I diabetes mellitus
270271	C107100	Diabetes mellitus, adult, peripheral circulatory disorder
233609	C10A100	Malnutrition-related diabetes mellitus with ketoacidosis
261001	C102000	Diabetes mellitus, juvenile type, with hyperosmolar coma
237987	250 AT	Diabetic Amyotrophy
308119	C109411	Type II diabetes mellitus with ulcer
341509	C10F500	Type 2 diabetes mellitus with gangrene
303262	250 JK	Ketoacidosis Diabetic
297726	C102100	Diabetes mellitus, adult onset, with hyperosmolar coma
308004	C108E11	Type I diabetes mellitus with hypoglycaemic coma
339527	C109K00	Hyperosmolar non-ketotic state in type 2 diabetes mellitus
247153	250 G	Ulcer Diabetic
258769	66AJz00	Diabetic - poor control NOS
347258	C10FJ11	Insulin treated Type II diabetes mellitus
297734	C108500	Insulin dependent diabetes mellitus with ulcer
309300	C109J00	Insulin treated Type 2 diabetes mellitus
341126	C10E800	Type 1 diabetes mellitus - poor control
309125	C108812	Type 1 diabetes mellitus - poor control
206454	C107400	NIDDM with peripheral circulatory disorder
343055	C10G.00	Secondary pancreatic diabetes mellitus
340580	C10EM00	Type 1 diabetes mellitus with ketoacidosis
331540	66AV.00	Diabetic on insulin and oral treatment
298869	L180500	Pre-existing diabetes mellitus, insulin-dependent

1	
2	
5 ⊿	
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 36 37 37 38 39 30 31 32 33 34 35 36 37 37 38 37 38 37 38 37 38 37 38 37 38 38 39 30 30 31 32 32 33 34 35 36 37 37 38 38 39 30 31 32 33 34 35 36 37 37 38 37 38 38 39 30 31 32 33 34 35 36 37 37 37 37 37 37 37 37 37 37	
5	
0	
/ 0	
0	
9	
10	
11	
12	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

Medcodes	Read code	Description
342313	C10FP00	Type 2 diabetes mellitus with ketoacidotic coma
297725	C100.00	Diabetes mellitus with no mention of complication
344338	C10E600	Type 1 diabetes mellitus with gangrene
333576	C109D12	Type 2 diabetes mellitus with hypoglycaemic coma
341127	C10FF00	Type 2 diabetes mellitus with peripheral angiopathy
261005	C108.12	Type 1 diabetes mellitus
206457	C109.00	Non-insulin-dependent diabetes mellitus
331823	C109D00	Non-insulin dependent diabetes mellitus with hypoglyca coma
242656	C10zz00	Diabetes mellitus NOS with unspecified complication
340814	C10EE00	Type 1 diabetes mellitus with hypoglycaemic coma
295382	66AS.00	Diabetic annual review
233606	C107000	Diabetes mellitus, juvenile ??? circulatory disorder
347648	C10E412	Unstable insulin dependent diabetes mellitus
341139	C10E900	Type 1 diabetes mellitus maturity onset
242642	C101y00	Other specified diabetes mellitus with ketoacidosis
344989	C10FL11	Type II diabetes mellitus with persistent proteinuria
247152	250 DR	Diabetic Diarrhoea
283822	250 NH	Hyperosmolar Diabetic State
303259	250 DC	Dietary Control Diabetes
310005	C109712	Type 2 diabetes mellitus - poor control
270372	Cyu2.00	[X]Diabetes mellitus
270268	C1000	Diabetes mellitus
346131	C10EA00	Type 1 diabetes mellitus without complication
279341	C100z00	Diabetes mellitus NOS with no mention of complication
297729	C103z00	Diabetes mellitus NOS with ketoacidotic coma
331809	C108G00	Insulin dependent diab mell with peripheral angiopathy
308089	C108E00	Insulin dependent diabetes mellitus with hypoglycaemic coma
215437	C101.00	Diabetes mellitus with ketoacidosis
347882	C10E812	Insulin dependent diabetes mellitus - poor control
341302	C10F700	Type 2 diabetes mellitus - poor control
222266	66AK.00	Diabetic - cooperative patient
270276	C10B000	Steroid induced diabetes mellitus without complication
233603	C100111	Maturity onset diabetes
339632	C10E.00	Type 1 diabetes mellitus

Medcodes	Read code	Description
223655	8H2J.00	Admit diabetic emergency
283823	2500AH	Latent Diabetes
285267	1434	H/O: diabetes mellitus
308820	C108811	Type I diabetes mellitus - poor control
344076	C10E.12	Insulin dependent diabetes mellitus
270269	C100100	Diabetes mellitus, adult onset, no mention of complication
341357	C10F400	Type 2 diabetes mellitus with ulcer
242655	C10z100	Diabetes mellitus, adult onset, unspecified complication
280482	L180X00	Pre-existing diabetes mellitus, unspecified
341557	8BL2.00	Patient on maximal tolerated therapy for diabetes
242653	C10yz00	Diabetes mellitus NOS with other specified manifestation
288455	C102.00	Diabetes mellitus with hyperosmolar coma
270275	C10A.00	Malnutrition-related diabetes mellitus
270273	C108.11	IDDM-Insulin dependent diabetes mellitus
215439	C101z00	Diabetes mellitus NOS with ketoacidosis
342317	C10FD00	Type 2 diabetes mellitus with hypoglycaemic coma
261007	C108800	Insulin dependent diabetes mellitus - poor control
303261	250 HP	Precoma Diabetic
341856	C10EK00	Type 1 diabetes mellitus with persistent proteinuria
303252	250 AD	Diabetes Mellitus Insulin Dependant
347025	C10H.00	Diabetes mellitus induced by non-steroid drugs
270270	C107.00	Diabetes mellitus with peripheral circulatory disorder
332066	C10D.11	Maturity onset diabetes in youth type 2
224506	C107300	IDDM with peripheral circulatory disorder
340332	C109F11	Type II diabetes mellitus with peripheral angiopathy
309143	C109D11	Type II diabetes mellitus with hypoglycaemic coma
341409	C10EL00	Type 1 diabetes mellitus with persistent microalbuminuria
242641	C100112	Non-insulin dependent diabetes mellitus
340474	C10FM00	Type 2 diabetes mellitus with persistent microalbuminuria
261095	Cyu2000	[X]Other specified diabetes mellitus
288460	C109.12	Type 2 diabetes mellitus
224501	C103y00	Other specified diabetes mellitus with coma
302788	C109.13	Type II diabetes mellitus
332948	C108511	Type I diabetes mellitus with ulcer

1
2 3
2 3 4 5 6 7 8 9 10 11 12
4
5
6
7
8
9
10
11
12
13
11
15
16
10
12 13 14 15 16 17 18 19 20
18
19
20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 28
21
22
23
24
25
26
20
27
20
29
30
31
32
33
34
35
36
37
38
39
40
40 41
42
43
44
45
46
47
48
49
50
51
52
52 53
53 54
55
56
57
58
50

Medcodes	Read code	Description
347834	C10EN11	Type I diabetes mellitus with ketoacidotic coma
297738	C109700	Non-insulin dependent diabetes mellitus - poor control
283819	250 H	Coma Diabetic
215444	C10y100	Diabetes mellitus, adult, other specified manifestation
346130	C10E.11	Type I diabetes mellitus
344745	C10N.00	Secondary diabetes mellitus
347629	C10F711	Type II diabetes mellitus - poor control
277055	66AI.00	Diabetic - good control
251805	C100000	Diabetes mellitus, juvenile type, no mention of complication
206900	F464000	Diabetic cataract
309738	C109212	Type 2 diabetes mellitus with neurological complications
224502	C104000	Diabetes mellitus, juvenile type, with renal manifestation
345097	C109111	Type II diabetes mellitus with ophthalmic complications
341813	2BBP.00	O/E - right eye background diabetic retinopathy
346841	C108C11	Type I diabetes mellitus with polyneuropathy
308934	C108H00	Insulin dependent diabetes mellitus with arthropathy
215442	C109C00	Non-insulin dependent diabetes mellitus with nephropathy
261008	C108B00	Insulin dependent diabetes mellitus with mononeuropathy
297732	C106100	Diabetes mellitus, adult onset, neurological manifestation
206455	C108000	Insulin-dependent diabetes mellitus with renal complications
309524	C109H00	Non-insulin dependent d m with neuropathic arthropathy
251806	C108200	Insulin-dependent diabetes mellitus with neurological comps
343081	C10F100	Type 2 diabetes mellitus with ophthalmic complications
341814	2BBQ.00	O/E - left eye background diabetic retinopathy
309275	C109011	Type II diabetes mellitus with renal complications
252191	F420200	Preproliferative diabetic retinopathy
288456	C105000	Diabetes mellitus, juvenile type, ophthalmic manifestation
347472	C10FR00	Type 2 diabetes mellitus with gastroparesis
288461	C109100	Non-insulin-dependent diabetes mellitus with ophthalm comp
306132	250 F	Neuropathy Diabetic
341286	C10FE00	Type 2 diabetes mellitus with diabetic cataract
308948	C108712	Type 1 diabetes mellitus with retinopathy
242643	C106.13	Diabetes mellitus with polyneuropathy
279760	F420.00	Diabetic retinopathy

Medcodes	Read code	Description
308463	C109612	Type 2 diabetes mellitus with retinopathy
270274	C109B00	Non-insulin dependent diabetes mellitus with polyneuropathy
309943	F420600	Non proliferative diabetic retinopathy
288457	C105y00	Other specified diabetes mellitus with ophthalmic complicatn
309614	C109E11	Type II diabetes mellitus with diabetic cataract
341801	C10FB00	Type 2 diabetes mellitus with polyneuropathy
340973	C10FA00	Type 2 diabetes mellitus with mononeuropathy
347417	C10F611	Type II diabetes mellitus with retinopathy
343003	C10E200	Type 1 diabetes mellitus with neurological complications
342681	C108B11	Type I diabetes mellitus with mononeuropathy
206459	C109600	Non-insulin-dependent diabetes mellitus with retinopathy
298103	F381300	Myasthenic syndrome due to diabetic amyotrophy
224505	C106z00	Diabetes mellitus NOS with neurological manifestation
224503	C104y00	Other specified diabetes mellitus with renal complications
342469	2BBV.00	O/E - left eye proliferative diabetic retinopathy
332953	C108711	Type I diabetes mellitus with retinopathy
279761	F420400	Diabetic maculopathy
201928	250 LG	Diabetic Glomerulos clerosis
309628	C109C12	Type 2 diabetes mellitus with nephropathy
224504	C106.11	Diabetic amyotrophy
207385	K01x111	Kimmelstiel - Wilson disease
206456	C108D00	Insulin dependent diabetes mellitus with nephropathy
341836	C108212	Type 1 diabetes mellitus with neurological complications
242645	C108100	Insulin-dependent diabetes mellitus with ophthalmic comps
288858	F3y0.00	Diabetic mononeuropathy
252174	F372.12	Diabetic neuropathy
234015	F420300	Advanced diabetic maculopathy
347410	C10F011	Type II diabetes mellitus with renal complications
344952	2BBI.00	O/E - left eye stable treated prolif diabetic retinopathy
339960	C10FC00	Type 2 diabetes mellitus with nephropathy
343345	C10EF00	Type 1 diabetes mellitus with diabetic cataract
308504	C109E12	Type 2 diabetes mellitus with diabetic cataract
309757	C108D11	Type I diabetes mellitus with nephropathy
308851	C109B11	Type II diabetes mellitus with polyneuropathy

1
2
_
3
4
5
ć
6
7
8
0
9
10
11
11
12
13
11
14
15
16
17
17
18
19
20
20
21
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 21 22 23 24 25 26 27 28 9 30 31 22 33 34 35 36 37
23
24
25
20
26
27
28
20
29
30
31
22
52
33
34
35
55
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
57
58
50

59	
60	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Medcodes	Read code	Description
341264	C10F200	Type 2 diabetes mellitus with neurological complications
346403	C10EB00	Type 1 diabetes mellitus with mononeuropathy
309007	C109H12	Type 2 diabetes mellitus with neuropathic arthropathy
333002	F420800	High risk non proliferative diabetic retinopathy
242647	C108700	Insulin dependent diabetes mellitus with retinopathy
341800	C10EC00	Type 1 diabetes mellitus with polyneuropathy
219965	250 M	Charcot's Diabetic Arthropathy
261411	F374z00	Polyneuropathy in disease NOS
309758	C109112	Type 2 diabetes mellitus with ophthalmic complications
306133	250 N	Diabetic Nephropathy
309796	2BBL.00	O/E - diabetic maculopathy present both eyes
331538	C109012	Type 2 diabetes mellitus with renal complications
242648	C109000	Non-insulin-dependent diabetes mellitus with renal comps
206458	C109200	Non-insulin-dependent diabetes mellitus with neuro comps
341701	F420700	High risk proliferative diabetic retinopathy
215440	C106.12	Diabetes mellitus with neuropathy
342045	2BBS.00	O/E - left eye preproliferative diabetic retinopathy
340163	C109E00	Non-insulin depend diabetes mellitus with diabetic cataract
340357	C10F600	Type 2 diabetes mellitus with retinopathy
297737	C108C00	Insulin dependent diabetes mellitus with polyneuropathy
336008	C108211	Type I diabetes mellitus with neurological complications
340987	C10E000	Type 1 diabetes mellitus with renal complications
310061	C109H11	Type II diabetes mellitus with neuropathic arthropathy
297731	C106.00	Diabetes mellitus with neurological manifestation
308830	C109611	Type II diabetes mellitus with retinopathy
233989	F372.11	Diabetic polyneuropathy
344951	2BBk.00	O/E - right eye stable treated prolif diabetic retinopathy
243072	F420z00	Diabetic retinopathy NOS
288458	C105z00	Diabetes mellitus NOS with ophthalmic manifestation
233604	C105100	Diabetes mellitus, adult onset, ophthalmic manifestation
340333	C10ED00	Type 1 diabetes mellitus with nephropathy
308871	C108F11	Type I diabetes mellitus with diabetic cataract
331568	C108011	Type I diabetes mellitus with renal complications
346291	C10FC11	Type II diabetes mellitus with nephropathy

Medcodes	Read code	Description
340162	C108012	Type 1 diabetes mellitus with renal complications
340507	C109A11	Type II diabetes mellitus with mononeuropathy
252180	F381311	Diabetic amyotrophy
308872	C109C11	Type II diabetes mellitus with nephropathy
347405	C10EQ00	Type 1 diabetes mellitus with gastroparesis
279345	C109A00	Non-insulin dependent diabetes mellitus with mononeuropathy
308715	C108F00	Insulin dependent diabetes mellitus with diabetic cataract
206453	C104.11	Diabetic nephropathy
342033	2BBR.00	O/E - right eye preproliferative diabetic retinopathy
333621	C108J12	Type 1 diabetes mellitus with neuropathic arthropathy
347771	C10FB11	Type II diabetes mellitus with polyneuropathy
297733	C106y00	Other specified diabetes mellitus with neurological comps
256383	250 LK	Kimmelstiel-Wilson Disease/Syndrome
340257	C10FH00	Type 2 diabetes mellitus with neuropathic arthropathy
341459	C10F000	Type 2 diabetes mellitus with renal complications
297730	C105.00	Diabetes mellitus with ophthalmic manifestation
261428	F420100	Proliferative diabetic retinopathy
333249	C109211	Type II diabetes mellitus with neurological complications
261003	C104z00	Diabetes mellitis with nephropathy NOS
341221	C10E100	Type 1 diabetes mellitus with ophthalmic complications
I0. Read code	s to identify dyspnoe	ea la
Medcode	Read_code	Description
3092	R060A00	[D]Dyspnoea
6434	1736.00	Paroxysmal nocturnal dyspnoea
7000	2322.00	O/E - dyspnoea
18116	173D.00	Nocturnal dyspnoea
53771	173C.11	Dyspnoea on exertion

10. Read codes to identify dyspnoea

Medcode	Read_code	Description
3092	R060A00	[D]Dyspnoea
6434	1736.00	Paroxysmal nocturnal dyspnoea
7000	2322.00	O/E - dyspnoea
18116	173D.00	Nocturnal dyspnoea
53771	173C.11	Dyspnoea on exertion

11. Read codes to identify ventilator requirement

Medcode	Read_code	Description
87337	7M36300	Ventilatory support

Medcode	Read code	Description
1001	H300	Chronic obstructive pulmonary disease
9520	66YB.00	Chronic obstructive pulmonary disease monitoring
9876	H3800	Severe chronic obstructive pulmonary disease
10802	H3700	Moderate chronic obstructive pulmonary disease
10863	H3600	Mild chronic obstructive pulmonary disease
11287	66YM.00	Chronic obstructive pulmonary disease annual review
18621	66YL.00	Chronic obstructive pulmonary disease follow-up
37247	H3z11	Chronic obstructive pulmonary disease NOS
45770	66Yg.00	Chronic obstructive pulmonary disease disturbs sleep
45771	66Yh.00	Chronic obstructive pulmonary disease does not disturb sleep
65733	Hyu3100	[X]Other specified chronic obstructive pulmonary disease
67040	H3y11	Other specified chronic obstructive pulmonary disease
93568	H3900	Very severe chronic obstructive pulmonary disease
102685	66YB000	Chronic obstructive pulmonary disease 3 monthly review
103007	66YB100	Chronic obstructive pulmonary disease 6 monthly review
103494	14B3.12	History of chronic obstructive pulmonary disease
104985	9NgP.00	On chronic obstructive pulmonary disease supprtv cre pathwa
105457	8CMW500	Chronic obstructive pulmonary disease care pathway
3. Read code	es to identify heart fa	ilure
Medcode	Read_code	Description
398	G580.00	Congestive heart failure

Medcode	Read_code	Description
398	G580.00	Congestive heart failure
2062	G5800	Heart failure
4024	G58z.00	Heart failure NOS
9913	10100	Heart failure confirmed
10079	G580.12	Right heart failure
15058	14A6.00	H/O: heart failure
17851	8HBE.00	Heart failure follow-up
21837	G232.00	Hypertensive heart&renal dis wth (congestive) heart failure
23707	G580000	Acute congestive heart failure
27964	G582.00	Acute heart failure
28684	G233.00	Hypertensive heart and renal disease with renal failure
30779	662W.00	Heart failure annual review
32671	G580100	Chronic congestive heart failure

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Medcode	Read_code	Description	
32898	8H2S.00	Admit heart failure emergency	
32911	9Or00	Heart failure monitoring administration	
32945	8CL3.00	Heart failure care plan discussed with patient	
46912	14AM.00	H/O: Heart failure in last year	
60099	67D4.00	Heart failure information given to patient	
66306	SP11111	Heart failure as a complication of care	
69062	9N6T.00	Referred by heart failure nurse specialist	
71235	8Hk0.00	Referred to heart failure education group	
83502	662p.00	Heart failure 6 month review	
94870	G580400	Congestive heart failure due to valvular disease	
96799	G5y4z00	Post cardiac operation heart failure NOS	
101137	G583.11	HFNEF - heart failure with normal ejection fraction	
101138	G583.00	Heart failure with normal ejection fraction	
103732	8CMK.00	Has heart failure management plan	
105002	679W100	Education about deteriorating heart failure	
105542	8CeC.00	Preferred place of care for next exacerbation heart failure	
106198	661M500	Heart failure self-management plan agreed	
4. Read code	s to identify renal fa	ilure	
Medcode	Read_code	Description	
350	K0600	Renal failure unspecified	

Medcode	Read_code	Description	
350	K0600	Renal failure unspecified	
512	K0500	Chronic renal failure	
2266	K0400	Acute renal failure	
6712	K050.00	End stage renal failure	
11554	SP15400	Renal failure as a complication of care	
11773	7L1A.11	Dialysis for renal failure	
15945	SK05.00	Renal failure following crush syndrome	
16929	D215.00	Anaemia secondary to renal failure	
24292	SP15412	Post operative renal failure	
24676	SK08.00	Acute renal failure due to rhabdomyolysis	
25394	D215000	Anaemia secondary to chronic renal failure	
25582	K04z.00	Acute renal failure NOS	
28684	G233.00	Hypertensive heart and renal disease with renal failure	
31549	7L1A.00	Compensation for renal failure	
32423	G222.00	Hypertensive renal disease with renal failure	

Medcode Read_code Description			
35235	K04y.00	Other acute renal failure	
48022	7L1Ay00	Other specified compensation for renal failure	
53852	K0512	End stage renal failure	
53940	Kyu2100	[X]Other chronic renal failure	
53945	Kyu2000	[X]Other acute renal failure	
56760	7L1B.00	Placement ambulatory apparatus compensation renal failure	
57919	K043.00	Acute drug-induced renal failure	
59194	7L1By00	Placement ambulatory apparatus- compensate renal failure OS	
61930	Kyu2.00	[X]Renal failure	
63277	L393.00	Acute renal failure following labour and delivery	
63760	SK05.11	Renal failure after crushing	
64636	7L1Az00	Compensation for renal failure NOS	
65089	7L1Cz00	Placement other apparatus- compensate for renal failure NOS	
71314	L093.00	Renal failure following abortive pregnancy	
72458	L393000	Post-delivery acute renal failure unspecified	
83513	7L1C.00	Placement other apparatus for compensation for renal failure	
96179	L393100	Post-delivery acute renal failure - delivered with p/n prob	
97198	K044.00	Acute renal failure due to urinary obstruction	
100205	K0E00	Acute-on-chronic renal failure	
101666	L070300	Unspecified abortion with renal failure	
104857	K043000	Acute renal failure due to ACE inhibitor	
105209	K045.00	Acute renal failure due to non-traumatic rhabdomyolysis	
105267	K04B.00	Acute renal failure due to traumatic rhabdomyolysis	
105739	K0411	ARF - Acute renal failure	
106860	C353600	Renal failure-associated hyperphosphataemia	
107241	K043400	Acute renal failure induced by non-steroid anti-inflamm drug	

15. Read codes to identify hypertension

Medcode	Read_code	Description
799	G2000	Essential hypertension
1894	G201.00	Benign essential hypertension
2666	14A2.00	H/O: hypertension
3425	662O.00	On treatment for hypertension
3712	G20z.11	Hypertension NOS
4372	G202.00	Systolic hypertension

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Medcode Read_code Description		Description	
7329	G2400	Secondary hypertension	
10818	G20z.00	Essential hypertension NOS	
12680	8CR4.00	Hypertension clinical management plan	
15377	G200.00	Malignant essential hypertension	
16059	G24z.00	Secondary hypertension NOS	
16565	6627	Good hypertension control	
18482	662c.00	Hypertension six month review	
18590	662b.00	Moderate hypertension control	
19070	662d.00	Hypertension annual review	
21826	662F.00	Hypertension treatm. started	
25371	G241000	Secondary benign renovascular hypertension	
27511	6628	Poor hypertension control	
30776	6629	Hypertension:follow-up default	
31387	G24z000	Secondary renovascular hypertension NOS	
31755	G240.00	Secondary malignant hypertension	
34744	G244.00	Hypertension secondary to endocrine disorders	
42229	G24zz00	Secondary hypertension NOS	
44549	L128.00	Pre-exist hypertension compl preg childbirth and puerperium	
51635	G241z00	Secondary benign hypertension NOS	
57288	G241.00	Secondary benign hypertension	
59383	G240000	Secondary malignant renovascular hypertension	
73293	G240z00	Secondary malignant hypertension NOS	
83473	G203.00	Diastolic hypertension	
85944	7Q01.00	High cost hypertension drugs	
97533	Gyu2100	[X]Hypertension secondary to other renal disorders	
98230	67H8.00	Lifestyle advice regarding hypertension	
101649	7Q01y00	Other specified high cost hypertension drugs	
102406	662P000	Hypertension 9 month review	
102458	Gyu2000	[X]Other secondary hypertension	
105274	G2800	Stage 2 hypertension (NICE - Nat Ins for Hth Clin Excl 2011)	
105316	G2511	Stage 1 hypertension	
105371	G2500	Stage 1 hypertension (NICE - Nat Ins for Hth Clin Excl 2011)	
105480	G2700	Hypertension resistant to drug therapy	
105487	G2611	Severe hypertension	

Medcode	Read_code	Description	
105989	G2600	Severe hypertension (Nat Inst for Health Clinical Ex 2011)	
61166	G21z000	Hypertensive heart disease NOS without CCF	
61660	G211000	Benign hypertensive heart disease without CCF	
95334	G210000	Malignant hypertensive heart disease without CCF	

16. Codes to identify open and closed tibial shaft fracture

Medcode	Read_code	Description	
20678	S333200	Open fracture of tibia and fibula, shaft	
28068	S333.00	Open fracture of tibia/fibula, shaft	
28118	S333000	Open fracture shaft of tibia	
28198	S333z00	Open fracture of tibia and fibula, shaft, NOS	
28233	S33y.00	Open fracture of tibia and fibula, unspecified part, NOS	
29084	S33y200	Open fracture of tibia and fibula, unspecified part	
29164	S33y000	Open fracture of tibia, unspecified part, NOS	
	•		

29084	S33y200	Open fracture of tibia and fibula, unspecified part	
29164	S33y000	Open fracture of tibia, unspecified part, NOS	
Medcode	Read_code	Description	
971	S33x000	Closed fracture of tibia, unspecified part, NOS	
4572	S33x200	Closed fracture of tibia and fibula, unspecified part	
29109	S33x.00	Closed fracture of tibia and fibula, unspecified part, NOS	
29121	\$332.00	Closed fracture of tibia/fibula, shaft	
33520	S332200	Closed fracture of tibia and fibula, shaft	
34021	S332000	Closed fracture shaft of tibia	
41971	S33xz00	Closed fracture of tibia and fibula, unspecified part, NOS	
55464	\$332z00	Closed fracture of tibia and fibula, shaft, NOS	

OPCS-4	Description	Open/closed fracture
S571	Debridement of skin NEC	Open
W332	Debridement of open fracture of bone	Open
T963	Debridement of soft tissue NEC	Open
W336	Debridement of bone NEC	Open

ICD-10	Description	Open/closed fracture
T14.1	Open wound of unspecified body region	Open
T01.3	Open wounds involving multiple regions of lower limb(s)	Open
S81.7	Multiple open wounds of lower leg	Open

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

ICD-10	Description	Open/closed fracture
S81.8	Open wound of other parts of lower leg	Open
S81.9	Open wound of lower leg, part unspecified	Open
T93.0	Sequelae of open wound of lower limb	Open
T93.2	Sequelae of other fractures of lower limb	Open
T01.9	Multiple open wounds, unspecified	Open
T13.1	Open wound of lower limb, level unspecified	Open
T01.8	Open wounds involving other combinations of body regions	Open
T94.0	Sequelae of injuries involving multiple body regions	Open
T94.1	Sequelae of injuries, not specified by body region	Open
T12.1	Fracture of lower limb, level unspecified, open	Open

17. Read codes to identify Charlson comorbidity index



Microsoft Excel 2003 Worksheet 18. OPCS Codes to identify reoperations

OPCS-4	Description
W242	Closed reduction of fracture of long bone and rigid internal fixation NEC
O172	Remanipulation of fracture of long bone and rigid internal fixation NEC
O173	Remanipulation of fracture of long bone and flexible internal fixation HFQ
O175	Remanipulation of fragment of bone and fixation using screw
O178	Other specified secondary closed reduction of fracture of bone and internal fixation
O179	Unspecified secondary closed reduction of fracture of bone and internal fixation
W231	Secondary open reduction of fracture of bone and intramedullary fixation HFQ
W232	Secondary open reduction of fracture of bone and extramedullary fixation HFQ
W236	Secondary open reduction of fracture of bone and internal fixation HFQ
W248	Other specified closed reduction of fracture of bone and internal fixation
W249	Unspecified closed reduction of fracture of bone and internal fixation
W281	Application of internal fixation to bone NEC
W282	Adjustment to internal fixation of bone NEC
W283	Removal of internal fixation from bone NEC
W288	Other specified other internal fixation of bone
W289	Unspecified other internal fixation of bone

Page 55 of 68		BMJ Open
1		
2 3	OPCS-4	Description
4 5	W235	Secondary open reduction of fracture of bone and external fixation HFQ
6	W252	Closed reduction of fracture of bone and fixation using functional bracing system
7 8	W253	Remanipulation of fracture of bone and external fixation HFQ
9	W258	Other specified closed reduction of fracture of bone and external fixation
10 11	W259	Unspecified closed reduction of fracture of bone and external fixation
12	W301	Application of external fixation to bone NEC
13 14	W302	Adjustment to external fixation of bone NEC
15	W303	Removal of external fixation from bone NEC
16 17	W303	Application of external ring fixation to bone NEC
18	W304	Other specified other external fixation of bone
19 20	W309	Unspecified other external fixation of bone
20	W35.3	Removal of implanted substance from bone
22 23	W32	Other graft of bone
24	W32.1	Prepared graft of bone
25 26	W32.2	Allograft of bone NEC
27	W32.3	Xenograft of bone
28 29	W32.4	Synthetic graft of bone
30	W32.5	Cancellous chip allograft of bone
31 32	W32.8	Other specified other graft of bone
33	W32.9	Unspecified other graft of bone
34 35	S31.3	Revision of flap of skin NEC
36 37	001.0	
38 39		
40		
41 42		
42 43		
44		
45 46		
47		
48 49		
50		
51 52		
53		
54 55		
56		
57 58		
59		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
60		. o. peci reven ony integration jection jicon about guidelines. Antini



Additional file 2: Baseline and results at all time points

Table C1. Patient demographic and clinical characteristics at all time points

6 7		All	Ir	ndex stay			30 days			90 days			1 year			2 years	
, 8 9		enrolled patients (N=805)	No infection (N=775)	Infection (N=30)	p- value ^a	No infection (N=736)	Infection (N=64)	p- value ^a	No infection (N=699)	Infection (N=71)	p- value ^a	No infection (N=606)	Infection (N=80)	p- value ^a	No infection (N=509)	Infection (N=79)	p- value ^a
	Demographics					•											
11 12	Age (years), mean (SD)	40.8 (17.2)	40.7 (16.8)	43.0 (23.9)	0.61	40.5 (16.9)	44.0 (19.1)	0.17	40.7 (16.9)	43.8 (19.1)	0.20	40.7 (16.8)	45.1 (19.1)	0.06	40.5 (16.4)	46.4 (20.0)	0.02
14	Gender, n (%) Male	590 (73.3)	569 (73.4)	21 (70.0)	0.84	539 (73.2)	47 (73.4)	1.00	508 (72.7)	52 (73.2)	1.00	438 (72.3)	59 (73.8)	0.89	368 (72.3)	57 (72.2)	1.00
5	Clinical history/c	comorbiditi	ies														
17	Charlson score, mean (SD)	0.04 (0.23)	0.04 (0.24)	0.00 (0.00)	<0.001	0.04 (0.24)	0.02 (0.12)	0.22	0.04 (0.3)	0.01 (0.12)	0.13	0.04 (0.24)	0.01 (0.11)	0.11	0.03 (0.22)	0.01 (0.11)	0.25
8	Smoker, n (%)	256 (31.8)	247 (31.9)	9 (30.0)	0.99	239 (32.5)	17 (26.6)	0.41	233 (33.3)	18 (25.4)	0.22	202 (33.3)	20 (25.0)	0.17	160 (31.4)	19 (24.1)	0.23
20	Diabetes, n (%)	27 (3.4)	27 (3.5)	0 (0.0)	0.62	26 (3.5)	1 (1.6)	0.72	26 (3.7)	1 (1.4)	0.50	21 (3.5)	3 (3.8)	0.75	15 (3.0)	3 (3.8)	0.72
21	COPD, n (%)	8 (1.0)	8 (1.0)	0 (0.0)	1.00	8 (1.1)	0 (0.0)	1.00	7 (1.0)	0 (0.0)	1.00	6 (1.0)	1 (1.3)	0.58	3 (0.6)	1 (1.3)	0.44
22 23	Congestive heart failure, n (%)	2 (0.3)	2 (0.3)	0 (0.0)	1.00	2 (0.3)	0 (0.0)	1.00	1 (0.1)	0 (0.0)	1.00	0 (0.0)	0 (0.0)	NA	0 (0.0)	0 (0.0)	NA
25	Hypertension, n (%)	12 (1.5)	12 (1.6)	0 (0.0)	1.00	12 (1.6)	0 (0.0)	0.61	12 (1.7)	0 (0.0)	0.62	10 (1.7)	0 (0.0)	0.62	7 (1.4)	0 (0.0)	0.60
27	Compartment syndrome, n (%)	27 (3.4)	22 (2.8)	5 (16.7)	0.00	19 (2.6)	8 (12.5)	<0.05	18 (2.6)	8 (11.3)	<0.05	17 (2.8)	9 (11.2)	0.00	15 (3.0)	8 (10.1)	<0.05
28	Index episode																
30 31	Year of intramedullary nailing, mean (SD)	2009 (3.6)	2009 (3.6)	2009 (3.6)	0.72	2009 (3.6)	2009 (3.6)	0.99	2009 (3.6)	2009 (3.6)	0.74	2008 (3.4)	2008 (3.4)	0.99	2008 (3.1)	2008 (3.1)	0.85
34 35	Inpatient waiting time (days) for surgery, mean (SD)	1.4 (2.4)	1.4 (2.4)	0.7 (2.4)	0.14	1.4 (2.4)	0.7 (1.7)	<0.05	1.4 (2.5)	0.8 (1.7)	<0.05	1.4 (2.4)	0.6 (1.0)	<0.001	1.4 (2.2)	0.6 (1.0)	<0.001
37	Fracture type, n (%) Closed fracture	663 (82.4)	648 (83.6)	15 (50.0)	<0.001	624 (84.8)	35 (54.7)	<0.001	595 (85.1)	42 (59.2)	<0.001	524 (86.5)	49 (61.3)	<0.001	438 (86.1)	52 (65.8)	<0.001

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	All	li	ndex stay			30 days			90 days		1 year			2 years		
	enrolled patients (N=805)	No infection (N=775)	Infection (N=30)	p- value ^a	No infection (N=736)	Infection (N=64)	p- value ^a	No infection (N=699)	Infection (N=71)	p- value ^a	No infection (N=606)	Infection (N=80)	p- value ^a	No infection (N=509)	Infection (N=79)	p- value ^a
Received ≥1 prescription for antibiotics in the 12 months prior to the index stay, n (%)	60 (7.5)	60 (7.7)	0 (0.0)	0.16	57 (7.7)	3 (4.7)	0.47	56 (8.0)	3 (4.2)	0.36	47 (7.8)	4 (5.0)	0.51	35 (6.9)	5 (6.3)	1.000
Received ≥1 prescription for opioids in the 12 months prior to the index stay, n (%)	16 (2.0)	15 (1.9)	1 (3.3)	0.46	15 (2.0)	1 (1.6)	1.00	15 (2.2)	1 (1.4)	1.00	11 (1.8)	2 (2.5)	0.66	8 (1.6)	2 (2.5)	0.63
)								••	SD, standa			(or Fishor (v oct to	sts when n	WOS	
1 2 <5) f		rison of ca							s variables		ii oqualou i				indo	
3 4 5																
5 7																
3 9 0																
1 2 3																
5 5																
5 7																
3 9 0																
1 2																
3 4 5				For pe	eer review c	only - http://	/bmjope	en.bmj.com/	′site/about/	'guidelir	nes.xhtml					
5 7																

Table D1.	Comparative results at all time points
-----------	--

Time period	Endpoint	Bivariate ana	Ilysis, mean (SD)		analysis, mean % CI)	Absolute difference (multivariate analysis)	
		Infection	No infection	Infection	No infection		
Index stay	Total costs (£)	11,695 (6,553)	6,669 (3,133; p<0.001)	10,384 (8,900, 12,116)	6,603 (6,411, 6,802)	3,781 p<0.001	
(N infection = 30; N no infection = 775)	Inpatient costs (£)	11,695 (6,553)	6,669 (3,133; p<0.001)	10,384 (8,900, 12,116)	6,603 (6,411, 6,802)	3,781 p<0.001	
	LOS (days)	22.6 (20.0)	9.7 (12.1; p<0.001)	17.6 (13.0, 23.7)	8.5 (8.0, 9.0)	9.05 p<0.001	
	ICU LOS (days)	1.5 (8.2)	0.1 (1.1; p=0.53)	0.1 (0.1, 0.2)	0.0 (0.0, 0.01)	0.115 p<0.001	
	Reoperations (number)	0.3 (0.8)	0.0 (0.1; p<0.001)	0.1 (0.0, 0.2)	0.0 (0.0, 0.0)	0.070 p<0.001	
	Reoperations (rate, %)	13.3	1.3 (p<0.001)	9.7 (3.1, 26.3)	1.1 (0.5, 2.1)	8.6 p<0.001	
				Q 01			

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 59 of 68

Time period	Endpoint	Bivariate ana	Ilysis, mean (SD)		analysis, mean % Cl)	Absolute difference (multivariate analysis	
		Infection	No infection	Infection	No infection		
Index stay + 30 days post-discharge	Total costs (£)	12,673 (7,345)	7,089 (3,588; p<0.001)	11,257 (10,045, 12,615)	7,017 (6,792, 7,248)	4,241 p<0.001	
(N infection = 64; N no	Inpatient costs (£)	12,367 (7,290)	6,829 (3,397; p<0.001)	11,008 (9,818, 12,343)	6,768 (6,551, 6,993)	4,240 p<0.001	
infection = 736)	Hospital outpatient/ambulatory costs (£)	215 (116)	155 (94; p=0.4)	245 (145, 345)	152 (125, 179)	93 p=0.07	
	Primary care costs (£)	289 (555)	254 (673, p=0.24)	243 (139, 426)	205 (175, 241)	38 p=0.57	
	LOS (days)	19.3 (19.2)	10.1 (12.2; p<0.001)	15.0 (12.1, 18.6)	8.9 (8.4, 9.5)	6.1 p<0.001	
	ICU LOS (days)	0.7 (5.6)	0.1 (1.1; p=0.4)	0.1 (0.0, 0.1)	0.0 (0.0, 0.0)	0.0 p<0.001	
	Readmissions (number)	0.6 (0.6)	0.1 (0.3; p<0.001)	0.5 (0.4, 0.7)	0.1 (0.1, 0.1)	0.4 p<0.001	
	Readmissions (rate, %)	48.4	7.6 (p<0.001)	44.1 (31.5, 57.5)	7.1 (5.4, 9.2)	37.0 p<0.001	
	Reoperations (number)	0.2 (0.7)	0.0 (0.1; p<0.001)	0.1 (0.1, 0.2)	0.0 (0.0, 0.0)	0.1 p<0.001	
	Reoperations (rate, %)	14.1	1.6 (p<0.001)	11.5 (5.4, 22.9)	1.3 (0.7, 2.5)	10.2 p<0.001	
	Amputation (rate, %)	3.1	0.1 (p<0.01)		Not feasib	ble	
	Hospital outpatient/ambulatory referrals (number)	1.6 (0.9)	1.2 (0.5; p=0.28)	1.6 (1.1, 2.2)	1.21 (1.0, 1.4)	0.45 p=0.13	
	Total costs (£)	13,621 (7,827)	7,527 (4,326; p<0.001)	11,949 (10,634,13,427)	7,423 (7,160, 7,696)	4,526 p<0.001	
	Inpatient costs (£)	13,154 (7,673)	7,157 (4,111; p<0.001)	11,532 (10,246,12,979)	7,072 (6,818, 7,336)	4,459 p<0.001	

Time period	Endpoint	Bivariate ana	Ilysis, mean (SD)		analysis, mean % Cl)	Absolute difference (multivariate analysis)	
		Infection	No infection	Infection	No infection		
Index stay + 90 days post-discharge	Hospital outpatient/ambulatory costs (£)	183 (87)	171 (135; p=0.53)	194 (125, 264)	170 (141, 198)	25 p=0.515	
	Primary care costs (£)	436 (637)	353 (737; p<0.05)	428 (290, 630)	299 (264, 338)	129 p=0.084	
infection = 699)	LOS (days)	21.7 (21.5)	11.1 (14.6 p<0.001)	16.4 (13.2, 20.4)	9.6 (9.0, 10.3)	6.8 p<0.001	
	ICU LOS (days)	0.7 (5.3)	0.1 (1.2; p=0.576)	0.0 (0.0, 0.1)	0.0 (0.0, 0.0)	0.0 p<0.001	
	Readmissions (number)	0.8 (0.8)	0.2 (0.6; p<0.001)	0.7 (0.5, 0.9)	0.2 (0.2, 0.2)	0.5 p<0.001	
	Readmissions (rate, %)	57.7	17.2 (p<0.001)	5.4 (41.5, 65.9)	16.5 (13.9, 19.5)	37.4 p<0.001	
	Reoperations (number)	0.3 (0.7)	0.1 (0.3; p<0.001)	0.2 (0.1, 0.3)	0.1 (0.0, 0.1)	0.1 p=0.001	
	Reoperations (rate, %)	18.3	6.0 (p<0.001)	14.3 (7.7, 25.0)	5.4 (3.9, 7.4)	9.0 p<0.05	
	Amputation (rate, %)	2.8	0.1 (p<0.05)	1	Not feasibl	е	
	Hospital outpatient/ambulatory referrals (number)	1.2 (0.6)	1.4 (0.9; p=0.92)	1.3 (0.9, 1.7)	1.4 (1.2, 1.5)	0.0 p=0.835	
Index stay + 1 year post-discharge	Total costs (£)	16,800 (12,663)	8,435 (5,330; p<0.001)	14,756 (13,123, 16,593)	8,279 (7,946, 8,626)	6,478 p<0.001	
(N infection = 80; N no	Inpatient costs (£)	15,580 (11,872)	7,746 (5,060; p<0.001)	13,672 (12,122, 15,420)	7,616 (7,301, 7,944)	6,056 p<0.001	
infection = 606)	Hospital outpatient/ambulatory costs (£)	250 (251)	239 (218; p=0.77)	220 (151, 288)	244 (211, 277)	25 p=0.516	
	Primary care costs (£)	1,139 (1,657)	630 (903; p<0.001)	1,017 (769, 1,344)	551 (498, 609)	466 p<0.001	

Page 61 of 68

Time period	Endpoint	Bivariate and	alysis, mean (SD)		analysis, mean % CI)	Absolute difference (multivariate analysis
		Infection	No infection	Infection	No infection	
	LOS (days)	28.5 (33.3)	12.6 (21.3; p<0.001)	21.9 (17.3, 27.7)	10.5 (9.7, 11.4)	11.4 p<0.001
	ICU LOS (days)	0.2 (1.5)	0.1 (1.1; p=0.758)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0p=0.914
	Readmissions (number)	1.5 (1.5)	0.5 (0.9; p<0.001)	1.5 (1.2, 1.8)	0.5 (0.4, 0.6)	1.0 p<0.001
	Readmissions (rate, %)	75	36 (p<0.001)	74.4 (63.4, 83.0)	35.9 (32.1, 39.9)	38.5 p<0.001
	Reoperations (number)	0.6 (1.0)	0.2 (0.5; p<0.001)	0.6 (0.5, 0.8)	0.2 (0.2, 0.3)	0.4 p<0.001
	Reoperations (rate, %)	37.5	21.3 (p<0.01)	38.6 (28.3, 50.0)	20.3 (17.2, 23.8)	18.2 p<0.001
	Amputation (rate, %)	2.5	0.2 (p<0.05)		Not feasibl	e
	Hospital outpatient/ambulatory referrals (number)	1.8 (1.6)	1.8 (1.5; p=0.66)	1.7 (1.2, 2.1)	1.8 (1.6, 2.1)	0.2 p=0.44
Index stay + 2 years post-discharge	Total costs (£)	18,779 (14,929)	9,611 (6,284; p<0.001)	16,626 (14,664, 18,849)	9,439 (8,998, 9,901)	7,187 p<0.001
(N infection = 79; N no	Inpatient costs (£)	16,900 (13,720)	8,573 (5,729; p<0.001)	14,898 (13,106, 16,935)	8,447 (8,044, 8,871)	6,451 p<0.001
infection = 509)	Hospital outpatient/ambulatory costs (£)	282 (296)	275 (265; p=0.893)	264 (189, 338)	277 (243, 310)	13 p=0.747
	Primary care costs (£)	1,758 (2,437)	929 (1,179; p<0.01)	1,487 (1,149, 1,924)	821 (742, 907)	666 p<0.001
	LOS (days)	31.5 (38.1)	13.4 (22.6; p<0.001)	24.6 (19.6, 30.8)	11.3 (10.4, 12.3)	13.3 p<0.001
	ICU LOS (days)	0.2 (1.5)	0.1 (1.2; p=0.24)	0.0 (0.0, 0.0)	0.0 (0.0, 0.0)	0.0 p=0.20

Time period	Endpoint	Bivariate and	alysis, mean (SD)		analysis, mean % CI)	Absolute difference (multivariate analysis)
		Infection	No infection	Infection	No infection	
	Readmissions (number)	2.1 (2.3)	1.0 (1.5; p<0.001)	2.2 (1.9, 2.6)	0.9 (0.8, 1.0)	1.3 p<0.001
	Readmissions (rate, %)	77.2	51.1 (p<0.001)	77.6 (67.0, 85.6)	51.4 (46.9, 56.8)	26.3 p<0.001
	Reoperations (number)	0.8 (1.1)	0.4 (0.7; p<0.01)	0.8 (0.6, 1.0)	0.4 (0.3, 0.4)	0.4 p<0.001
	Reoperations (rate, %)	46.8	32.4 (p<0.05)	49.0 (37.7, 60.3)	31.2 (27.2, 35.5)	17.7 p<0.05
	Amputation (rate, %)	3.8	0.2 (p<0.01)		Not feasibl	e
	Hospital outpatient/ambulatory referrals (number)	2.0 (2.0)	2.1 (1.9; p=0.55)	2.0 (1.5, 2.5)	2.1 (1.8, 2.3)	0.1 p=0.82

Abbreviations: CI, confidence interval; ICU, intensive care unit; LOS, length of stay; NA, not applicable; SD, standard deviation.

Table D2. 1 year cost breakdown (£) - inpatient setting

Endpoint	Bivariate analysis,	mean (SD)
	Infection	No infection
Total inpatient costs	15,580 (11,872)	7,746 (5,060)
HRG costs	15,488 (11,743)	7,702 (4,985)
Unbundled HRG costs	36 (116)	16 (72)
Critical care costs	56 (381)	26 (208)
Specialised care costs	0 (0)	2 (42)

Abbreviations: HRG, Healthcare Resource Group; SD, standard deviation.

Table D3. 1 year healthcare resource use and cost breakdown – primary care

Endpoint	Bivariate analysis	s, mean (SD)
	Infection	No infection
Costs (£)	· · ·	
Total primary care costs	1,139 (1,657)	630 (903)
Total drug costs	368 (1,031)	198 (681)
Total test costs	147 (247)	95 (186)
Imaging test costs	27 (71)	25 (72)
Total consultation costs	625 (721)	338 (334)
GP	322 (317)	212 (225)
Nurse	140 (362)	36 (75)
Other healthcare professional	120 (243)	55 (121)
Administrative	42 (36)	35 (30)
Healthcare resource use (number)	Vi	
Total tests	25 (52)	14 (30)
Imaging tests	0.4 (0.8)	0.5 (1.5)
Total consultations	52 (51)	33 (25)
GP	14 (13)	9 (9)
Nurse	10 (21)	3 (5)
Other healthcare professional	9 (17)	4 (8)
Administrative	22 (18)	18 (15)

Abbreviations: GP, General Practitioner; SD, standard deviation.

Table D4. Subgroup analyses of 1 year inpatient costs – infection type (deep versus superficial)

	No infection (N=606)	Superficial infection (N=54)	Deep infection (N=26)
Bivariate analysis, mean (SD)	£7,746 (£5,060)	£14,232 (£8,633)	£18,378 (£16,592)
Multivariate analysis, mean (95% CI) ^a	£7,614 (£7,301, £7,941)	£12,814 (£11,093, £14,803)	£15,513 (£12,640, £19,040)

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; SD, standard deviation.

^a Adjusted for open/closed fracture, age, smoker, year at index, diabetes, COPD, days prior nailing and compartment syndrome.

Table D5. Subgroup analyses of 1 year inpatient costs – fracture type (open versus closed)

		ection 606)		ection =80)
Fracture type	Closed	Open	Closed	Open
	(N=524)	(N=82)	(N=49)	(N=31)
Bivariate analysis, mean (SD)	£7,433 (£3,957)	£9,741 (£9,247)	£12,291 (£7,366)	£20,778 (£15,451)
Multivariate analysis,	£7,278 (£6,956,	£9,495 (£8,469,	£12,178 (£10,492,	£19,542 (£16,166,
mean (95% Cl)ª	£7,614)	£10,645)	£14,136)	£23,623)

Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; SD, standard deviation.

^a Adjusted for age, smoker, year at index, diabetes, COPD, days prior nailing and compartment syndrome.

Table D6. Sensitivity analyses

Time period	Endpoint	Bivariate anal	Bivariate analysis, mean (SD)		Multivariate analysis, mean (95% CI)	
		Infection	No infection	Infection	No infection	(multivariate analysis)
Index stay	Total costs (£)	12,554 (6,832)	6,580 (3,123; p<0.001)	11,110 (9,328, 13,232)	6,517 (6,295, 6,747)	4,593 p<0.001
(N infection = 24; N no infection = 564)	LOS (days)	24.2 (20.9)	9.4 (11.7; p<0.001)	18.6 (13.1, 26.4)	8.5 (7.9, 9.1)	10.1 p<0.001
	Reoperations (number)	0.3 (0.9)	0.0 (0.1; p<0.001)	0.1 (0.0, 0.3)	0.0 (0.0, 0.0)	0.1 p<0.001
	Reoperations (rate)	12.5	1.6 (p<0.01)	9.9 (2.7, 30.6)	1.4 (0.7, 2.8)	8.5 p<0.05
Index stay + 30 days post-discharge	Total costs (£)	12,957 (7,385)	7,077 (3,747; p<0.001)	11,453 (10,016, 13,096)	7,010 (6,739, 7,292)	4,444 p<0.001
(N infection = 51; N	LOS (days)	20.2 (19.4)	10.0 (12.4; p<0.001)	15.6 (12.1, 20.0)	9.1 (8.4, 9.8)	6.5 p<0.001
no infection = 537)	Readmissions (number)	0.6 (0.6)	0.1 (0.3; p<0.001)	0.5 (0.3, 0.7)	0.1 (0.1, 0.1)	0.4 p<0.001
	Readmissions (rate)	47.1	8.4 (p<0.001)	45.7 (32.0, 60.0)	7.9 (5.9, 10.5)	37.8 p<0.001
	Reoperations (number)	0.3 (0.7)	0.0 (0.2; p<0.001)	0.1 (0.1, 0.3)	0.0 (0.0, 0.0)	0.1 p<0.001
	Reoperations (rate)	13.7	2.2 (p<0.001)	11.7 (5.0, 25.3)	1.8 (1.0, 3.4)	9.9 p<0.001
Index stay + 90 days post-discharge	Total costs (£)	13,620 (7,762)	7,584 (4,622; p<0.001)	11,869 (10,364, 13,593)	7,480 (7,160, 7,813)	4,389 p<0.001
(N infection = 59; N	LOS (days)	21.9 (21.8)	11.2 (15.2; p<0.001)	16.3 (12.7, 21.0)	9.8 (9.1, 10.7)	6.5 p<0.001
no infection = 529)	Readmissions (number)	0.8 (0.8)	0.2 (0.5; p<0.001)	0.7 (0.5, 0.9)	0.2 (0.2, 0.2)	0.5 p<0.001

Time period	Endpoint Bivariate analysis, mean			Multivariate a	Absolute difference		
		Infection	No infection 18.1 (p<0.001)	Infection 54.9 (41.1, 68.0)	No infection	(multivariate analysis)	
	Readmissions (rate)	57.6			17.2 (14.1, 20.8)	37.7 p<0.001	
	Reoperations (number)	0.3 (0.7)	0.1 (0.3; p<0.05)	0.2 (0.1, 0.3)	0.1 (0.0, 0.1)	0.1 p<0.05	
	Reoperations (rate)	15.3	7.0 (p<0.05)	11.1 (5.2, 22.0)	6.1 (4.3, 8.7)	5.0 p=0.1438	
Index stay + 1 year post-discharge	Total costs (£)	16,788 (12,914)	8,449 (5,525; p<0.001)	14,597 (12,841, 16,593)	8,294 (7,920, 8,686)	6,303 p<0.001	
(N infection = 72; N	LOS (days)	29.2 (34.6)	12.3 (21.1; p<0.001)	22.5 (17.7, 28.5)	10.3 (9.4, 11.2)	12.2 p<0.001	
no infection = 516)	Readmissions (number)	1.5 (1.6)	0.5 (0.9; p<0.001)	1.5 (1.2, 1.8)	0.5 (0.4, 0.6)	1.0 p<0.001	
	Readmissions (rate)	75.0	35.5 (p<0.001)	75.0 (63.6, 83.8)	35.3 (31.2, 39.6)	39.7 p<0.001	
	Reoperations (number)	0.6 (0.9)	0.2 (0.5; p<0.01)	0.5 (0.4, 0.7)	0.2 (0.2, 0.3)	0.3 p<0.001	
	Reoperations (rate)	36.1	21.7 (p<0.05)	37.4 (26.7, 49.5)	20.7 (17.3, 24.5)	16.8 p<0.05	
Index stay + 2 years post-discharge	Total costs (£)	18,779 (14,929)	9,611 (6,284; p<0.001)	16,626 (14,664, 18,849)	9,439 (8,998, 9,901),	7,187 p<0.001	
(N infection = 79; N	LOS (days)	31.5 (38.1)	13.4 (22.6; p<0.001)	24.6 (19.6, 30.8)	11.3 (10.4, 12.3)	13.3 p<0.001	
no infection = 509)	Readmissions (number)	2.1 (2.3)	1.0 (1.5; p<0.001)	2.2 (1.9, 2.5)	0.9 (0.8, 1.0)	1.3 p<0.001	
	Readmissions (rate)	77.2	51.1 (p<0.001)	77.6 (67.0, 85.6)	51.4 (46.9, 55.8)	26.3 p<0.001	
	Reoperations (number)	0.8 (1.1)	0.4 (0.7; p<0.01)	0.8 (0.6, 1.0)	0.4 (0.3, 0.5)	0.4 p<0.001	

Page 67 of 68

1	
2 3 4 5 6 7	
4	
5	
6	
7 8	
9	
10	
11	
12	
13	
14 15	
16	
16 17	
18	
19	
20	
∠1 22	
23	
20 21 22 23 24 25 26 27 28 29	
25	
26	
2/	
20 29	
30	
31	
32	
33	
34 35	
36	
37	
38	
39	
40 41	
41	
43	
44	
45	
46	
47	

Time period	Endpoint	Bivariate ana	ate analysis, mean (SD) Multivariate analysis, mean (SD) CI)			Absolute difference
		Infection	No infection	Infection	No infection	(multivariate analysis)
	Reoperations (rate)	46.8	32.4 (p<0.05)	49.0 (37.7, 60.3)	31.2 (27.2, 35.5)	17.7 p<0.05
Abbreviations: CI, c	confidence interval; LOS, ler	ngth of stay; NA, r	not applicable; SD, s	standard deviation	l.	
	For peer re	eview only - http://	bmjopen.bmj.com/si	te/about/guideline	es.xhtml	

BMJ Open

Section/Topic	ltem #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6-7
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	7
		(b) For matched studies, give matching criteria and number of exposed and unexposed	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7:9
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	7
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9-10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9-10
		(b) Describe any methods used to examine subgroups and interactions	9-10
		(c) Explain how missing data were addressed	9
		(d) If applicable, explain how loss to follow-up was addressed	10
		(e) Describe any sensitivity analyses	9-10

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cohort studies

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

 BMJ Open

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed	10:14
		eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	10
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential	10-11
		confounders	
		(b) Indicate number of participants with missing data for each variable of interest	10:14
		(c) Summarise follow-up time (eg, average and total amount)	10
Outcome data	15*	Report numbers of outcome events or summary measures over time	10:14
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence	11:14
		interval). Make clear which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were categorized	10:14
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	14-15
Discussion			
Key results	18	Summarise key results with reference to study objectives	15
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from	16
		similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	15-16
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on	17
		which the present article is based	

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.